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 SU M M A R Y 
Worldwide, cholera was responsible for 317,534 cases and 7,543 deaths in 2010, mainly reported 
from Africa, South Asia and the Caribbean. The true burden of cholera is likely to be more than 
ten times higher since underreporting due to technical issues and political motivations is 
suspected.  
 
Cholera is caused by the bacterium Vibrio cholerae serogroup O1 and O139, which spreads 
mainly through fecal contamination of water and food by infected persons. Patients develop 
acute watery diarrhea and vomiting. Large volumes of rice-water-like stool and concurrent loss 
of electrolytes can lead to severe dehydration and eventually death if patients are not rapidly 
treated. Treatment includes rehydration with intravenous fluids for severe cases and 
administration of oral rehydration solution for moderate cases. Without treatment the case-
fatality rate may reach 50%. 
 
Classical cholera control is based on prevention—safe water, sanitation and education of people 
on the importance of hygiene and diarrheal diseases (WASH)—health system preparedness and 
a timely response to provide appropriate treatment in the event of an outbreak. The World 
Health Organization (WHO) recommends vaccination with an oral cholera vaccine (OCV) as a 
supplement to WASH for prevention and control of epidemic and endemic cholera. Two killed 
whole-cell OCVs are currently available for public use in low- and middle income countries. 
 
Consideration of local cultural concepts of illness among potential vaccine recipients and how 
these may affect vaccine acceptance is crucial. To date, no published studies have examined the 
influence of social and cultural features of cholera on vaccine acceptance in African settings. 
 
Cholera is endemic on the archipelago of Zanzibar, East Africa. A collaborative research project 
between the WHO, the International Vaccine Institute, the Swiss Tropical and Public Health 
Institute, and the Ministry of Health and Social Welfare of Zanzibar (MoHSW) was launched in 
2008. The project’s overall goal was to reduce the burden of cholera on Zanzibar by vaccinating 
a target population of 50,000 residents living in cholera hotspots and by conducting studies to 
address key research questions that remained unanswered from an earlier OCV mass campaign 
in Mozambique.  
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The overall aims of the research presented here were to study social and cultural features of 
OCV acceptance and to assess the cost-effectiveness of the 2009 OCV mass campaign in 
Zanzibar. Findings should inform governments and ministries, in particular the MoHSW, 
regarding the introduction of an OCV as part of a sustainable and financially viable strategy to 
improve prevention and control of endemic cholera on this archipelago. 
 
To address the first aim, the integrated-methods approach of cultural epidemiology was used to 
study local views of cholera-like illness and to examine their influence on OCV acceptance in 
endemic communities in Zanzibar before and after the mass vaccination campaign. The second 
aim was addressed by estimating public and private costs of illness due to cholera and costs of 
the OCV mass campaign to assess the cost-effectiveness of using OCVs from a health care 
provider and a societal perspective. 
 
A prevaccination survey was conducted with a locally adapted semi-structured interview based 
on the Explanatory Model Interview Catalogue (EMIC). Vignette-based EMIC interviews 
assessed sociocultural features of illness, operationalized as categories of distress, perceived 
causes, self treatment and help seeking outside the household. A random sample of 356 
unaffected adults from a periurban and a rural community was interviewed. This descriptive 
study showed that cholera was more often recognized as serious illness that may be fatal without 
appropriate treatment than shigellosis. Features of distress were primarily related to the 
negative social and financial impact cholera can have on a patient’s life. Interference with work- 
or income-related activities was the most prominent category of distress. The most prominent 
somatic symptoms were related to dehydration and to general gastrointestinal features. Cholera 
was mainly attributed to a dirty environment and microbiological contamination while causes 
unrelated to the biomedical basis were also identified, but with less prominence. Even though 
rehydration of the patient (primarily in the periurban community) and use of herbal treatment 
and antibiotics (rural community) were the preferred self-treatment options, professional health 
facilities were universally recommended at both sites. This survey showed that cholera 
represented a significant perceived illness burden in periurban and rural Zanzibar. 
 
Subsequent analysis showed that community willingness for a free OCV was almost universal 
(94%), but declined with increasing price to 61% if the OCV was offered at a low price (~USD 
0.9), to 19% if offered at a medium price (~USD 4.5) and to 15% if offered at a high price (~USD 
9). Logistic regression models including somatic symptoms (low and high price), social impact 
(low and medium price) and perceived causes (medium and high price) explained anticipated 
OCV acceptance better than models containing only sociodemographic characteristics. This 
showed that prevaccination assessments of community demand for OCV should not only 
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consider the social epidemiology, but also examine local sociocultural features of cholera-like 
illness. 
 
Since only 50% of the interviewed respondents had drunk two doses of the free OCV—with 
higher priority in the rural (59%) than in the periurban (41%) community (p<0.01)—study of 
social and cultural determinants of OCV uptake was deemed necessary. Similar to the previous 
study of determinants of anticipated OCV acceptance, this study showed that consideration of 
sociocultural features of illness explained uptake better than a purely social epidemiological 
analysis. Loss of appetite and nausea, both nonspecific features of cholera were negative 
determinants. Recognition of unconsciousness as a sign of serious dehydration and concern that 
cholera outbreaks could negatively impact the local health care system in the rural area were 
positive determinants of acceptance. Female gender, rural residence and older age were also 
positive determinants of OCV uptake. 
 
A sample of 367 vaccinated and unvaccinated adults from the same two communities was 
studied in a postvaccination survey with a revised EMIC interview. Factors associated with 
uptake indicated a positive impact of the vaccination campaign and of sensitization activities on 
vaccine acceptance behaviour. Analysis of barriers among unvaccinated people identified 
logistical issues as main reasons for the low community coverage, with people’s own busy daily 
schedules as the most prominent feature. Unlike communities opposed to cholera control or in 
settings where public confidence in vaccines is lacking, this study indicated a good campaign 
implementation and trust in the health system. 
 
The incremental cost-effectiveness ratio (ICER) of USD 119,339 per disability-adjusted life-year 
averted exceeded three times the Tanzanian per capita gross domestic product; thus, use of 
OCVs was not considered a cost-effective strategy in comparison to the current practice based 
on decentralized cholera treatment centers in Zanzibar. This was probably due to the expensive 
OCV (Dukoral® was purchased at a price of USD 10.28 per course) and use of it in a relatively 
low incidence setting (mean annual incidence was 0.65 per 1,000 population). 
 
In conclusion, the research presented here suggests little community opposition to vaccination 
and good prospects to use OCVs for endemic cholera control in Zanzibar. Future campaigns 
should offer OCVs at no cost, be announced a few months before vaccination posts open, extend 
hours and days for improved access and concentrate efforts among young adults, periurban 
areas, and men. Information material for community sensitization and mobilization for a 
campaign should emphasize that cholera causes severe dehydration and highlight the value of 
vaccination for prevention rather than antibiotics for treatment. The usually mild side effects of 
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OCVs should also be better explained to maintain or improve community coverage. From an 
economic perspective, prospects to use OCV mass campaigns under current conditions seem to 
be limited. However, at a subsidized purchase price and subsidized delivery costs of ~USD 1 
each per immunized individual, OCV mass campaigns may become economically and financially 
feasible for cholera control in high-incidence areas of Zanzibar.  
 
 ZU S A M M E N F A S S U N G 
Im Jahr 2010 wurden weltweit 317’534 Krankheits- und 7’543 Todesfälle wegen Cholera 
gemeldet, wobei vor allem Länder in Afrika, Südasien und der Karibik betroffen waren. Dies ist 
jedoch nur die offizielle Statistik. Aufgrund von technischen Unzulänglichkeiten und politischen 
Motiven muss von einer mehr als zehnfach erhöhten Fall- und Todeszahl ausgegangen werden. 
 
Cholera wird durch das Bakterium Vibrio cholerae (Serogruppen O1 und O139) verursacht. Die 
Übertragung geschieht hauptsächlich durch fäkale Kontamination von Wasser und Esswaren 
durch infizierte Personen. Cholera verursacht beim Patienten akuten, wässrigen Durchfall und 
Erbrechen. Grosse Mengen an Stuhl, der Reiswasser ähnlich sieht, mit gleichzeitigem Verlust 
von Elektrolyten, können zu schwerer Dehydratation und schliesslich zum Tod führen, wenn die 
Patienten nicht schnell behandelt werden. Die Behandlung besteht aus intravenöser 
Rehydratation bei schweren Fällen; bei milderen Fällen genügt oft die Gabe von oralen 
Rehydratations-Lösungen. Ohne Behandlung kann die Letalität 50% erreichen. 
 
Die herkömmliche Cholerabekämpfung beruht auf Prävention – Bereitstellung von sauberem 
Wasser, einer sanitären Infrastruktur und Aufklärung über Hygiene und Durchfallkrankheiten – 
und einem Gesundheitssystem, das bereit ist, im Falle eines Ausbruchs rechtzeitig mit einer 
adäquaten Behandlungsstrategie zu reagieren. Die Weltgesundheitsorganisation (WHO) 
empfiehlt deshalb Schluckimpfungen gegen Cholera (Oral Cholera Vaccines, OCVs) als 
Ergänzung zur herkömmlichen Prävention bei der Bekämpfung von epidemischer und 
endemischer Cholera. Zurzeit sind zwei auf inaktivierten Bakterien beruhende OCVs erhältlich, 
die für den Gebrauch in Ländern mit niedrigen und mittleren Einkommen zugelassen sind. 
 
Lokale kulturelle Sichtweisen zum Kranksein können sich bei potentiellen Impfempfängern auf 
die Impfakzeptanz auswirken. Bislang wurden aber noch keine Artikel über Studien publiziert, 
die den Einfluss sozialer und kultureller Merkmale hinsichtlich der Impfakzeptanz im 
afrikanischen Kontext studiert haben. 
 
Cholera ist endemisch auf dem ostafrikanischen Archipel Sansibar. Im Jahr 2008 wurde ein 
Forschungsprojekt zwischen der WHO, dem Internationalen Impfinstitut, dem Schweizerischen 
Tropen- und Public Health-Institut und dem Ministerium für Gesundheit und Wohlfahrt von 
Sansibar (MoHSW) gestartet. Ziel dieses Projekts war die Reduktion der Cholerafälle mittels 
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einer Impfkampagne; es war geplant, 50’000 Bewohner in Gegenden, die als Cholera-Hotspots 
bekannt sind, zu impfen. Dazu wurden Studien durchgeführt, um wichtige Fragen zur 
Forschung, die nach einer früheren Massen-Impfkampagne in Mosambik offen geblieben 
waren, weiter zu bearbeiten. 
 
Die Hauptziele der hier präsentierten Arbeit bestanden darin, soziale und kulturelle Merkmale 
zur Akzeptanz von OCVs in der lokalen Bevölkerung zu untersuchen und die Kosten-Effektivität 
der 2009 in Sansibar durchgeführten Massen-Impfkampagne zu beurteilen. Die Ergebnisse 
sollen dazu dienen, Regierungen und Ministerien, insbesondere aber das MoHSW, über die 
Einführung von OCVs als Teil einer nachhaltigen und finanziell tragfähigen Strategie zur 
Prävention und Bekämpfung von endemischer Cholera auf dem Archipel zu informieren. 
 
Zur Bearbeitung des ersten Ziels wurden lokale Sichtweisen zu Cholera-ähnlichen 
Erkrankungen in endemischen Gemeinden in Sansibar vor und nach der Massen-
Impfkampagne untersucht, um deren Einfluss auf die Akzeptanz von OCVs abzuschätzen. Dazu 
wurde der auf integrativen Methoden beruhende Forschungsansatz der Kulturellen 
Epidemiologie verwendet. Als zweites Ziel wurde die Kosten-Effektivität von OCVs aus Sicht des 
öffentlichen Gesundheitswesens und aus gesellschaftlicher Perspektive abgeschätzt. Dazu 
wurden durch Cholera verursachte Behandlungskosten für die öffentliche Hand und die 
Betroffenen und die Kosten der Massen-Impfkampagne erhoben. 
 
Zuerst wurde eine Umfrage mit einem auf die lokalen Verhältnisse angepassten 
halbstrukturierten Interview, basierend auf dem Explanantory Model Interview Catalogue 
(EMIC), durchgeführt. Mit Vignetten eingeführte EMIC-Interviews wurden für die Erhebung 
der lokal relevanten soziokulturellen Merkmale von Cholera eingesetzt. EMIC-Interviews 
untersuchten Kategorien im Bezug auf Krankheitserfahrungen, deren wahrgenommenen 
Ursachen, und Behandlungsoptionen inner- und ausserhalb des Haushalts. Es wurde eine 
Zufalls-Stichprobe von 356 nicht von Cholera betroffenen Erwachsenen aus einer periurbanen 
und einer ländlichen Gemeinde interviewt. Diese deskriptive Studie zeigte, dass Cholera 
häufiger als Shigellose als schwere Krankheit, die ohne angemessene Behandlung tödlich sein 
kann, eingeschätzt wurde. Die negativen sozialen und finanziellen Auswirkungen einer 
Choleraepisode auf das Leben eines Menschen wurden als Hauptmerkmale dieser Erkrankung 
identifiziert. Darunter wurde die Beeinträchtigung von Arbeits- oder Einkommens-relevanten 
Tätigkeiten als grösstes Problem angesehen. Als prominenteste somatische Symptome wurden 
solche, die auf Dehydratation und allgemeine Magen-Darm-Infektionen hinwiesen, genannt. 
Cholera wurde vor allem im Zusammenhang mit einer schmutzigen Umgebung und mit 
mikrobiologischer Kontamination gesehen; Ursachen ohne schulmedizinischen Hintergrund 
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wurden auch genannt, jedoch mit weniger Priorität. Obwohl Rehydratation (vor allem in der 
periurbanen Gemeinde) und pflanzenmedizinische Behandlungen und der Gebrauch von 
Antibiotika (ländliche Gemeinde) bevorzugte Optionen für die Behandlung zu Hause waren, 
wurden öffentlichen Gesundheitseinrichtungen von jeder interviewten Person empfohlen. Die 
Umfrage ergab, dass Cholera im periurbanen und ländlichen Sansibar als eine signifikante 
Krankheitsbelastung wahrgenommen wird. 
 
Eine an diese Untersuchung anschliessende Analyse zeigte eine fast universelle Bereitschaft der 
lokalen Bevölkerung zum Empfang einer kostenlosen Schluckimpfung gegen Cholera (94%). 
Diese Rate sank jedoch auf 61% ab, wenn der OCV zu einem niedrigen Preis von ~USD 0.9 
angeboten wurde. Bei einem mittlerem Preis von ~USD 4.5 waren noch 19% und bei einem 
hohen Preis von ~USD 9 noch 15% der Befragten bereit für die Impfung. Logistische 
Regressionsmodelle, die somatische Symptome (bei niedrigem und hohem Preis), soziale 
Auswirkungen (niedriger und mittlerer Preis) und lokal wahrgenommene Ursachen (mittlerer 
und hoher Preis) untersuchten, erklärten die Impfabsicht besser als Modelle, die nur 
soziodemographische Merkmale beinhalteten. Diese Ergebnisse zeigten, dass sich 
Nachfrageabschätzungen bezüglich OCV in der lokalen Bevölkerung nicht nur auf die 
Sozialepidemiologie abstützen sollten, sondern auch lokal relevante soziokulturelle Merkmale 
von Cholera-ähnlicher Erkrankung in Betracht gezogen werden müssen. 
 
Da nur 50% der befragten Personen die benötigten zwei Dosen des gratis angebotenen OCVs – 
mit höherem Anteil in der ländlichen (59%) verglichen mit der periurbanen (41%) Gemeinde 
(p<0.01) – getrunken hatten, wurde eine Untersuchung der sozialen und kulturellen 
Determinanten der Impfakzeptanz als notwendig erachtet. Ähnlich wie bei der 
vorangegangenen Studie wurde hier aufgezeigt, dass eine Berücksichtigung soziokultureller 
Krankheitsmerkmale die Impfakzeptanz besser erklären kann, als eine rein 
sozialepidemiologische Analyse. Appetitlosigkeit und Übelkeit, beides nicht Cholera-spezifische 
Merkmale, wurden als negative Determinanten identifiziert. Die Wahrnehmung, dass 
Bewusstlosigkeit als ein ernstes Zeichen von Dehydratation gilt, und die Sorge, dass sich 
Choleraausbrüche negativ auf die lokale Gesundheitsversorgung in den ländlichen Gegenden 
auswirken könnten, waren positive Determinanten der Impfakzeptanz. Weibliches Geschlecht, 
ländliches Umfeld und zunehmendes Alter waren auch positive Determinanten der 
Impfakzeptanz. 
 
Nach der Impfkampagne wurde eine zweite Zufalls-Stichprobe aus den gleichen zwei 
Gemeinden der ersten Umfrage gezogen. Es wurden 367 geimpfte und nicht geimpfte 
Erwachsene mit einem überarbeiteten EMIC-Interview befragt. Faktoren, die mit 
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Impfakzeptanz assoziiert waren, zeigten eine positive Auswirkung der Impfkampagne und der 
Sensibilisierungsaktivitäten auf das Impfverhalten. Logistische Probleme, vor allem im 
Zusammenhang mit täglichen Aktivitäten, wurden als Haupthürden für die tiefe 
Durchimpfungsrate identifiziert. Im Gegensatz zu Bevölkerungsgruppen, die in Opposition zur 
staatlichen Cholerabekämpfung stehen, oder wo das Vertrauen der Öffentlichkeit in Impfstoffe 
fehlt, zeigte diese Studie eine gute Umsetzung der Massen-Impfkampagne und Vertrauen der 
lokalen Bevölkerung in das Gesundheitssystem. 
 
Das inkrementelle Kosten-Effektivitäts-Verhältnis (ICER) von USD 119’339 pro abgewendetes 
behinderungsbereinigtes Lebensjahr betrug mehr als dreimal so viel wie das tansanische Pro-
Kopf-Bruttoinlandprodukt; somit kann die Verwendung von OCVs in Sansibar nicht als 
wirtschaftliche Strategie angesehen werden im Vergleich zur derzeitigen Praxis, welche auf 
dezentralen Cholera-Behandlungszentren beruht. Als Hauptgründe sind wahrscheinlich der 
hohe Einkaufskaufpreis (Dukoral® wurde zu einem Preis von USD 10.28 pro Person beschafft) 
und die relativ niedrige Cholerainzidenz (die mittlere jährliche Inzidenz betrug 0.65 pro 1’000 
Personen) zu nennen. 
 
Fazit: die hier vorgestellte Forschung hat gezeigt, dass in der Bevölkerung wenig Opposition 
gegen Impfungen besteht und dass die Aussichten für den Einsatz von OCVs zur Bekämpfung 
von endemischer Cholera in Sansibar gut sind. Zukünftige Kampagnen sollten OCVs kostenlos 
anbieten. Dazu sollten sie mindesten einige Monate im Voraus, bevor die Impfposten öffnen, 
angekündigt werden. Für einen verbesserten Zugang sollte die Anzahl Tage und Stunden, an 
denen die Impfposten offen sind, verlängert werden. Besonders im Fokus der Anstrengungen 
sollten junge Erwachsene, periurbanen Gebiete, und Männer sein. Informationsmaterial zur 
Sensibilisierung und Mobilisierung der Bevölkerung vor einer Impfkampagne sollte 
insbesondere das Dehydratations-Potenzial von Cholera betonen und den Wert von Impfungen 
für die Prävention, anstelle von Antibiotika für die Behandlung, unterstreichen. Die 
hauptsächlich milden Nebenwirkungen von OCVs sollten noch besser erklärt werden, um die 
Durchimpfungsrate der Bevölkerung aufrechtzuerhalten oder weiter anzuheben. Aus 
wirtschaftlicher Sicht scheinen die Aussichten auf Massen-Impfkampagnen unter den 
gegenwärtigen Bedingungen noch begrenzt zu sein. Jedoch könnten ein subventionierter 
Impfstoffeinkaufspreis und Verimpfungskosten von je ~USD 1 pro Impfling dazu beitragen, dass 
die Cholerabekämpfung mittels Massen-Impfkampagnen in Sansibar in Gebieten mit hoher 
Inzidenz wirtschaftlich und finanziell machbar wird. 
 
 MU H T A S A R I 
Kipindupindu kilikuwa chanzo cha matukio 317,534 na vifo 7, 543 kwa mwaka 2010 duniani, 
matukio haya yaliripotiwa hasa katika nchi za Afrika, kusini mwa bara la Asia na Caribbean. 
Ugonjwa huu unakadiriwa kuwa mara kumi zaidi kuliko unavyotazamiwa na hii ni kutokana na 
kwamba matukio haya yamekuwa yanatolewa taarifa kwa kiwango cha chini kutokana na 
sababu zinazodhaniwa kuwa ni za kiufundi na motisha za kisiasa. 
 
Kipindipindu kinasababishwa na bakteria aitwae Vibrio cholerae serogroup O1 na O139, na 
kinaenezwa hasa na mtu aliyeathirika kupitia chakula na maji vilivyochanganyika na kinyesi. 
Wagonjwa hutokewa na tatizo sugu la kuharisha maji maji na kutapika. Choo 
kinachoshabihiana na maji ya mchele kwa wingi pamoja na upungufu wa elekroliti vinaweza 
kusababisha upungufu mkubwa wa maji mwili na hatimaye kifo iwapo wagonjwa hawatapata 
tiba ya haraka. Matibabu yake ni pamoja na kuongezewa maji mwilini hasa kwa wagonjwa walio 
kwenye hali mbaya zaidi na wagonjwa walio katika hali ya kawaida hupatiwa maji au dawa ya 
kunywa maalum kwa tatizo hilo. Bila matibabu, kiwango cha matukio ya vifo kinaweza kufikia 
asilimia 50.  
 
Mikakati ya kisasa ya kudhibiti kipindupindu imelenga katika uzuiaji- maji salama, usafi wa 
mazingira na kuelimisha watu juu ya umuhimu wa usafi na magonjwa ya kuharisha (hii 
inajulikana zaidi kwa Kingeraza kawa WASH ikimaanisha, Water, Sanitation and Hygiene na 
Kiswahili kama Maji, Usafi wa mazingira na Usafi), Utayari wa mfumo wa afya na uwajibikaji wa 
kutoa matibabu kwa wakati muafaka katika tukio la mlipuko. Shirika la Afya duniani (WHO) 
linapendekeza chanjo ya kipindupindu kwa njia ya matone ijulikanayo kwa Kingereza kama 
Oral Cholera Vaccine (OCV) kama mbadala wa mkakati wa kisasa ujulikano kama WASH 
unaolenga katika uzuiaji na udhibiti wa maradhi na usugu wa magonjwa ya kipindupindu. 
Chanjo ya kipindupindu ijulikanayo kama Two killed whole-cell OCVs inapatikana kwa ajili ya 
matumizi ya umma katika nchi zenye kipato cha chini na kati.  
 
Uzingatiaji wa dhana za magonjwa za kiutamaduni ndani ya sehemu husika na hasa kwa 
wapokeaji wa chanjo na jinsi gani zinaweza kuathiri ukubalikaji wa chanjo kwa jamii ni suala 
muhimu. Hadi sasa, hakuna matokeo ya utafiti yaliyochapishwa katika majarida ya kisayansi 
yanayoelezea ushawishi wa vipengele vya kijamii na kiutamaduni vya kipindupindu juu ya 
ukubalikaji wa chanjo ya kipindupindu katika mazingira ya Afrika.  
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Kipindupindu kimeenea zaidi katika kisiwa cha Zanzibar, Afrika Mashariki. Ushirikiano kati ya 
mradi wa utafiti wa Shirika la Afya Duniani (WHO), Taasisi ya Kimataifa ya Chanjo na Wizara 
ya Afya na Ustawi wa Jamii ya Zanzibar (MoHSW) ulizinduliwa mwaka 2008. Lengo kuu la 
mradi ilikuwa ni kupunguza tatizo la kipindupindu Zanzibar, kwa kutoa chanjo kwa wakazi 
50,000 wanaoishi maeneo yenye kipindupindu na kwa kufanya utafiti ili kujibu maswali 
muhimu ya utafiti ambayo yalikaa bila kuwa na majibu tokea kampeni umma za mwanzo za 
chanjo ya kipindupindu ya matone (OCV) zilizofanyika nchini Msumbiji.  
 
Malengo ya jumla ya utafiti huu ilikuwa ni kutafiti vipengele vya kijamii na kiutamaduni 
vinavyohusiana na ukubalikaji wa chanjo ya kipindupindu ya matone na kutathmini gharama 
fanisi za kampeni ya umma ya chanjo ya matone ya mwaka 2009 kisiwani Zanzibar. Matokeo ya 
utafiti huu yanalenga kuipa taarifa serikali na wizara, hususani Wizara ya Afya na Ustawi wa 
Jamii (MoHSW), kuhusu kuanzishwa kwa chanjo ya kipindupindu ya matone kama sehemu ya 
mkakati endelevu na wa kifedha, juu ya faida ya kuboresha kinga na udhibiti wa kipindipindu 
katika kisiwa hiki kilichoenea tatizo hilo.  
 
Kuelezea lengo la kwanza, mfumo wa njia za pamoja unaochanganua vipengele vya kitamaduni 
vya matukio ya magonjwa ulitumika kujifunza maoni ya jamii juu ya magonjwa yanayoendana 
na kipindupindu na kuchunguza ushawishi wake juu ya ukubalikaji wa chanjo ya matone ya 
kipindipindu katika jamii zilizoenea na tatizo hili kisiwani Zanzibar, kabla na baada ya kampeni 
umma ya chanjo. Lengo la pili lilielezewa kwa kukadiria gharama za umma na gharama binafsi 
za ugonjwa zinazotokana na kipindupindu, gharama za kampeni ya umma ya chanjo ya matone 
ya kipindupindu pamoja na gharama fanisi ya kutumia chanjo ya matone ya kipindupindu 
kutoka kwa mtoa huduma wa afya na mtazamo wa jamii kwa ujumla. 
 
Utafiti kabla ya chanzo ulifanyika kwa kutumia zana ya utafiti iliyorakabishiwa kutokana na 
mazingira halisi, zana hii ilitokana na mahojiano yanayolenga kupata maelezo ya kina ya 
mgoinjwa kuhusu ugonjwa wake inayojulikana kwa Kingereza kama Explanatory Model 
Interview Catalogue. Pia mahojiano kwa kutumia njia ya kulezea tatizo la mtu na kusubiri 
wahojiwa wajibu wangefanya nini ilitumika kutathmini vipengele jamii-tamaduni vya ugonjwa, 
vinavyotumika na kuelezewa kama dalili, chanzo, tiba binafsi na utafutaji wa matibabu nje ya 
kaya. Jumla ya watu 356 wasioathirika na kipindupindu walihojiwa, watu hawa walichaguliwa 
bila utaratibu maalum kutoka jamii za miji midogo na vijijini. Utafiti huu ulionyesha kuwa 
kipindupindu kilichukuliwa na jamii kama ugonjwa hatari unaoweza kusababisha kifo 
pasipokuwa na tiba sahihi kuliko magonjwa mengine ya tumbo na kuhara. Vipengele vya dhiki 
vilihusiana zaidi na madhara hasi ya kijamii na kifedha ambayo kipindupindu kinaweza 
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kusababisa kwa maisha ya mgonjwa. Muingiliano wa shughuli za kikazi au kipato ilionekana 
kuwa tatizo kubwa wakati wa ugonjwa. Dalili kuu zilihusiana zaidi na kuishiwa maji mwilini na 
matatizo yanayohusiana na tumbo. Kipindipindu kilihusishwa zaidi ya uchafu wa mazingira na 
maambukizo ya mikorobiojia wakati sababu za msingi zisizohusiana na kitabibu pia zilitajwa 
ingawa zilipewa umuhimu kidogo zaidi. Pamoja na kwamba uongezewaji wa maji mwilini (hasa 
kwa jamii za miji midogo) na utumiaji wa tiba za kiasili na dawa za vijiua sumu (kwa jamii za 
vijijini) zilipendelewa zaidi kama tiba binafsi, vituo vya afya vilipendekezwa zaidi katika maeneo 
yote mawili. Utafiti huu ulionyesha kuwa kipindupindu kinasimama kama ugonjwa muhimu na 
tatizo katika jamii za miji midogo na Zanzibar vijijini.  
 
Uchambuzi wa utafiti ulionyesha ukubalikaji kwa asilimia 94 wa chanjo ya kipindupindu ya 
matone inayotolewa bure, lakini asilimia hii ilipungua kufikia 61 iwapo bei ya chanjo 
ingeongezeka, kama chanjo hii ingetolewa kwa bei ndogo (dola ya kimarekani 0.9), mpaka 
asilimia 19 iwapo itatolewa kwa bei ya kati (dola za kimarekani 4.5) na mpaka asilimia 15 kama 
itatolewa kwa bei ya juu (dola za kimarekani 9). Mahesabu ya uwezekano wa kutokea matokeo 
fulani ikiwemo dalili (bei ya chini na juu), madhara ya kijamii (bei ya chini na ya kati) na sababu 
zinazofikiriwa (bei ya kati na juu) yalielezea matarajio ya ukubalikaji wa chanjo ya matone ya 
kipindupindu vizuri zaidi kuliko mahesabu yaliyohusisha sifa ya kijamii kuhusiana na idadi ya 
watu. Hii ilionyesha kuwa tathmini ya mahitaji ya jamii kabla ya chanjo haipaswi kuzingatia tu 
matukio ya afya jamii lakini pia kuchunguza vipengele vya jamii na tamaduni vya magonjwa 
yanayoshabihiana na kipindupindu.  
 
Kwa vile ni asilimia 50 tu ya watu waliohojiwa walishakunywa dozi mbili ya chanjo ya matone ya 
kipindupindu iliyotolewa bure, iliyopata kipaumbele hasa katika maeneo ya vijijini (asilimia 59) 
kuliko miji midogo (asilimia 41) (p<0.01), ilkuwa ni muhimu kufanya utafiti unaoangalia ni kwa 
jinsi gani vigezo vya kijamii na kitamaduni vinavyoweza kuchangia upokelewaji wa chanjo hii. 
Kama ilivyokuwa kwa utafiti wa awali ulioangalia mchango wa vigezo vilivyopelekea ukubalikaji 
wa chanjo hii, utafiti huu umeonyesha kwamba mchango wa vigezo vya kijamii na kitamaduni 
kuhusu magonjwa, vilielezea vizuri upoekelewaji wa chanjo kuliko uchambuzi wa kijamii wa 
matukio ya magonjwa. Kupoteza hamu ya kula na kichefuchefu vilikuwa vigezo hasi ambavyo 
havikuambatana na ukubalikaji wa chanjo. Kupoteza fahamu kama ishara hatari ya kuishiwa 
maji mwilini na wasiwasi kuwa kipindupindi kinaweza kuathiri vibaya mfumo wa huduma za 
afya katika maeneo ya vijijini vilikuwa ni vigezo chanya vilivyopelekea ukubalikaji wa chanjo 
katika jamii. Jinsia ya kike, kuishi vijijini na umri mkubwa vilikuwa pia ni vigezo chanya 
vilivyopelekea ukubalikaji wa chanjo ya matone ya kipindupindu.  
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Idadi ya watu wazima 367 waliochanjwa na wasiochanjwa kutoka katika jamii mbili 
zinazoshabihiana, walifanyiwa utafiti katika zoezi lililofanyika baada ya shughuli ya chanjo 
kuisha, watu hawa walifanyiwa mahojiano kwa kutumia hojaji iliyorakabishiwa kutokana na 
mazingira halisi, ijulikanayo kwa Kingereza kama Explanatory Model Interview Catalogue. 
Mambo yanayohusiana na upokelewaji wa chanjo yalionyesha matokeo mazuri ya kampeni ya 
chanjo na shughuli za uhamasishaji wa chanjo sababu zilizopelekea ukubalikaji wa chanjo kwa 
jamii. Uchambuzi wa vikwazo kwa wale ambao hawakupata chanjo ulionyesha shughuli 
rasilimali kama sababu ya watu wengi kutokupata chanjo, hasa shughuli za binadamu ya kila 
siku. Tofauti na jamii ambazo zilikuwa kinyume na udhibiti wa kipindipindu au maeneo 
amabapo wanajamii walishindwa kujiamini kuhusu chanjo, utafiti huu ulionyesha utekelezaji 
mzuri wa kampeni ya chanjo na imani katika mfumo mzima wa afya.  
 
Kwa sababu gharama fanisi zilizoongezeka kwa uwiano wa dola za kimarekani 119,339 kwa 
makadirio ya janga la magonjwa, hii ilikuwa zaidi ya mara tatu kwa mtanzania kulingana na 
pato la ndani, matumizi ya chanjo ya matone ya kipindupindu hayakuchukuliwa kama mkakati 
wa gharama nafuu kulinganisha na shughuli za kawaida za tiba katika vituo vya tiba za 
kipindupindu. Pengine hii ilitokana na matumizi ghali ya chanjo ya matone ya kipindupindu 
(Dukoral® ilinunuliwa kwa dola za kimarekani 10.28 kwa dozi) katika mazingira yaliyokuwa na 
matukio machache ya ugonjwa (wastani wa matukio kwa mwaka ilikuwa 0.65 kwa kila watu 
1,000) 
 
Kwa kuhitimisha, utafiti huu unaonyesha kuwa jamii ilipinga chanjo ya kipindipindu kwa kiasi 
kidogo, wakati huo huo unaonyesha matarajio mazuri ya kutumika kwa chanjo hii kudhibiti 
kipindupindu katika maeneo yenye tatizo hili kisiwani Zanzibar. Kampeni za baadae zinapaswa 
kutoa chanjo ya matone ya kipindupindu bila gharama yoyote, itangazwe miezi michache kabla 
ya kufunguliwa vituo vya chanjo, masaa na siku za chanjo ziongezwe kuboresha upatikanaji wa 
chanjo na nguvu ziongezwe hasa kwa vijana, watu wazima, wanaume na pia katika maeneo ya 
miji midogo. Elimu inatakiwa kusisitiza kuwa kipindupindu kinasababisha upungufu hatari wa 
maji mwilini na kuongeza mkazo juu ya umuhimu wa chanjo kwa ajili ya kujikinga na 
maambukizi kuliko utumiaji wa dawa za viua sumu kama tiba. Madhara ya kawaida ya chanjo ya 
matone ya kipindupindu yanatakiwa yaelezwe kwa kina kwa wanajamii ili kuboresha ukubalikaji 
wa chanjo. Kwa mtazamo wa kiuchumi na kulingana na hali halisi, matarajio ya matumizi ya 
kampeni za chanjo ya matone ya kipindupindu yanaonekana kuwa madogo. Hata hivyo kwa bei 
ya ruzuku na gharama za utoaji ruzuku ya dola ya kimarekani moja, kwa kila chanjo, kampeni za 
chanjo ya matone ya kipindupindu zinaweza kuwa yakinifu kiuchumi na kifedha kwa ajili ya 
kudhibiti kipindupindu kwenye maeneo yenye matukio zaidi ya kipindupindu kisiwani Zanzibar.  
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IN T R O D U C T I O N 
1.1 Cholera: an old scourge still raging today 
Cholera is a disease that has affected humans since antiquity. Although its origins are not 
known, Sanskrit texts describe the presence of an acute form of diarrhea with cholera-like 
symptoms in South Asia, especially in the Ganges Delta, since at least the fifth century BCE [1]. 
The disease was first documented in 1817 in what was later to be defined as the first pandemic, 
affecting not only the Indian subcontinent but also other parts of Asia, eastern Africa, the Indian 
Ocean islands and even present-day Armenia. The reasons why cholera became an international 
menace after being rather geographically confined for many centuries remains unclear until 
today. According to Echenberg [1], extreme climate change following the eruption of the volcano 
Mount Tambora in Indonesia in 1815 might have been a factor together with political change as 
“the first modern cholera pandemic coincided with the beginning of a new era in world history: 
the economic transformation of the world system […] after Britain led a European alliance to 
defeat France in 1815 [and] people’s lives everywhere were changed by the economic reordering 
of their societies.” (p. 15) Cholera’s spread throughout the modern world was greatly increased 
by global trade driven by colonial powers (e.g., the British East India Company in South Asia) as 
well as accompanying warfare. Five pandemics followed after 18171 up to the seventh pandemic, 
which began in 1961 in Indonesia and then spread to India in 1964, Africa and Southern Europe 
in 1970 and South America in 1991 [2]. Cholera now affects populations across the entire globe. 
 
In 1884 the German scientist Robert Koch identified the bacterium Vibrio cholerae as the cause 
of the disease [3,4]; however, risk factors for cholera had been identified more than 30 years 
earlier by John Snow in his seminal epidemiological study on London’s Broad Street pump 
cholera outbreak [5]. Snow referred to a “cholera poison” in water contaminated by effluents 
from a nearby sewer and vigorously advocated for boiling water as a means of protection against 
                                                        
1First pandemic: 1817-1826, second: 1828-1836, third: 1839-1861, fourth: 1863-1879, fifth: 1881-1896, sixth: 1899-
1947 [1] 
2 
the illness [6]. Since the first pandemic, cholera has become widely feared, mainly due to the 
speed with which it can spread and escalate mortality in vulnerable populations. 
 
In response to the second and third pandemics, which affected many countries across the globe 
including in Europe, several countries convened in 1851 in Paris for the first International 
Sanitary Conference to reach an international agreement on the standardization of quarantine 
regulations to prevent the importation of cholera (in addition to plague and yellow fever) [7]. A 
series of conferences followed thereafter aimed at limiting the epidemic, eventually leading to 
the establishment of the World Health Organization (WHO) in 1948. Although it was removed 
from the International Health Regulations in 1973 [8], cholera remains politically stigmatized 
today. Cases are systematically underreported to the WHO or are termed as acute watery 
diarrhea by certain authorities that wish to keep a low profile on cholera [9].  
 
Zanzibar was likely the first region in sub-Saharan Africa to be affected by cholera in the modern 
age [1]. This East African archipelago was an easy target for cholera due to its links with Oman2 
and the Indian Ocean trade system. It is believed that cholera reached Zanzibar as early as 1821; 
but this assumption is not verified by historical documentation. However, it is known that 
pilgrims returning in 1836 from Mecca brought cholera to Somalia, from where dhows, engaged 
in the East African coastal trade, transported cholera to Zanzibar and further down the coast to 
Mozambique [1]. The impact of the epidemics in Europe was indeed considerable3 but in Africa, 
they were catastrophic. During the fourth pandemic, for example, an outbreak affected not just 
poor people or slaves, but also French elites, and reportedly took the lives of 10% of the 
population of Zanzibar island (Text box 1-1).  
Text box 1-1: Description of a cholera outbreak in Zanzibar that literally decimated the population in 
1869/1870  
 
                                                        
2Zanzibar was ruled by the sultans of Oman between 1698 and 1890 and was an important hub in the slave trade 
between the interior of Africa and the Arabian Peninsula and the Persian Gulf. 
3A detailed overview of cholera outbreaks and related morbidity and mortality before systematic collection of data 
began with the seventh pandemic is given by Echenberg [1] (p. 13-85). 
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Despite the emergence of modern medicine and improvements in infrastructure and health 
education, the disease continues to wreak havoc around the world, especially in populations 
affected by humanitarian crisis situations. Examples abound of cholera outbreaks following 
natural or man-made disasters in the 20th and the 21st century [9,11]. The large outbreak that 
happened in a refugee camp near Goma in northeastern Democratic Republic of Congo (then 
Zaïre), after ~700,000 Rwandans had fled the genocide in their country in July 1994, was 
another stark reminder of cholera’s potential for inflicting massive devastation and suffering. 
During this three-week period, an estimated 35,000 cases were treated for cholera-like diarrhea 
from July 20 to August 12, 1994, which roughly equaled the number of presumed unreported 
cases. This epidemic caused the loss of ~23,800 lives; the maximum case-fatality rate (CFR) for 
cases seen in facilities reached 22% [12]. 
1.2 Global cholera-related morbidity and mortality 
In 2010, a total of 317,534 cases and 7,543 deaths (CFR: 2.4%) were reported by 48 countries to 
the WHO (Figure 1-1) [9].  
 
Figure 1-1: Countries reporting cholera in 2010  
Source: Adapted from WHO [9] 
 
Twenty-three of these countries are located in Africa, but the majority of cases were reported 
from the Caribbean island of Hispaniola. This peak was mainly due to a large outbreak that 
started in October 2010 in Haiti in the aftermath of the devastating earthquake that had shaken 
the island on January 12, 2010. Even though an increase in diarrhea-related morbidity and 
mortality had been anticipated following this natural disaster in Haiti, the authorities were not 
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prepared for a cholera outbreak as the island had been considered cholera-free for over 100 
years [13].4 As of July 10, 2011, a total of 388,958 cases and 5,899 deaths (CFR: 1.5%) have been 
reported from Haiti and the Dominican Republic—and the epidemic is still raging [16]. 
 
Despite this huge outbreak and an exception in the early 1990s—after V. cholerae O1 had hit 
Peru in 1991 and subsequently affected all but three Latin American countries [17]—the majority 
of the ~50,000 to 600,000 cases of cholera that were reported every year to the WHO over the 
past two decades had come from Africa (Figure 1-2) [9].  
Figure 1-2: Global annual number of cholera cases reported to the WHO, by continent, 1989-2010 
Source: Adapted from WHO [9] 
 
The number of cases from Africa increased considerably from 20% in the 1970s to 94% in the 
years from 2000 to 2005; with Asian rates dropping from 80% to 5.2% over the same three 
decades [18]. A similar trend is found with regard to reported deaths: Africa’s share increased 
from 22% to 97% and Asia’s share showed a steep decline from 77% to 2.4%. Among the 32 
countries that reported deaths due to cholera in 2010, 20 of them are in the Africa continent 
(Figure 1-1).  
 
                                                        
4A cholera strain originating from South Asia was later identified as the causal agent; it had inadvertently been 
introduced by UN peacekeepers [14]. The official UN report stated that “the evidence overwhelmingly supports the 
conclusion that the source of the Haiti cholera outbreak was due to contamination of the Meye Tributary of the 
Artibonite River with a pathogenic strain of current South Asian type Vibrio cholerae as a result of human activity.” 
[15] (p. 29) 
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As noted above, these official figures do not reflect the true burden of cholera since serious 
underreporting due to technical issues (i.e., surveillance system limitations, problems with case 
definition and lack of standard vocabulary) and political motivations (i.e., fear of travel or trade 
sanctions) is suspected [9]. Zuckerman et al. [19] identified mainly underreporting from the 
Indian subcontinent and Southeast Asia in a review carried out in 2004. The WHO estimates 
that annual morbidity and mortality may exceed three million cases and 100,000 deaths [20].  
1.3 Economic burden due to cholera 
The public health importance of cholera and its micro- and macroeconomic impacts are widely 
recognized. However, systematic data on costs due to cholera outbreaks are still relatively scarce 
in the published literature. 
 
Detailed local data about public and private costs of illness (COI) due to cholera are needed for 
economic evaluations to improve planning of cholera control. The first systematic study on COI 
was published very recently only [21]; it compared public costs of treatment and private, i.e., 
direct and indirect, costs borne by patients between four different cholera-endemic sites in Asia 
and Africa in a standardized manner. Total COI per episode of hospitalized cases amounted to 
2005 USD 31.5 in Matlab, Bangladesh, USD 205.7 in North Jakarta, Indonesia,5 USD 35.4 in 
Kolkata, India, and USD 47.2 in Beira, Mozambique. 
 
For the WHO African Region,6 Kirigia et al. [22] estimated that public and private COI 
amounted to 2002 USD 53 million in 2005, USD 128 million in 2006 and USD 60 million in 
2007. At a first glance, these figures do not seem to be very substantial, but since they are based 
on the annual number of documented cholera cases, they are also likely to be underestimated 
and thus only represent the tip of the iceberg of the economic burden due to cholera. 
Mozambique alone, for example, reported annual costs of USD 145 million to respond to cholera 
outbreaks [23].  
 
In addition to costs borne by the health system and by families in response to outbreaks, cholera 
can also negatively affect national economies. Even though trade sanctions are not believed to 
limit the spread of cholera effectively, losses due to restricted or even interrupted trade have had 
a significant negative impact on African economies. Based on a EU embargo to export fresh fish 
from Lake Victoria imposed in 1998 on Uganda, Kenya, Tanzania and Mozambique, Kimball et 
                                                        
5Costs were highest in Jakarta due to higher fees than in the other sites and inclusion of private treatment facilities in 
the study. 
6Consisting of 46 countries, excluding Morocco, Tunis, Libya, Egypt, Sudan, South Sudan, Djibouti and Somalia 
(http://www.afro.who.int/en/countries.html). 
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al. [24] modeled the loss in trade as a percentage of total gross domestic product (GDP) and 
total export. They showed that the combined GDP of these four countries dropped by 1% and 
total export volumes by over 10%, totaling a loss in trade of ~USD 1 billion over the five-year 
period from 1998 to 2002. They concluded that such losses represent a significant 
macroeconomic burden for poor countries where fishery products are important export 
commodities and called “for additional resources to prevent or curtail epidemic threats in a 
timely way.” [24] (p. 829)  
1.4 Etiology and clinical features of cholera 
Cholera is an intestinal disease caused by the rod-shaped gram-negative bacterium V. cholerae 
that spreads mainly through fecal contamination of water and food by infected individuals [2]. 
Eating raw or undercooked seafood can also cause infection since V. cholerae was found on 
phyto- and zooplankton in marine, estuarine and riverine environments independent of infected 
human beings [25,26]. Two out of ~240 serogroups of V. cholerae—O1 and O139—have shown 
the potential to cause outbreaks and pandemics [2]. The O1 serogroup can be divided into two 
biotypes, classical and El Tor, both of which can further be subdivided into two major serotypes, 
Ogawa and Inaba. V. cholerae colonizes the upper small intestine and releases an enterotoxin 
that is the direct cause of cholera diarrhea. The B subunit of the cholera toxin binds to the small 
intestine mucosa while the active A subunit interferes with the sodium and chloride transport 
leading to massive outpouring of water and electrolytes. Contrary to other enteropathogens like 
Salmonella spp. or Shigella spp. that cause diarrhea with blood or mucus and pus in stool, 
cholera is a non-inflammatory diarrhea since the cholera toxin only stimulates secretory 
processes without invading the mucosa. 
 
After an incubation period of 18 hours to five days, infected individuals develop acute watery 
diarrhea. Large volumes of rice-water-like stool and concurrent loss of electrolytes can lead to 
severe dehydration and eventually death if patients are not rapidly treated. Most of the infected 
individuals, however, are asymptomatic or suffer only from mild diarrhea. An inoculum of ~108 
bacteria is needed in healthy individuals to cause severe acute watery diarrhea while a 1,000-
fold lower dose is sufficient to cause the disease when gastric acid production is reduced. Other 
clinical features besides profuse diarrhea (more than three loose stools per day) to establish a 
cholera diagnosis include abdominal and muscle cramps and frequent vomiting [20,27]. 
Without treatment the case-fatality rate (CFR) may reach 50% [2].  
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1.5 Treatment of cholera 
Timely rehydration with compensation of electrolyte loss (i.e., potassium, sodium, calcium and 
chloride) is the mainstay of treatment. According to WHO guidelines, rehydration of cases 
depends on the severity of dehydration and includes (i) giving oral rehydration solutions (ORS) 
after each stool even if no dehydration is apparent, (ii) giving ORS in larger amounts if moderate 
dehydration7 is apparent, or (iii) using intravenous drips8 for severely dehydrated patients9 
[20,27]. Antibiotics can be administered to shorten episodes in severe cases, to diminish the 
amount of intravenous fluids required and to reduce shedding of V. cholerae. In addition to 
WHO guidelines, researchers have suggested that carefully timed use of antibiotics also include 
moderately dehydrated cases [28].  
1.6 Cholera control strategies 
Cholera control is based on prevention—safe water, improved sanitation and education of 
people on the importance of hygiene and diarrheal diseases (WASH)—health system 
preparedness and a timely response to provide appropriate treatment in the event of an 
outbreak. Recognizing that the occurrence of cholera in a specific setting is essentially a 
structural issue,10 improving water supply and sanitation, i.e., making sure that bacterial 
contamination of drinking water is no longer possible due to a careful separation of water supply 
systems and sewage, would be the most effective solution to permanently protect a population 
from cholera (and also other fecal-orally transmitted waterborne diseases).  
 
In spite of cholera’s tendency to occur in outbreaks, the public health literature has been 
distinguishing endemic, i.e., based on recurrence in time and place, from epidemic cholera, i.e., 
based on relatively unpredictable occurrence in settings that have been cholera-free for some 
time. To better guide control strategies, the Strategic Advisory Group of Experts on 
Immunization to the WHO (SAGE) has recently defined endemic cholera as “the occurrence of 
fecal culture-confirmed cholera diarrhea in a population in at least 3 of the past 5 years.” [30] 
(p. 526) 
                                                        
7Two or more of the following signs have to be present: sunken eyes, absence of tears, dry mouth and tongue, patient 
is thirsty and drinks eagerly, skin pinch goes back slowly 
8Ringer’s Lactate, Hartmann’s solution or saline 
9In addition to the above signs, a severely dehydrated patient is lethargic, unconscious or floppy, is unable to drink, 
has a weak radial pulse and a skin pinch that goes back very slowly 
10Because low- and middle-income countries are characterized by a poor or absent infrastructure, they bear the brunt 
of the global cholera burden [29]. Before heavy investments were made in their infrastructure, cholera had once also 
been endemic in today’s high-income countries [1]. The few cases that are currently reported in North America or 
Europe have usually been imported from cholera-endemic countries (Figure 1-1).  
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1.6.1 From classical prevention to consideration of oral cholera vaccines 
as public health tool 
With the advent of two promising oral cholera vaccines (OCVs),11 the WHO for the first time 
recommended vaccination for cholera prevention in acute emergency situations in 1995 [11,12]. 
This recommendation was drafted against the background of several large outbreaks that had 
happened in the early 1990s. Subsequent WHO meetings of experts in 1999 [31], 2002 [23] and 
2005 [32] reevaluated the evidence regarding use of OCVs in emergencies. Because of cholera’s 
persistence after decades of promoting WASH activities, the use of OCVs in endemic settings 
was also recommended in 2002 [23]. Following a demonstration project in Beira, Mozambique, 
where feasibility and effectiveness of a mass OCV vaccination campaign in an endemic 
environment was shown [33,34], the WHO reinforced the role of OCVs as a supplementary 
measure for endemic cholera control in 2005, but requested that more research be done under 
field conditions to validate the findings from this project [32].  
1.6.2 WHO recommendations for use of OCVs in endemic settings 
Text box 1-2 summarizes the current WHO position on the use of OCVs for endemic cholera 
control [30]. These recommendations were proposed by SAGE in October 2009 based on a 
comprehensive background paper that reviewed recent evidence regarding cholera burden, 
epidemiology and use of OCVs [35]. 
 
Text box 1-2: WHO recommendations for use of OCVs for cholera control in endemic settings 
Source: SAGE [30] 
 
                                                        
11An earlier parenteral vaccine that was developed soon after V. cholerae had been detected as causative agent in the 
19th century has never been recommended by the WHO for public health use due to its limited protective efficacy and 
considerable side effects [1,8]. 
Scope 
Vaccination should not target the whole population, but focus on high-risk areas and populations. 
 
Criteria for vaccination 
Two out of the following criteria have to be met: (i) detection of culture-confirmed cholera in ≥ 3 of the past 5 years, (ii) 
incidence ≥ 1 per 1,000, (iii) in the absence of surveillance data, high-risk areas/groups have been identified by local 
public health officials. 
 
Target groups 
Even though all age groups are vulnerable to cholera, priority should be given to children and older age groups if 
resources are limited. 
 
Vaccine delivery strategy 
Periodic mass vaccination campaigns are the preferred option for delivery. 
 
Frequency of vaccination 
Booster vaccinations are recommended every second year based on the maximum duration of protection of currently 
available OCVs. 
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Vaccination should not disrupt the provision of safe water and sanitation to prevent or contain 
cholera outbreaks. Vaccination should only be considered as supplement to WASH activities. 
Cholera control should ideally be a multisectoral approach involving different ministries and 
research institutes as well as local (and international) non-governmental organizations (NGOs) 
that coordinate activities towards improvement of structural issues (water supply and 
sanitation), disease surveillance and reporting, case management, food safety, and health and 
hygiene education.  
1.7 Oral cholera vaccines 
Development and production of several oral cholera vaccines started in the 1980s and led to 
licensure of the first OCVs in the 1990s. Two types of OCVs—based on killed whole-cells (WCs) 
and on live, attenuated strains—have been available in the market [9]. Until very recently only 
one OCV, Dukoral®, was prequalified by the WHO and thus available for public health use in 
low- and middle-income countries. Dukoral® was initially designed as a traveler’s vaccine 
containing not just killed WCs, but also recombinant cholera toxin (CT) B subunit for faster 
protection among immunologically naïve people and because this component also provides 
some cross-protection against traveler’s diarrhea caused by enterotoxigenic Escherichia coli 
[36]. Because this composition was not a viable option for use in low- and middle-income 
countries, the technology was transferred to Vietnam to manufacture a simpler and cheaper 
variant containing only the killed WCs. However, because the Vietnamese regulatory agency is 
not approved by the WHO, this OCV has never been prequalified by the WHO. Another transfer 
was thus made to manufacture this WC vaccine in India, where WHO prequalification is 
possible. The Indian OCV was licensed under the trade name of ShancholTM in 2009 and 
received WHO prequalification on September 29, 2011.12 
 
The main characteristics of the three currently available OCVs, and of promising candidates at 
different stages of development, are presented in Table 1-1. Not mentioned are several other less 
advanced candidates. 
                                                        
12http://www.who.int/immunization_standards/vaccine_quality/pq_250_cholera_1dose_shantha/en/index.html  
10 
Table 1-1: Main characteristics of currently available and future OCVs 
Type WC-rCT B WC Modified WCa CVD 103-HgRb Peru-15 
Trade name Dukoral® ShancholTM mORC-Vax® NA CholeraGarde® 
Description Inactivatedc Inactivatedc Inactivatedc Live, attenuated Live, attenuated 
Components Whole-cell V. 
cholerae O1 
and 
recombinant CT 
B subunit 
Whole-cell V. 
cholerae 
O1/O139 
Whole-cell V. 
cholerae 
O1/O139 
V. cholerae O1, with 
94% deletion of gene 
encoding CT A1 
subunit and mercury 
resistance marker 
V. cholerae O1, 
genetically engineered to 
be nontoxigenic, 
nonmotile and 
nonrecombinational 
Number of doses 2, given 7-14 
days apart 
2, given 14 
days apart 
2, given 14 
days apart 
1 1 
Formulation/Buffer Liquid/yes Liquid/no Liquid/no Lyophilized/yes Lyophilized/yes 
Administration Diluted in ~1.5 
dl buffer using 
cup 
Undiluted, 
using oral 
syringe 
Undiluted, 
using oral 
syringe 
Diluted in 1 dl buffer 
using cup 
Diluted in 20-45 ml of 
buffer 
Shelf life (years) 3d 2+d 2d 2d, 3e >1d 
Protective efficacy 
(PE) (%) 
~60-85 66-67 67 79 NA 
Duration of 
protection (years) 
~2 2-3 2 NA NA 
Age groups (years) ≥2 ≥1 ≥2 ≥2 >9 months 
Price/dosef ~5g ≤1.85 ~0.75 ~1 (target price) NA 
WHO 
prequalification 
Yes Yes No No No 
First licensure 1993  2009 1997 (old 
formulation),  
2009 (new 
formulation) 
Clinical trials planned Clinical trials ongoing 
Licensed in >60 countries India Vietnam USA in 2014 NA 
Use since 
licensure 
>14 million 
doses 
NA >20 million 
doses 
NA NA 
Manufacturer Crucell/SBL 
Vaccines, 
Sweden 
Sanofi/Shanta 
Biotech, India 
Vabiotech, 
Vietnam 
PaxVax, USA VTI, USA, China 
aBased on Dukoral and technology transfer to Vietnam, several formulations followed since first vaccine was licensed 
in 1997 as ORC-Vax®; bManufactured by Berna Biotech AG, Bern, Switzerland, as Orochol/Mutachol until 2004; cBy 
heat or formalin; dAt 2-8°C; eAt -30°C; fPurchase price in USD considered for use by UN agencies; gDepending on the 
agreement with the implementing institution. Source: Chowdhury et al. [37], Qadri et al. [38], Shin et al. [39], Sur et 
al. [40,41], WHO [35] 
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1.8 Research on social, cultural and economic features of 
cholera and vaccine acceptance 
1.8.1 Population perceptions of illness and vaccination 
Successful public health interventions for disease control are in principle based on three pillars: 
(i) an efficacious intervention, such as a drug, a treatment plan or a vaccine, (ii) a functional 
health system to deliver or implement the intervention, and (iii) willingness among the target 
population to accept the intervention.  
 
Ironically, public perception of the importance of vaccination, especially against childhood 
diseases, has been waning in many high-income countries in Europe and North America due to 
the immensely positive impact vaccination has had on people’s lives over the past ~100 years. 
Because vaccination programs against previously much-feared child killers like measles, 
diphtheria or pertussis have been so successful, many people no longer believe in the benefit of 
vaccines or even oppose them [42]. The collective memory of the once terrible impacts of 
pathogens such as polio and tetanus on all ages has diminished dramatically over the past ~30 
years. Instead of being concerned about the negative consequences caused by vaccine-
preventable diseases, fears of people living in the industrialized world have mainly shifted away 
to the alleged severe side effects of vaccines [43]. Anti-vaccine movements ignore the scientific 
evidence regarding safety and efficacy of modern vaccines and often base their resistance on 
unethical or even fraudulent research.13 They have become powerful players and negatively 
influence public perception on vaccination by using the internet or engaging stars of film and TV 
to fuel resentment and resistance against vaccines [42,45]. As a consequence of such activities 
that undermine previous efforts to control, eliminate or even eradicate disease, measles 
morbidity and mortality, for example, has recently increased in the USA and the plan to 
eliminate this disease from Europe by 2010 failed [46].  
 
Compared to the industrialized world however, vaccines seem to be much more appreciated in 
low- and middle-income countries because many people still see or experience the serious 
consequences of infection with vaccine-preventable diseases every day. Meningococcal 
meningitis, for instance, contributes substantially to child morbidity and mortality in sub-
Saharan African countries that belong to the so-called meningitis belt.14 But vaccination 
programs have also suffered in the developing world, especially when not enough attention was 
                                                        
13See the recent ‘MMR Scare’ [40-42] as an extreme example of fraudulent research that has had a significant 
negative impact on global MMR vaccination coverage and consequently morbidity and mortality [44]. 
14http://www.who.int/immunization/topics/meningitis/en/  
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paid to potential unwillingness or even resistance of communities to accept vaccines [47-49]. 
Rumors about tetanus toxoid causing infertility have hampered national vaccination efforts in 
Africa [50,51]; programs were even brought to a halt because of an ignorance of local realities, as 
was the case with the global polio eradication campaign in Northern Nigeria [52,53].  
 
Hence, in addition to recognizing the importance of infrastructural, logistical and political issues 
for the success of immunization programs in low-income countries [54], consideration of local 
cultural concepts of illness among potential vaccine recipients and how these may affect vaccine 
acceptance is crucial [49,55,56].  
 
The influence of policy makers’ and communities’ perceptions on vaccine acceptance was 
assessed in various recent studies for cholera, shigellosis and typhoid fever in several Asian 
countries [55,57-65]. This research reaffirmed the importance of investigating the social and 
cultural contexts into which vaccines are introduced in order to better understand their effects 
on improving vaccination coverage [66]. However, no studies have been published yet that 
examine the influence of social and cultural features of cholera on vaccine acceptance in African 
settings. This includes attention to cultural variation within and across local communities and in 
gender dynamics [67].  
1.8.2 Economic evaluation of oral cholera vaccine use 
Economic evaluations are conducted to guide decision makers on making choices in the health 
sector between potentially available alternatives in the context of scarce resources. Economic 
evaluations compare the costs and outcomes of at least two alternative programs [68] (Table 
1-2).  
Table 1-2: Costs and consequences in economic evaluations 
Type of study Measurement/valuation of 
costs in both alternatives 
Identification of 
consequences 
Measurement/valuation of 
consequences 
Cost analysis  Monetary units None None 
Cost-
effectiveness 
analysis 
Monetary units Single effect of interest, 
common to both alternatives, 
but achieved to different 
degrees 
Natural units, e.g., life-years gained, 
disability-adjusted life-years (DALYs) 
saved, points of blood pressure reduction, 
etc. 
Cost-utility 
analysis 
Monetary units Single or multiple effects, not 
necessarily common to both 
alternatives 
Healthy years, typically measured as 
quality-adjusted life-years (QALYs) 
Cost-benefit 
analysis 
Monetary units Single or multiple effects, not 
necessarily common to both 
alternatives 
Monetary units 
Source: Adapted from Drummond et al. [68] 
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A series of studies have been published over the past two decades on the economic evaluation of 
using different OCVs in endemic and epidemic settings throughout the world [69-74]. More 
recently, the Disease of the Most Impoverished (DOMI) program has been at the forefront of 
economic evaluation research for cholera by conducting private demand studies, COI studies 
and examining cost-effectiveness (CE) and cost-benefit for OCV across several endemic settings 
[21,75-86]. Despite DOMI studies have shown that OCVs can be cost-effective in certain settings 
according to WHO criteria [87], further country-specific studies are required to provide national 
policy makers with local data on cholera-related costs and CE of OCVs before they can make an 
informed decision regarding the use of OCVs for cholera control [88]. 
 
Relating costs and consequences to determine economic efficiency, however, is not the only 
criterion for decision making on public spending for health; additional economic criteria as well 
as ethical and political criteria are relevant for priority-setting [89]. Since cost-effective 
interventions, for example, are not always affordable, it is important to differentiate cost-
effectiveness (value for money) from affordability (financial resources required). To determine 
affordability, budget impact analyses are required. Additional economic criteria are related to 
whether an intervention is a public good and whether it yields substantial externalities, which 
are classical justifications for public health intervention, because private markets could not 
supply them efficiently, just as in other sectors. Ethical considerations that may affect priorities 
include poverty, horizontal equity (equal treatment for people in equal circumstances), vertical 
equity (priority for people with worse problems) and the rule of rescue (priority of saving lives 
over interventions that do not make a big difference). The political criterion is related to the 
adequacy of demand, public attitudes and needs.  
1.9 Overview of research approaches 
1.9.1 Cultural epidemiology 
Although many studies in the published literature have examined people’s perceptions and 
behavior regarding diarrheal diseases, most of them have been done with a strong disciplinary 
focus, based on either medical anthropology [90-92] or classical or social epidemiology. 
 
Following the central paradigm of epidemiology that “patterns of disease in populations may be 
analyzed systematically to provide understanding of the causes and control of disease” [93], 
epidemiologists are mainly concerned with the collection of quantitative data and use of 
statistical tools. Epidemiological studies typically work with random samples drawn from a 
defined population and apply standardized questionnaires and/or use clinical examinations, 
laboratory analyses of biological specimens, etc., to acquire numerical information needed for 
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statistical analysis. Anthropologists, on the other hand, are primarily concerned with qualitative 
data and use methods for data collection based on ethnographic research. They focus more on 
local knowledge and contextual data to gain a deeper understanding of the perspective of 
patients or affected people and how consideration of their social, cultural, political and natural 
environment may affect illness- or health-related behavior. Research in anthropology involves 
focus group discussions, open-ended interviews, participatory mapping, participant 
observation, etc., and typically does not require large sample sizes as in epidemiological studies 
since the focus is clearly on in-depth information rather than on making decisions for public 
health based on statistical inferences. 
 
Despite the important contributions both disciplines have made to international public health, 
attempts to connect them have been limited [94]. A methodological approach called cultural 
epidemiology15 has been developed and implemented over the past two decades to address a 
persistent gap between both traditional disciplines [95,96]. This approach integrates qualitative 
and quantitative methods for interdisciplinary health research in order to harness the 
explanatory power of epidemiology and the local validity of anthropology.  
 
Cultural epidemiology is defined as the study of the distribution of locally valid representations 
of illness-related experience, meaning and behavior—i.e., sociocultural features of illness—in a 
population [96]. On the one hand it draws on medical anthropology, most notably Arthur 
Kleinman’s concept of illness explanatory models [98]. On the other, it uses tools and statistical 
techniques common to epidemiology to answer locally relevant descriptive, analytical or 
comparative questions for the benefit of public health (Figure 1-3). But compared to classical 
epidemiology that typically adopts the professional or outsider’s, i.e., etic, perspective, cultural 
epidemiology examines people’s ideas on illness and health-related behavior from the vantage 
point of the affected persons, thus making it an emic approach [99].  
 
                                                        
15The framework of cultural epidemiology that was used in this study refers to the work of Mitchell Weiss [95,96]. 
Other formulations of cultural epidemiology for health social science research have been described by James Trostle 
[94,97].  
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Figure 1-3: Multidisciplinary framework: contributions of epidemiology and anthropology to cultural 
epidemiology 
Source: Adapted from Weiss et al. [100] 
 
Semi-structured interviews based on the Explanatory Model Interview Catalogue (EMIC) 
constitute the principal tool for cultural epidemiological research. The EMIC framework 
provides a guide based on Kleinman’s original eight questions for eliciting patient explanatory 
models [98] (p. 106). EMIC interviews are used to assess sociocultural features of illness, 
operationalized as patterns of distress, perceived causes and help seeking (Table 1-3). EMIC 
interviews produce numerical and narrative data for integrated quantitative and qualitative 
analysis. 
Table 1-3: Operational formulation of sociocultural features of illness for cultural epidemiology 
 Experience Meaning Behavior 
Operationalized as  Patterns of distress Perceived causes Help seeking 
Categories related to  Problems and concerns; 
name of illness, symptoms, 
anticipated outcome; 
psychological, social, and 
economic impact; stigma, 
disclosure, and self-esteem; 
marriage prospects and 
marital relations, etc. 
Ingestion, psychological 
factors, psychosocial 
stressors and victimization; 
sanitation, hygiene, 
contamination, and health 
habits; infection, prior 
illness, constitutional 
factors; magico-religious 
forces; heredity; retribution 
of previous deeds, etc. 
Family support and home 
remedies; private practitioners 
and public clinics; Western-styled 
health professionals, 
paraprofessionals, and 
specialists; traditional healers of 
various types; past experience 
and current preferences, etc. 
Source: Adapted from Weiss [95] 
 
The design of a cultural epidemiological study typically includes an ethnographic component to 
derive locally valid categories—i.e., to adapt the EMIC interview to the local context and the 
Epidemiology
! Measures of
disease burden
! Risk factors and
determinants of
outcome
! Etic assessment
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! Relationship of
culture and illness
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! Locally relevant
concepts and
categories
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Cultural
epidemiology
! Descriptive and comparative accounts
of illness experience, meaning, and
behaviour
! Cultural determinants of occurrence,
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illness of interest—and a survey component to interview patients, community members, health 
care personnel and so forth. The first step in cultural epidemiological analysis is descriptive and 
clarifies the distribution of categories of distress, perceived causes and help seeking. In a second 
step, comparative analysis based on statistical testing examines which categories are similar or 
different between genders or between sites, etc. The analytical step involves uni- and/or 
multivariable testing, i.e., linear or logistic regression, to study how sociocultural features of 
illness affect health-related behavior, e.g., treatment delay, appropriate treatment seeking, 
vaccine acceptance, etc., or stigma.  
 
Integrated analysis of cultural epidemiological data requires importation of numerical variables 
and narrative texts into qualitative data analysis software and follows a deductive and inductive 
strategy to coding [101]. Narratives are transcribed from respondents’ accounts and imported in 
a precoded structure that reflects major interview items. This helps retrieve relevant text 
segments to clarify categories and their context and explain the nature of associations found in 
statistical analysis. Additional issues emerging from statistical or qualitative analysis may 
require coding of further themes. 
 
Cultural epidemiological studies using EMIC interviews have been conducted in a variety of 
settings in high-income as well as middle- and low-income countries to inform policy makers 
and public health professionals in the fields of mental health [102-106], chronic [107] and 
infectious diseases [108-110] as well as stigma and gender [111-116].  
1.9.2 Cost-effectiveness analysis 
The most commonly used method to measure the value of an intervention is the cost-
effectiveness analysis (CEA). CEA links costs and effects of a health intervention with reference 
to doing nothing or current practice by comparing the differences in costs with the differences in 
health outcomes. The difference in program costs between two alternatives that compete for the 
same resources divided by the difference in health outcomes, i.e., the additional cost required 
per additional unit of health benefit, is expressed as incremental cost-effectiveness ratio (ICER) 
[117]. The ICER to evaluate immunization programs is calculated by dividing incremental 
costs—calculated as the difference between costs of the vaccination program and costs of 
treatment saved due to the vaccination—by the difference in deaths, cases or disability-adjusted 
life-years (DALYs) averted. DALYs represent an aggregate measure combining mortality and 
morbidity by quantifying the number of years lost due to premature death and the number of 
years lived with disability. 
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Recommendations endorsed by the WHO commission on Macroeconomics and Health are 
frequently used to guide decision making about whether an intervention is cost-effective or not 
compared to one or several alternatives [117]. Results of CEAs, if expressed in ICERs per DALY 
averted, can be classified with regard to national per capita GDP [87]: an intervention is 
considered highly cost-effective if the ICER is less than per capita GDP, cost-effective if the 
ICER is between one and three times per capita GDP, and cost-ineffective if the ICER exceeds 
three times per capita GDP.  
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ST U D Y  D E S C R I P T I O N 
2.1 Rationale and framework for research 
Cholera remains a serious public health burden in low- and middle-income countries despite the 
promotion of safe water, improved sanitation, and health education (WASH) over the past 
decades. The World Health Organization (WHO) recommends the use of oral cholera vaccines 
(OCVs) as a supplementary measure for epidemic and endemic cholera control. In 2006, the 
WHO received a grant from the Bill & Melinda Gates Foundation, Seattle, USA, to work on the 
preemptive use of OCVs in populations at risk. Following an earlier demonstration project in 
urban cholera-endemic Mozambique [1-7], this grant made it possible to further examine how 
OCVs—in addition to WASH—can be used in a sustainable manner in countries with endemic 
cholera and to gain more evidence on the usefulness of establishing a global OCV stockpile.  
 
Zanzibar has been regularly affected by cholera since 1978. The government has proposed using 
OCVs for populations living at risk of recurrent outbreaks as a strategy for enhancing disease 
control. As a result, an agreement to establish a collaborative research project was signed in 
2oo8 between the WHO, the International Vaccine Institute (IVI), Seoul, Korea, the Swiss 
Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland, and the Ministry of Health 
and Social Welfare of Zanzibar (MoHSW). 
 
The project’s overall goal was twofold: (i) to reduce the burden of cholera on Zanzibar by 
vaccinating a target population of 50,000 residents living in cholera hotspots and (ii) to 
complement this intervention with a series of studies to address key research questions that 
remained unanswered from the demonstration project in Mozambique [8].  
 
In response to the need for detailed data on a variety of epidemiological aspects, and to inform 
public health policy regarding the use of OCVs for endemic cholera control, the project 
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embarked on a series of classical epidemiological studies under the scientific leadership of the 
IVI.1  
 
Consideration of social and cultural features of diarrheal illness and of people’s intention and 
actual behavior to use a vaccine is essential to improve and sustain community vaccination 
coverage of mass vaccination campaigns. Since no such studies for cholera and OCVs have yet 
been conducted in African settings, a socioeconomic and behavioral (SEB) study was conceived 
among the MoHSW, the WHO and the Swiss TPH. The latter assumed scientific leadership of 
this component of the project. 
2.2 Aims 
The overall aims of this thesis research were (i) to study social and cultural features of OCV 
acceptance from a community perspective and (ii) to assess the cost-effectiveness (CE) of the 
2009 OCV mass campaign in Zanzibar.  
 
Findings presented here should inform governments and ministries, in particular the Ministry 
of Health and Social Welfare of Zanzibar, regarding the introduction of an OCV as part of a 
sustainable and financially viable strategy to improve prevention and control of endemic 
cholera. 
2.3 Research questions and objectives 
Based on the two aims, this thesis project addressed the following general and specific research 
questions in the context of an OCV mass campaign in cholera-endemic communities in 
Zanzibar: 
 
• What are the social and cultural features of OCV acceptance? 
- What are the perceptions and essential features of cholera in the context of diarrheal 
diseases? 
- What is the anticipated OCV acceptance? 
- What is the actual OCV acceptance, i.e., uptake? 
- What are the social and cultural determinants of anticipated OCV acceptance and 
uptake? 
- What are the barriers to OCV uptake? 
                                                        
1Studies on cholera epidemiology, vaccine effectiveness, vaccine safety for pregnant women, herd protection etc., were 
conducted and have either been published [9-11] or are being written up for publication. 
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• Does use of an OCV in a mass vaccination campaign in Zanzibar provide value for money? 
- What are the public and private costs of illness (COI) due to cholera? 
- What are the costs of the OCV mass campaign? 
- What is the CE of using an OCV? 
 
Based on these questions, five objectives were defined that are reported in the next chapters:2 
 
Part I: Social and cultural features of OCV acceptance in Zanzibar3 
 
1. To clarify the social and cultural features of cholera with reference to diarrheal diseases, in 
particular shigellosis, among community residents before the vaccination campaign 
(Chapter 3). 
 
2. To identify the social and cultural determinants of anticipated acceptance of an OCV 
among community residents before the vaccination campaign (Chapter 4). 
 
3. To identify the social and cultural determinants of OCV uptake among community 
residents (Chapter 5). 
 
4. To evaluate the influence of social and cultural factors on OCV uptake and to identify the 
logistical, medical, social and system-related barriers to OCV uptake among community 
residents (Chapter 6). 
 
Part II: CE of oral cholera mass vaccination in Zanzibar 
 
5. To estimate public and private COI due to cholera, costs of the OCV mass campaign, and 
the CE of using OCVs in an endemic setting from a health care provider and a societal 
perspective (Chapter 7). 
 
                                                        
2These chapters constitute the core of this thesis and report findings as self-contained papers that have either been 
published in international peer-reviewed journals or are under review or have been prepared for submission. 
3Findings presented in Part I come from studies done among community residents in Zanzibar. Additional data on 
cholera and vaccine use that have been collected on the level of policy makers, allopathic and traditional health care 
professionals and formal and informal community leaders are currently being analyzed and written up and will be 
published as separate papers (lead investigator: Dr. Al Pach, IVI, Seoul, Korea). 
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2.4 Study setting 
Zanzibar consists of two major islands, Unguja (also named Zanzibar) and Pemba, and is 
situated in the Indian Ocean ~40 to 60 km off the coast of Tanzania, East Africa (Figure 2-1). In 
1964, shortly after independence from the British colonial powers, the archipelago of Zanzibar 
and Tanganyika formed the United Republic of Tanzania. As a semiautonomous polity within 
Tanzania, Zanzibar consists of five regions which are subdivided into ten districts, 50 
constituencies and 296 communities (so-called Shehias). The main islands cover ~2,557 km2 
(Unguja: ~1,651 km2, Pemba ~906 km2). Unguja is mostly flat and sandy while Pemba has hilly 
terrain that is fertile and heavily vegetated. The climate is humid tropical with a long (March to 
June) and a short rainy season (October to December). Mean temperature on Unguja varies 
between 21 and 33°C and monthly rainfall between 25 and 434 mm [10].  
 
Figure 2-1: Map of Zanzibar with the two main islands and the periurban and rural sites selected for 
study of social and cultural features of OCV acceptance 
Map: courtesy of the University of Texas Libraries (The University of Texas at Austin); Photos: C. Schaetti 
 
Rural community: Mwambe 
Periurban community: Chumbuni
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Approximately 1.2 million people live in Zanzibar and the population is growing rapidly.4 The 
inhabitants are predominantly Muslim and the main language is Kiswahili, but English is also 
widely used. According to the most recent household budget survey from 2004/2005, one-
fourth of the population had not received any education and the primary education net 
enrolment ratio amounted to 77% [13]. The majority (71 %) had access to piped water while a 
minority relied on drinking water from wells (27 %) and other sources like street vendors, 
rainwater, spring water, and open water sources (2 %) [13]. Fifty-three percent had access to pit 
latrines and 12 %, mainly living in urban areas, used a flush toilet. As a possible consequence of 
poor water supply and sanitation, street food sold in Pemba was found to be bacteriologically 
contaminated and unsafe for consumption [14]. 
 
Top three causes of admission to Zanzibar hospitals in 2007 were due to malaria (27.4% of all 
admissions), gastroenteritis (12.7%) and pneumonia (9.9%) [15]; in 2008, pneumonia was the 
top cause of admission (12.2%), followed by malaria (10.8%) and gastroenteritis/diarrhea 
(8.6%) [16]. Main causes of death in 2007 in rank order were related to malaria (18.4%), 
hypertension (8.5%), pneumonia (7.9%) and gastroenteritis (7.5%). In 2008, pneumonia 
(11.8%), hypertension (7.6%) and septicemia (7.0%) were the three top causes of death [16]. 
Main sources of help consulted are primary health care units (PHCU) which are situated within 
four kilometers of households for over 90% of the population. Monthly mean per capita 
expenditure for all goods and services was TZS 21,000 (~USD 18) in 2004/2005 with a 2.1% 
share for health-related expenditures [13]. Life expectancy at birth rose from 47 years in 1988 to 
57 years in 2002 [12]. 
 
Zanzibar has been affected by cholera since the days of the first pandemic in 1821. It was again 
reported in 1978 when an outbreak with 411 cases and 51 deaths affected two fishermen villages 
[17]. Thirteen outbreaks followed since then with almost annual episodes since the year 2000 
and with case-fatality rates (CFRs) ranging from 0% to 17%. Reyburn et al. reported an annual 
incidence of 0.5 cases per 1,000 population based on a review of routine surveillance data for 
the years 1997 to 2007 [11]. A seasonal pattern can be observed that follows the rainy seasons 
when widespread flooding occurs; this has recently been confirmed by a study that linked 
cholera incidence to rainfall and temperature [10]. Such environmental conditions, together 
with the scarcity of safe drinking water and a generally poor, and sometimes even lacking 
sanitation infrastructure, frequently expose the majority of inhabitants on both islands to an 
increased risk of waterborne diseases. 
                                                        
4Intercensal annual growth rates (1988-2002) varied from 2.1% to 4.5% [12]. 
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2.5 Research instruments and data analysis strategies 
The following sections give an overview of the instruments and data analysis approaches used. 
Detailed descriptions are included in the respective chapters in Part I and II.  
 
All instruments were developed in English. Translation into Kiswahili and back translation into 
English was done by language teachers from the State University of Zanzibar. Instruments were 
only finalized after pilots had been done in areas adjacent to the study communities and any 
remaining issues had been resolved. 
2.5.1 Part I: Social and cultural features of OCV acceptance 
A semi-structured interview based on the Explanatory Model Interview Catalogue (EMIC) was 
employed to study social and cultural features of cholera and shigellosis. The EMIC interview 
was developed based on a series of focus group discussions with community residents and 
several meetings with local social scientists and health care professionals (Appendix 9.2). Since 
people without current diarrhea, rather than patients, were the focus of research, clinical 
vignettes were developed and formulated in an easily understandable language to describe a 
local person suffering from cardinal somatic symptoms of cholera and shigellosis, respectively 
(Appendix 9.3).  
 
The EMIC interview examined illness-related experience, meaning and behavior operationalized 
as categories of distress, perceived causes and help seeking [18]. Categories of distress were 
elicited in relation to somatic symptoms not mentioned in the vignette, psychosocial problems 
and financial issues that may have an impact on patients. To elicit perceived causes, 
respondents were questioned about their views and opinions on why and how they think one 
can get the illness with regard to ingestion- and behavior-related factors, and environmental 
and traditional/magico-religious causes. To find out more about sources of help seeking, 
respondents were asked to identify and assess health care providers, including locally available 
allopathic and traditional forms of treatment, which patients described in the vignette would 
likely consult. Possible options for self treatment at home were also elicited. Separate sections 
inquired about sociodemographic characteristics, previous experience with vaccines and 
whether respondents would swallow a vaccine against cholera if it was made available at no cost, 
which was the case during the mass vaccination campaign, and at three different price levels. 
The prevaccination EMIC interview was slightly adapted to the postvaccination phase and a new 
section on potential barriers to vaccination included.  
 
Quantitative data were double-entered in Epi Info and cleaned before importation into 
statistical analysis software (Stata, SAS). Clarification of the relative prominence of categories of 
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distress, perceived causes and help seeking involved a weighted coding of responses, based on 
the approach and rationale used in many cultural epidemiological studies and recommended for 
analysis of EMIC interviews [18]. A value of 3 was assigned if a category was identified as most 
troubling, most important or most useful; a value of 2 if a category was reported spontaneously 
without probe; a value of 1 if a category was reported after probing only; and a value of 0 for no 
response. This coding facilitated calculation of the mean prominence for each category.  
 
Descriptive analyses compared mean prominence for each category between site and gender 
using the nonparametric Wilcoxon test. Numerical variables were compared using the t test; 
categorical variables were compared using the Pearson Chi2 of Fisher’s exact test. Analysis of 
determinants of vaccine acceptance used uni- and multivariable logistic regression analysis. 
 
Narratives for each question were written down in Kiswahili during the interview, translated 
into English and typed in word processor software by using templates with a precoded structure 
according to interview items. Narratives were then automatically coded upon importation into 
qualitative data analysis software (MAXQDA). Importation of selected quantitative variables 
into MAXQDA enabled integrated analysis of numerical findings based on statistically 
significant relationships. 
2.5.2 Part II: CE of oral cholera mass vaccination 
Treatment of cholera patients in Zanzibar is usually done in temporary cholera treatment 
centers (CTCs) that are erected in public health facilities in the vicinity of the outbreak. 
Questionnaires were developed based on WHO guidelines [19] to elicit fixed and variable public 
COI from health care providers and public health officials; private direct and indirect COI were 
elicited from patients (or their caregivers) (Table 7-1). To estimate costs of the mass vaccination 
campaign, relevant records were reviewed and reports collected from local and international 
public health experts and non-governmental organizations (NGOs). Parameters on 
epidemiology and vaccine performance, such as protective efficacy, duration of protection etc., 
were obtained from the mass vaccination database developed by the IVI, or if unavailable, from 
published studies or experts. 
 
All data were entered into Microsoft Excel for analysis of total and average costs and to develop 
a CE model based on a study from Bangladesh [20]. Incremental cost-effectiveness ratios 
(ICERs) per death, per case and per disability-adjusted life-year (DALY) averted were calculated 
from the health care provider and the societal perspective. Incremental costs from the health 
care provider perspective were calculated as the difference between costs of the vaccination 
program and public COI saved due to the vaccination. Private direct COI saved were added to 
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the model from the societal perspective. The number of deaths, cases or DALYs averted was 
equal to the difference in numbers with and without the vaccination program. Relevant CE 
model parameters like incidence, protective efficacy, OCV purchase price etc. were varied in 
one-way sensitivity analyses to assess the influence of parameter uncertainty on outcomes.  
2.6 Study design 
2.6.1 Part I: Social and cultural features of OCV acceptance 
Based on a review of epidemiological data from recent cholera outbreaks in Zanzibar, the mass 
vaccination campaign was planned to take place in selected periurban and rural districts on both 
islands. The periurban Shehia of Chumbuni (Unguja) and the rural Shehia of Mwambe (Pemba), 
both representing core areas of the mass vaccination campaign, were selected as study 
communities (Figure 2-1). Both sites are described in detail in Table 3-1. 
 
A cross-sectional cultural epidemiological study was repeated in the designated periurban and 
rural study communities (Figure 2-2). The study began in 2008 with a preparatory phase to 
develop and test an EMIC interview for the prevaccination survey. A random sample of 
community residents aged ≥18 years with an equal gender ratio was drawn. After completion of 
the mass vaccination campaign in early 2009, two new samples of vaccinated and unvaccinated 
adults were randomly drawn from the same two communities based on the vaccination 
database; the prevaccination EMIC interview was modified and piloted before use in the 
postvaccination survey. 
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Figure 2-2: Outline of the repeated cross-sectional design for community study with EMIC interviews 
F: female gender, M: male gender 
 
The sample size calculation for the pre- and postvaccination EMIC interview surveys was based 
on the comparison of mean prominence of categories of distress, perceived causes, and help 
seeking between periurban and rural sites and between female and male gender. To detect a 
difference of 0.5 between prominence means with equal standard deviations of 1.5, at a level of 
95% significance and 80% power, a sample size of at least 164 respondents for each group was 
required. This calculation was based on a two-sample t test assuming a worst-case scenario, i.e., 
no underlying distribution in the data, which requires that the sample size derived from the t 
test (n=142) be divided by 0.864 [21]. 
2.6.2 Part II: CE of oral cholera mass vaccination 
Cost data were collected in 2009 based on primary and secondary data sources. Private COI 
were collected from a sample of ~100 laboratory-confirmed cholera cases from Pemba. Public 
COI from three cholera outbreaks were obtained from local experts and public health officials. 
Costs of the mass vaccination campaign were obtained from implementers, i.e., from the WHO 
(headquarters and consultants) and the local Expanded Program on Immunization (EPI). 
2.7 Ethics 
The work presented in this thesis has been reviewed by internal and external scientific experts. 
The protocol on social and cultural determinants of OCV acceptance [22] and the protocol on 
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the CE of using OCVs in Zanzibar have both been reviewed and approved by the WHO Research 
Ethics Review Committee and the MoHSW Ethics Committee. The Ethics Committee of Basel 
(EKBB) was also informed about both protocols and no ethical concerns were raised.  
 
Participants were informed about study aims and objectives and written consent was obtained 
from all respondents from the general population and from patients and caregivers. All data 
were handled with utmost care and confidentiality and made anonymous before analysis and 
reporting. 
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Abstract 
Background 
Responding to the high burden of cholera in developing countries, the WHO now considers 
vaccination as a supplement to the provision of safe drinking water and improved sanitation in 
the strategy for cholera control in endemic settings. Cultural concepts of illness affect many 
aspects of public health. In the first step of a two-step strategy to examine determinants of 
cholera vaccine acceptance, this study identified social and cultural features of diarrheal illness 
for cholera control in endemic communities.  
 
Methods 
A cultural epidemiological study with locally adapted vignette-based interviews was conducted 
in two cholera-endemic communities of Zanzibar. A random sample of unaffected periurban 
(n=179) and rural (n=177) adults was interviewed to study community ideas of cholera and 
shigellosis, considering categories of distress, perceived causes, and help-seeking behavior. 
 
Results 
Cholera was recognized by 88%. Symptoms of dehydration were most prominent in reports at 
the periurban site. Interference with work leading to strain on household finances was 
frequently emphasized. Dirty environment was the most prominent perceived cause, followed by 
unsafe drinking water and germ-carrying flies. Causes unrelated to the biomedical basis of 
cholera were reported more often by rural respondents. Rural women had more difficulty (20%) 
to identify a cause than men (7.1%, p=0.016). Periurban self treatment emphasized rehydration; 
the rural community preferred herbal treatment and antibiotics. Shigellosis was recognized by 
70%. Fewer regarded it as very serious compared with cholera (76% vs. 97%, p<0.001) and 
regarded it as less likely to be fatal (48% vs. 78%, p<0.001). More respondents could not explain 
causes of shigellosis (23%) compared with cholera (7.3%, p<0.001). Community respondents 
less frequently identified dehydration and contagiousness for shigellosis. Government facilities 
were preferred health care providers for both conditions.  
 
Conclusions 
This study clarified local views of cholera and shigellosis relevant for diarrheal disease control in 
Zanzibar. The finding that rural women were less likely than men to specify causes of cholera 
suggests more attention to them is required. Better health education is needed for cholera in 
rural areas and for shigellosis in general. This study also identified variables for subsequent 
analysis of social and cultural determinants of cholera vaccine acceptance. 
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3.1 Background 
Cholera is an intestinal disease characterized by acute and profuse watery diarrhea, caused by 
the bacterium Vibrio cholerae O1 or O139. A total of 190,130 cases and 5,143 deaths globally 
were reported to the World Health Organization (WHO) in 2008 [1], which is an underestimate; 
the annual burden is likely to exceed 3 million episodes and over 100,000 deaths [2,3]. The 
approach to control involves treatment of patients with rehydration and prevention of new 
cases, based on improved sanitation, hygiene and safe water supply. Because of persistence of 
cholera as a public health problem, the WHO now recommends vaccines as an additional tool to 
control cholera in endemic areas [3].  
 
Cultural concepts about illness and how to treat and prevent it are important for many aspects 
of public health. The role of various social and cultural factors (e.g., sociodemographic 
characteristics, gender, urban and rural setting, and cultural concepts of illness and treatment) 
has practical implications for behavior, public health, and disease control that need to be 
considered. Such factors are also likely to be especially important considerations for the 
acceptance and demand for vaccines [4-7]. Effective disease control with a vaccine requires not 
only an efficacious vaccine and health system to deliver it, but also recognition among the 
general population of its benefits and their willingness to use such a vaccine [8]. Consideration 
of cultural concepts of cholera and of a comparable serious disease, such as shigellosis, which 
has both similar and distinctive features, may help to formulate effective strategies, general and 
specific, for cholera control. 
 
Studies have begun to address questions of vaccine acceptance and demand for diarrheal 
diseases, including recent research on typhoid fever and shigellosis in Asian countries [9-13], 
but not yet for cholera in Africa. Such research requires consideration of how cultural concepts 
of cholera affect acceptance and demand for a vaccine. To achieve that, two steps are essential: 
First, it is necessary to identify social and cultural features of the disease, and in a second step to 
explain how these features of cholera influence vaccine acceptance. This study was concerned 
with the first of these two questions, and the second will be addressed in a subsequent paper.  
 
Fieldwork was undertaken in Zanzibar, motivated by the interest of the Ministry of Health and 
Social Welfare (MoHSW) in using a cholera vaccine for control in endemic periurban and rural 
areas of the archipelago. Because shigellosis, caused by enteropathogenic Shigella spp., is also 
endemic, and it has a profile of symptoms different from cholera, it was included for 
comparative study of local experience, meaning and preferred sources of help for diarrheal 
illness.  
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Specific aims of the study were (i) to examine the variety and distribution of social and cultural 
views of cholera, (ii) to compare these views in periurban and rural endemic communities, and 
(iii) to identify common and distinctive features of cholera and shigellosis that clarify how well 
differentiated these conditions are in these communities.  
3.2 Methods 
3.2.1 Setting and study sites 
The survey was conducted from June to August 2008 in Zanzibar, United Republic of Tanzania. 
This Indian Ocean archipelago consists of two major islands—Unguja and Pemba—inhabited by 
a rapidly growing population of ~1.2 million Kiswahili-speaking people, who are predominantly 
Muslim. Medical morbidity in the population of Zanzibar mainly results from communicable 
diseases like upper respiratory tract infections, including pneumonia (33% of outpatient visits to 
primary and secondary hospitals in 2008), malaria (9.7%) and diarrheal diseases (8.6%) [14]. 
According to the latest Tanzanian national census (2002), the health situation on the islands has 
been improving, and the life expectancy at birth rose from 47 to 57 years between 1988 and 
2002 [15]. 
 
A periurban and a rural community (locally termed Shehia) in core areas for a subsequent mass 
vaccination campaign were selected as study sites. This campaign with the killed whole-cell oral 
cholera vaccine Dukoral® was conducted in January and February 2009. Interviews for this 
study were conducted simultaneously in the periurban Shehia of Chumbuni and the rural Shehia 
of Mwambe. A description of the study sites is given in Table 3-1. Both Shehias are served by a 
primary health care unit within walking distance, which is staffed with nurses and stocked with 
basic drugs and equipment mainly for outpatient treatment [16].  
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Table 3-1: Overview of study sites 
  Periurban site   Rural site 
Administrative structure    
Community (Shehia) Chumbuni  Mwambe 
District  Urbana  Mkoani 
Island Unguja  Pemba 
Population estimates    
Number of inhabitantsb 10,869  8,164 
Population density 15,300/km2  800/km2 
Characteristics    
Environment Unplanned, slum-like extension of the 
capital, situated along a main road, 
narrow alleys, sandy ground, few trees 
and shrubs, few plots for farming  
Coastline community with widely 
scattered hamlets, lush green 
vegetation, livestock, cassava, banana, 
paddy rice and coconuts 
Main housing structure Brick houses, corrugated iron roofs  Mud houses, thatched roofs 
Access toc (%)    
Electricity 34  6.2 
Private or community piped water 84  59 
Public wells 8.1  39 
Latrines 70  32 
No access to toilet facilities 7.0  57 
Economyc    
Main economic activities Informal business, government 
employees 
 Fishing, farming 
Monthly median per capita expenditure USD 22.6  USD 17.5 
Annual incidence of cholera per 1,000 
populationd    
Mean (standard deviation)  2.9 (1.7)  2.5 (6.0) 
Median (range) 2.2 (1.3-5.7)  0 (0-14.8) 
Annual incidence of shigellosis per 1,000 
populatione    
Mean (standard deviation) 4.6 (1.6)  1.9 (0.3) 
Median (range)  4.9 (2.9-6.1)  2.0 (1.7-2.2) 
aDespite belonging to the Urban district, this community is of periurban character; bCensus data from cholera control 
research project, 2008; cDistrict-level data from Zanzibar Household Budget Survey, 2004/5 [16]; dEstimates (2002-
2007) from Reyburn et al. (unpublished data) and WHO Cholera Country Profile for Zanzibar, 2006; eDistrict-level 
estimates (2006-2008) from health facility-based surveillance [14,36] 
3.2.2 Research framework and instrument 
Among the various formulations of cultural epidemiology for health social science research [17], 
this study is based on an approach for examining the distribution of community ideas of illness-
related experience, meaning and behavior [18,19]. A semi-structured Explanatory Model 
Interview Catalogue (EMIC) interview was developed to study community views of cholera and 
shigellosis in a periurban and rural community of Zanzibar. These EMIC interviews produce 
complementary data sets with numeric data for quantitative analysis and illness narrative data 
for qualitative analysis [20].  
 
42 
A first version of the interview was drafted in English during several scientific workshops and 
translated locally into Kiswahili. A series of focus group discussions and a field assistant training 
workshop with piloting of the instrument among people living adjacent to the study 
communities followed. This was crucial to further refine the EMIC interview with regard to 
clarity, field applicability and questions concerning translation. Because people without a 
current diarrheal disease were interviewed, rather than cases, the conditions that were the focus 
of the interview were introduced as clinical vignettes. For each condition, the respondent was 
asked to consider the case of a person typical of community residents with pathognomonic 
somatic symptoms presented in simple, easily understandable terms (see Appendix 9.3). The sex 
of the vignette and respondent were matched. All questions of the interview that was based on 
the vignette referred to the diarrheal illness of the person described in the vignette. 
 
Selected sociodemographic variables were recorded at the outset before enquiring about illness-
related experience, meaning and behavior operationalized as categories denoting patterns of 
distress (referring to additional somatic symptoms not mentioned in the vignettes and 
psychosocial problems), perceived causes, self treatment at home, and outside help seeking. The 
selection of the most relevant locally valid categories of distress, perceived causes, and help-
seeking behavior required for a meaningful description of the insider’s perspective was based on 
discussions with local researchers, field workers and focus group discussions among purposively 
selected community residents.  
3.2.3 Study design and participant selection 
This cross-sectional survey was conducted prior to a mass oral cholera vaccination campaign to 
provide baseline data on community views of diarrheal illness in areas of Zanzibar at high risk 
for cholera among unaffected adults [21]. A simple random sample of 180 houses per site was 
drawn based on enumerated houses from an existing geographic information system for the 
periurban and a census database for the rural site. Sampled periurban houses were approached 
with the help of aerial photographs and a global positioning system device. Sampled houses in 
the rural community were located through census house numbers nailed on doorframes. If the 
house selected for sampling did not contain dwellings (e.g. if it was a business place, mosque or 
under construction), then the field teams would move on to the house which was closest to the 
front door of the originally selected house. If the second house was not inhabited either, then a 
third house was identified following the above procedure, and so forth until a household with 
eligible participants was found. A household is defined by people sharing the same kitchen or 
pot. Eligible participants had to be 18 years or older and willing enough to give time for an 
interview of approximately one hour duration.  
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Three field teams plus a coordinator on both islands were recruited by the MoHSW and trained 
in a ten-day workshop to conduct this survey. Each team consisting of an interviewer and a note 
taker completed on average two interviews per day. Written informed consent was obtained 
from all participants prior to the interview and no compensation was offered to them. 
3.2.4 Data management and analysis strategy 
For cholera, the categories related to illness experience, meaning and help-seeking behavior 
were coded for their prominence with a value of 2 after a spontaneous response, a value of 1 
after a probed response and a value of 0 if not considered at all to reflect the response style. An 
additional value of 3 was assigned to the category of response if the category was considered the 
most troubling category of distress, the most important perceived cause or the most helpful self 
treatment or source of help. The cumulative prominence by respondent (ranging from 0-5) was 
then used to calculate the mean prominence for each category. Thematically similar individual 
categories were grouped under specific headings (e.g. related to dehydration among somatic 
symptoms) for the analysis of broader concepts of experience, meaning and behavior. 
Calculation of the grouped prominence followed the same procedure as with the individual 
variables. To identify significant differences for cholera between the two sites and between 
sexes, a non-parametric statistic, the Wilcoxon rank-sum test, was used when comparing 
prominence variables; the Pearson Chi2 and Fisher’s exact test were applied when comparing 
proportions. This particular approach to comparing prominence, which has been widely used in 
other cultural epidemiological studies, takes more information about a category into account 
than a simple comparison of frequencies of report without considering how they are reported.  
 
A similar series of questions were asked to elicit shigellosis-related illness experience, meaning 
and help-seeking behavior. The same categories that were coded for cholera were also coded for 
shigellosis. Comparative analysis between the two conditions considered only spontaneously 
reported categories, because the interview coded only spontaneous responses for shigellosis. 
The proportion of positive responses by category was tabulated individually for each vignette, 
and for a report in both vignettes. To determine whether a category was associated more with 
one vignette than the other, McNemar’s Chi2 test for paired data was used. To examine whether 
or not individual categories were differentiated between both conditions, Cohen’s kappa was 
calculated. The kappa statistic indicates the strength of agreement for a categorical assessment, 
corrected for agreement by chance. The analysis identified the two conditions as distinct for a 
category if the kappa coefficient was below 0.4, a level commonly accepted as a threshold for 
moderate agreement [22].  
 
Narrative information was written down during the interview in Kiswahili, then translated into 
English and typed in a word processor. The qualitative software MAXQDA, version 2007, was 
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used for managing the textual data and to facilitate further analyses of findings from 
quantitative data. Quantitative data was entered twice and verified in Epi Info software, version 
3.4.3, and cleaned. Statistical analyses were done with Stata, version 10. 
3.2.5 Sample size 
The sample size calculation was based on comparison of mean prominence of categories of 
distress, perceived causes, self treatment and outside help seeking for periurban–rural and 
female–male differences. The detection of a difference of 0.5 between prominence means with 
equal standard deviations of 1.5 at 95% significance and 80% power required a sample size of at 
least 164 individuals per independent group. This calculation was based on a two-sample t test 
assuming no underlying distribution in the data [23]. Ten percent was added to this sample size 
to compensate for missing data. 
3.2.6 Ethics 
The protocol describing the study presented here was cleared by the WHO Research Ethics 
Review Committee and the MoHSW Ethics Committee in Zanzibar and later published in an 
open access journal to make it freely available to the research community [21]. Only individuals 
who gave written informed consent were interviewed. All data were handled with strict 
confidentiality and made anonymous before analysis. 
3.3 Results 
3.3.1 Sample characteristics 
A total of 356 interviews were conducted, with very few people among the visited households 
who refused to be interviewed. The sociodemographic characteristics of the sample are 
summarized by site in Table 3-2. All respondents were Tanzanians and Muslims except a 22-
year-old woman from Chumbuni who was Christian. The majority of the periurban sample 
consisted of married housewives and men doing small businesses. Periurban residents lived in 
bigger families than their rural counterparts and were also better educated. The rural sample in 
contrast consisted primarily of married persons mostly active in farming, fishing and also small 
informal businesses.  
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Table 3-2: Sample characteristics of study respondents from the general adult population of 
Zanzibar, n=356 
  Periurban site, n=179   Rural site, n=177 
Sex (%)      
Female 48.6  52.0 
Age (years)      
Mean (standard deviation) 36.5 (14.1)  34.4 (14.9) 
Median (range) 35 (18-85)  30 (18-90) 
Marital statusa ** (%)      
Never married 23.5  11.9 
Married 68.7  84.2 
Separated 0.6  0.0 
Divorced 4.5  3.4 
Widowed 2.8  0.6 
Household sizeb *** (number of persons)      
Mean (standard deviation) 7.4 (3.2)  6.2 (2.7) 
Occupationa *** (%)      
Agriculture 4.5  57.1 
Fishing 2.2  12.4 
Self-employment 22.3  11.9 
Formal employment 11.7  4.0 
Housewife 33.5  9.0 
Casual labourer 2.2  0.6 
Student 14.5  4.0 
Not active/retired 8.9  1.1 
Highest educational level attainedc *** (%)      
No education 9.5  4.5 
Koranic school 10.1  34.5 
Primary school 23.5  33.9 
Secondary school 54.2  25.4 
Higher education 2.8  1.7 
Educationc *** (years)      
Median (range) 10 (0-16)  6 (0-20) 
Household income (%)      
More regular and dependable 59.8  52.0 
Less regular and dependable 40.2   48.0 
aPearson Chi2 or Fisher’s exact test; bt test; cWilcoxon test; *p≤0.05, **p≤0.01, ***p≤0.001 
3.3.2 Recognition and importance of illnesses and past episodes 
The vignette describing an adult person with symptoms of acute watery diarrhea was named by 
88.2% of the sample as kipindupindu, which is the Kiswahili name for the disease entity cholera. 
The rural villagers recognized cholera less often than the periurban residents (80.8% vs. 95.5%, 
p<0.001, Chi2 test). Other names given by rural villagers were kuharisha kawaida for normal 
diarrhea (6.2%) and kuharisha maji for watery diarrhea (4.0%) while 6.2% could not identify 
the condition at all. The condition described in the shigellosis vignette was identified by 69.9% 
of the respondents as kuharisha damu, which refers to the disease entity bloody diarrhea. While 
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12.9% could not name it at all, 19 individuals (5.3%) confused the case presented in the 
shigellosis vignette with cholera. 
 
The perceived severity and likely fatality for cholera and shigellosis vignettes was assessed in the 
periurban and rural areas. Cholera was more frequently said to be “very serious” (96.6%) than 
shigellosis (76.1%, p<0.001, McNemar’s Chi2 test). Cholera was also more often anticipated to 
be “usually fatal without treatment” (77.5%) than shigellosis (47.8%, p<0.001, McNemar’s Chi2 
test). Although there was no difference in perceived severity for cholera at the two sites, for 
shigellosis more periurban respondents considered it very serious (86.0%) than rural 
respondents (66.1%, p<0.001, Chi2 test). Periurban respondents more frequently anticipated 
fatality for cholera (84.4%) than rural respondents (70.6%, p=0.002, Chi2 test), and periurban 
respondents were also more likely to anticipate fatality for shigellosis (65.4%) than rural 
respondents (29.9%, p<0.001, Chi2 test). 
 
When asked about previous experiences of the condition described in the cholera vignette, 5.3% 
of the total sample reported an individual episode. Stratified analyses revealed a significant 
difference between the periurban and rural community (2.8% vs. 7.9%, p=0.032, Chi2 test), but 
not between women and men (3.4% vs. 7.3%, p=0.094, Chi2 test). 
3.3.3 Patterns of distress for cholera 
Weakness was reported as the most prominent somatic symptom by the total sample (Table 3-3, 
upper panel). Categories related to dehydration, none of which were mentioned in the vignette, 
featured more prominently in the periurban site. This difference was primarily due to 
unconsciousness, a symptom which was identified by almost one-third of the periurban sample 
as most troubling. The respondents’ views regarding this category were related to the loss of 
body fluid or the advanced stage of the illness. Almost one-fifth could not report any other 
somatic symptom apart from the ones described in the vignette. Symptoms related to shigellosis 
were probed for consistency under the cholera vignette but were less often mentioned 
spontaneously or identified as most troubling and hence yielded a lower prominence than 
symptoms of general gastroenteritis or dehydration. 
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Table 3-3: Somatic symptoms and psychosocial problems for a cholera vignette in periurban and 
rural Zanzibar, n=356 
  Periurban site, n=179   Rural site, n=177  
 How reported?b   How reported?b   
Categorya 
Total 
reported 
% 
Fraction 
spon. 
Most 
troubling 
% 
Mean 
prom.c  
Total 
reported 
% 
Fraction 
spon. 
Most 
troubling 
% 
Mean 
prom.c  
Somatic symptoms                   
Related to general 
gastrointestinal illness 
98.9 0.81 14.5 2.23  99.4 0.67 16.4 2.15  
Abdominal pain/discomfort 91.1 0.47 2.8 1.42  88.7 0.06 6.2 1.13 *** 
Headache 64.8 0.02 0.0 0.66  55.4 0.02 0.6 0.58  
Loss of appetite 92.2 0.20 1.7 1.16  83.6 0.06 1.1 0.92 *** 
Nausea 87.7 0.04 0.6 0.93  88.1 0.03 0.6 0.93  
Weakness 96.6 0.69 9.5 1.92  97.7 0.64 7.9 1.84  
Related to shigellosis 97.2 0.20 3.9 1.28  96.0 0.10 13.0 1.45  
Abdominal cramps 76.5 0.11 2.8 0.93  75.1 0.08 6.8 1.01  
Bloody stool 23.5 0.14 0.6 0.28  50.3 0.03 2.8 0.60 *** 
Fever 82.7 0.11 0.6 0.93  87.0 0.03 1.7 0.95  
Pus in stool 8.9 0.06 0.0 0.09  37.9 0.00 0.0 0.38 *** 
Rectal pain 69.3 0.00 0.0 0.69  73.4 0.00 1.7 0.79  
Related to dehydration 98.3 0.31 46.9 2.70  98.3 0.51 18.6 2.04 ** 
Confusion 87.7 0.01 2.2 0.95  81.9 0.01 2.3 0.89  
Palpitations 84.4 0.03 9.5 1.16  73.4 0.02 1.7 0.80 *** 
Loose skin 90.5 0.17 1.1 1.09  88.1 0.24 0.6 1.11  
Sunken eyes 93.9 0.21 0.6 1.15  96.0 0.41 0.6 1.37 *** 
Unconsciousness 92.7 0.04 32.4 1.94  90.4 0.06 11.3 1.30 *** 
Very thirsty 76.5 0.03 1.1 0.82  78.5 0.06 2.3 0.90  
Miscellaneous 25.1 1.00 1.7 0.55  38.4 1.00 1.7 0.82 ** 
Other symptoms 10.1 1.00 1.1 0.23  16.4 1.00 0.6 0.34  
Cannot say 15.1 1.00 0.6 0.32  22.0 1.00 1.1 0.47  
Psychosocial problems                   
Social impact 99.4 0.88 36.9 2.97  99.4 0.91 50.3 3.41 ** 
Disruption of health 
services 
48.0 0.01 1.7 0.54  88.1 0.01 1.7 0.94 *** 
Fear of infecting others 83.8 0.28 2.2 1.14  72.9 0.22 6.8 1.09  
Fear of isolation from others 62.6 0.36 8.4 1.10  53.1 0.12 14.7 1.03  
Interference with social 
relationships 
65.4 0.08 3.9 0.82  74.6 0.60 2.8 1.28 *** 
Interference with work/daily 
activities 
96.6 0.73 20.7 2.30  97.2 0.72 24.3 2.40  
Emotional impact 100.0 0.75 10.1 2.06  94.9 0.45 11.3 1.72 *** 
Sadness, anxiety, worry 100.0 0.75 10.1 2.06  94.9 0.45 11.3 1.72 *** 
Financial impact 99.4 0.62 52.5 3.18  99.4 0.73 38.4 2.88  
Costs  
(transport, food, drugs) 
97.2 0.08 34.1 2.07  96.0 0.32 13.6 1.67  
Loss of family income 98.3 0.58 18.4 2.11  92.7 0.52 24.9 2.16  
aCategories ordered alphabetically within each group (bold). Categories reported by less than 5% not listed; bColumns 
indicate percentage of reported categories, fraction of spontaneously mentioned categories and whether a category 
was identified as most troubling; cMean prominence based on values assigned to each reported category (0=not 
reported, 1=reported after probing, 2=reported spontaneously, 3=identified as most troubling); Wilcoxon test used to 
compare mean prominence between both sites (*p≤0.05, **p≤0.01, ***p≤0.001) 
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When assessing the potential impact of cholera on a person’s life, interference with work or daily 
activities was ranked as the highest category in both sites, followed by financial and emotional 
distress (Table 3-3, lower panel). The disruption of local health services was rated as the least 
important problem overall, but it was seen more as a problem in the rural community. The 
spontaneous account of a 75-year-old man from Chumbuni indicates how respondents describe 
the impact of cholera:  
“It affects life in general. Emotionally, the patient thinks that he is going to die. Also, financially, he 
will spend a lot of money to buy medicine and at the same time he cannot work because of the 
disease.”  
The emotional impact was more prominently expressed in the periurban community, where the 
fraction of spontaneous replies for this category was higher. Despite this significant difference, 
the dangerousness of cholera, especially in relation to the possibility of death as exemplified in 
the statement above, featured equally in both communities. 
3.3.4 Perceived causes for cholera 
A dirty environment (mazingira machafu), related to general in- and outdoor dirtiness, was by 
far the most prominently reported perceived cause overall, but particularly notable in the 
periurban site (Table 3-4). Among the causes related to ingestion, which were the second most 
prominent group in both sites, drinking contaminated water was ranked highest. This category 
was coded when respondents mentioned drinking unboiled or dirty water, or water containing 
feces—some respondents explicitly mentioned cholera bacteria. Drinking contaminated water 
ranked as the second most prominent cause in total followed by flies, which were seen as disease 
transmitters in both communities. Flies, which can actually transmit V. cholerae [24,25], were 
mostly mentioned in connection with uncovered, i.e. unprotected, food, which was more 
prominently reported in the periurban community:  
“Yes, because usually flies carry dirt and spread it everywhere, especially in the food.” (Housewife 
from Chumbuni, 32 years old).  
“It is possible that the flies coming from the toilet contaminate the food.” (Male coffee seller from 
Mwambe, 50 years old).  
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Table 3-4: Perceived causes for a cholera vignette in periurban and rural Zanzibar, n=356 
  Periurban site, n=179   Rural site, n=177  
 How reported?b   How reported?b   
Categorya 
Total 
reported 
% 
Fraction 
spon. 
Most 
important 
% 
Mean 
prom.c  
Total 
reported 
% 
Fraction 
spon. 
Most 
important 
% 
Mean 
prom.c  
Ingestion 98.3 0.61 17.3 2.11  96.6 0.37 22.6 2.00 * 
Drinking contaminated 
water 
96.1 0.40 10.1 1.65  94.4 0.24 16.4 1.66  
Eating 
unprotected/spoiled food 
95.5 0.45 7.3 1.60  94.4 0.18 5.1 1.27 *** 
Eating forbidden food 27.4 0.00 0.0 0.27  54.8 0.00 1.1 0.58 *** 
Eating soil 36.9 0.00 0.0 0.37  48.6 0.01 0.0 0.49 * 
Behavior 96.1 0.28 4.5 1.36  94.4 0.44 11.3 1.69 ** 
Contact with 
contaminated water 
85.5 0.20 1.7 1.07  91.0 0.42 9.6 1.58 *** 
Not washing hands 92.2 0.14 2.8 1.13  88.1 0.12 1.7 1.03  
Environment 100.0 0.89 70.9 4.02  98.3 0.68 37.3 2.77 *** 
Dirty environment 99.4 0.84 61.5 3.68  96.0 0.62 24.9 2.30 *** 
Flies 99.4 0.34 9.5 1.62  94.4 0.28 12.4 1.58  
Malaria 15.1 0.00 0.0 0.15  48.0 0.02 0.0 0.49 *** 
Worms 13.4 0.00 0.0 0.13  46.9 0.00 0.0 0.47 *** 
Magico-religious causes 94.4 0.07 7.3 1.23  91.0 0.16 28.8 1.92 *** 
God's will 93.3 0.07 7.3 1.22  86.4 0.16 27.7 1.83 *** 
Witchcraft 20.7 0.00 0.0 0.21  45.8 0.01 1.1 0.50 *** 
Miscellaneous 5.0 1.00 0.0 0.10  27.1 1.00 0.0 0.54 *** 
Other 3.9 1.00 0.0 0.08  13.6 1.00 0.0 0.27 ** 
Cannot say 1.1 1.00 0.0 0.02  13.6 1.00 0.0 0.27 *** 
aCategories ordered alphabetically within each group (bold), except “cannot say”. Categories reported by less than 5% 
not listed; bColumns indicate percentage of reported categories, fraction of spontaneously mentioned categories and 
whether a category was identified as most important; cMean prominence based on values assigned to each reported 
category (0=not reported, 1=reported after probing, 2=reported spontaneously, 3=identified as most important); 
Wilcoxon test used to compare mean prominence between both sites (*p≤0.05, **p≤0.01, ***p≤0.001) 
 
Among the causes not related to the fecal-oral route of transmission, God’s will was the most 
prominent category and ranking higher among rural residents. A statement from a 30-year-old 
female farmer from Mwambe helps to explain the commonly expressed notion regarding this 
finding, i.e. that God overrules people’s prevention efforts if only it wished: 
“There is no cause except God’s will, which cannot be changed; and it is not caused by dirty 
environment because there are some dirty places where people do not get the disease.”  
Further perceived causes not linked to cholera disease etiology—like witchcraft, malaria and 
worms—had lower prominence ratings since they were almost never mentioned spontaneously 
nor identified as most important. And these categories were more characteristic for the rural 
compared with the periurban community. A substantial proportion of the respondents from 
Mwambe—more than one-tenth, compared to only two periurban residents—had no idea what 
could have made the person suffer from the symptoms described in the vignette (coded as 
cannot say). Among rural respondents who could not spontaneously identify a cause, women 
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featured significantly more often than men (19.6% vs. 7.1%, p=0.016, Wilcoxon test) (not shown 
in Table 3-4). 
3.3.5 Self treatment and help seeking for cholera 
The most prominent self treatment at home in the rural community was herbal treatment, 
followed by giving antibiotics or other drugs like pain killers or antacids and then home-made or 
ready-to-use oral rehydration solution (ORS) (Table 3-5, upper panel). In contrast, the 
periurban residents’ preference for herbal treatment was less pronounced as they primarily 
suggested giving someone like the person described in the cholera vignette more water or other 
liquids, like tea or porridge, or ORS. For most respondents, local herbal treatment, used for 
relief or cure of symptoms, comprised concoctions of water with locally grown spices like cumin 
or cloves, or with leaves, barks and roots of herbs and trees (e.g., mpatakuva (Plectranthus 
spp.), neem tree, guava). Doing nothing at home, i.e., sending the person described in the 
cholera vignette immediately to allopathic health care facilities, was considered as the least 
prominent category in the rural community, while it ranked fourth in the periurban community 
and was regarded as the most helpful thing one can do at home. The following statement from a 
housewife, aged 47 years, from Chumbuni is typical for what the communities would do for 
people with cholera at home:  
“At home we give water and other people give local treatment. […] and if the condition becomes 
worse, we will send the patient to the hospital.” 
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Table 3-5: Self treatment and help seeking for a cholera vignette in periurban and rural Zanzibar, 
n=356 
  Periurban site, n=179   Rural site, n=177  
 How reported?b    How reported?b    
Categorya 
Total 
reported 
% 
Fraction 
spon. 
Most 
helpful 
% 
Mean 
prom.c  
Total 
reported 
% 
Fraction 
spon. 
Most 
helpful 
% 
Mean 
prom.c  
Self treatment at home                   
Antibiotics/drugs 44.7 0.26 15.6 1.03  72.3 0.14 24.9 1.57 *** 
Doing nothing at home 27.9 1.00 22.9 1.25  19.8 1.00 4.5 0.53 ** 
Drinking more water or liquids 68.7 0.45 19.6 1.58  69.5 0.10 9.6 1.05 ** 
Herbal treatment 49.7 0.75 14.0 1.29  83.1 0.73 28.8 2.31 *** 
Oral rehydration 
therapy/solution 
59.8 0.28 21.2 1.40  72.9 0.07 23.7 1.49  
Prayers 55.9 0.02 5.6 0.74  47.5 0.00 8.5 0.73  
Outside help seeking           
Faith healers 11.7 0.00 0.0 0.12  18.1 0.00 2.3 0.25  
Health facilities 100.0 1.00 95.5 4.87  100.0 1.00 80.2 4.41 *** 
Informal help from health 
worker/friend 
38.5 0.00 4.5 0.52  73.4 0.00 15.8 1.21 *** 
Pharmacy/OTC 27.4 0.00 0.0 0.27  40.7 0.00 1.1 0.44 ** 
Traditional healers 3.9 0.00 0.0 0.04  9.6 0.06 0.6 0.12 * 
aCategories ordered alphabetically. Categories reported by less than 5% not listed; bColumns indicate percentage of 
reported categories, fraction of spontaneously mentioned categories and whether a category was identified as most 
helpful; cMean prominence based on values assigned to each reported category (0=not reported, 1=reported after 
probing, 2=reported spontaneously, 3=identified as most helpful); Wilcoxon test used to compare mean prominence 
between both sites (*p≤0.05, **p≤0.01, ***p≤0.001) 
 
Public primary health care units and hospitals were mentioned by all respondents (Table 3-5, 
lower panel). More than 95% of the periurban residents identified health facilities as most 
helpful source of treatment, while the rural residents’ preference was around 15% lower. Faith 
healers and traditional healers were of little importance and probing revealed that they would 
only be consulted after allopathic treatment had failed. 
3.3.6 Shigellosis versus cholera 
Similar to the cholera vignette, weakness was also rated as the most prominent somatic 
symptom for the shigellosis vignette (Table 3-6, top panel). Among symptoms related to 
dehydration, only loose skin and sunken eyes were mentioned; and both categories were 
reported significantly less for shigellosis than for cholera. The remaining symptoms of 
dehydration fell under the 5% threshold. All categories of somatic symptoms were differentiated 
on the individual level in both sites. 
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Table 3-6: Symptoms, perceived causes, and self treatment for a cholera and a shigellosis vignette in 
Zanzibar, n=356 
 
Only 
cholera 
vignetteb  
Only 
shigellosis 
vignetteb  
Both 
cholera & 
shigellosis 
vignettec   Kappa coefficiente 
Categorya % % % p valued Estimate 95% CI 
Somatic symptoms           
Abdominal pain/discomfort 24.2 38.2 13.2 <0.001 0.18 0.08 - 0.28 
Loose skin  18.3 5.6 3.4 <0.001 0.21 0.09 - 0.34 
Loss of appetite  11.8 13.5 3.1 0.467 0.14 0.01 - 0.26 
Sunken eyes  29.5 8.4 5.1 <0.001 0.16 0.06 - 0.25 
Weakness 64.9 57.0 45.2 0.008 0.34 0.25 - 0.44 
Other somatic symptoms  13.2 12.4 2.5 0.726 0.08 -0.04 - 0.20 
Cannot say  18.5 22.8 9.8 0.087 0.34 0.23 - 0.46 
Psychosocial problems       
Costs (transport, food, drugs) 19.1 20.8 12.6 0.405 0.54 0.43 - 0.65 
Fear of infecting others 19.7 2.0 1.1 <0.001 0.07 -0.01 - 0.15 
Fear of isolation from others 14.3 4.2 2.0 <0.001 0.16 0.03 - 0.29 
Interference with social 
relationships 
24.7 15.2 12.6 <0.001 0.55 0.44 - 0.65 
Interference with work/daily 
activities 
70.5 61.8 53.9 0.001 0.46 0.35 - 0.55 
Loss of family income 52.8 43.5 34.0 0.001 0.44 0.35 - 0.53 
Sadness, anxiety, worry 59.3 58.7 47.2 0.827 0.51 0.42 - 0.60 
Perceived causes       
Contact with contaminated water 27.5 2.8 1.7 <0.001 0.06 -0.01 - 0.13 
Dirty environment 71.6 32.6 28.4 <0.001 0.17 0.11 - 0.25 
Drinking contaminated water 30.6 21.6 9.6 0.003 0.15 0.04 - 0.26 
Eating unprotected/spoiled food 30.1 29.8 12.1 0.929 0.15 0.04 - 0.26 
Flies 30.3 13.2 5.9 <0.001 0.11 0.01 - 0.21 
God's will 10.1 13.8 3.9 0.085 0.24 0.10 - 0.38 
Not washing hands 11.5 9.0 1.1 0.264 0.01 -0.10 - 0.12 
Cannot say 7.3 23.0 5.6 <0.001 0.29 0.18 - 0.41 
Self treatment at home       
Antibiotics/drugs 11.0 20.5 3.4 <0.001 0.08 -0.03 - 0.19 
Doing nothing at home 23.9 20.2 10.4 0.154 0.32 0.21 - 0.44 
Drinking more water or liquids 18.8 10.7 5.9 <0.001 0.31 0.18 - 0.43 
Herbal treatment 49.2 55.6 35.7 0.035 0.33 0.24 - 0.43 
Oral rehydration therapy 11.0 5.9 2.8 0.004 0.28 0.12 - 0.44 
aCategories ordered alphabetically, except “cannot say”. Categories reported by less than 5% of the sample for each 
vignette not listed; bProportion of categories reported spontaneously for either cholera or shigellosis vignette; 
cProportion of categories reported spontaneously for both vignettes; dMcNemar’s Chi2 test used to compare 
population proportions between both vignettes. Bold figures (p≤0.05) indicate significant differences; eKappa 
coefficients (presented with 95% confidence intervals) greater than or equal to 0.4 suggest no differentiation of illness 
categories (bold figures) 
 
Notable among psychosocial problems was fear of infection and fear of isolation from others. 
Both categories were reported considerably less for shigellosis than for cholera, and were also 
well-differentiated (Table 3-6, second panel). All the other categories, which represent general 
features of diarrheal illness, i.e. costs, loss of family income, interference with social 
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relationships and with daily activities, and being sad, anxious or worried, were not differentiated 
between both conditions (kappa coefficient greater than 0.4). 
 
A dirty environment was perceived to be the most prominent cause of shigellosis (Table 3-6, 
third panel). The percentage of this category, however, was less than half the percentage for 
cholera, and was closely followed by the category of eating unprotected or spoiled food. All 
categories of perceived causes that showed a significant difference between the two conditions 
were mentioned less frequently for shigellosis, with the exception of cannot say, which was 
reported three times more often for shigellosis than for cholera. Kappa coefficients for all 
categories were below the threshold of 0.4 suggesting differentiation of the meaning of cholera 
from shigellosis. 
 
The distribution of respondents’ answers for self-treatment options showed that the population 
proportions related to rehydration were higher for cholera (Table 3-6, bottom panel). 
Conversely, a likely benefit for shigellosis was reported for antibiotics/drugs and for herbal 
treatment. Kappa coefficients were also below the threshold of 0.4 for all help-seeking 
categories. 
 
Similar to the observed preponderance in the case of cholera, health facilities were regarded as 
the sole source of outside help for treating people with shigellosis (354 out of 356 respondents). 
3.4 Discussion 
Findings from both periurban and rural areas of Zanzibar were notable for the high perceived 
severity and anticipated fatality of cholera. Even though the condition described in the cholera 
vignette was similarly regarded as very serious in both communities, it was more often named as 
cholera and considered as a serious life-threatening illness in the periurban community. The 
lower recognition of the condition described in the cholera vignette in the rural community, 
which is consistent with lower prominence of reported signs and symptoms of dehydration and 
higher prominence for the two most conspicuous shigellosis signs (bloody stool, pus in stool), 
may be explained by poorer education. It cannot be explained by less personal illness experience 
of cholera, however, since rural residents reported the occurrence of an individual episode 2.8 
times more often than periurban residents.  
 
The severity of the condition in the cholera vignette was also elaborated with reference to its 
impact on affected persons and household livelihoods. Absence from work was felt to be the 
major effect at both sites leading to strain for household finances because of reduced or lost 
income and treatment costs. Compared to the shigellosis vignette, the condition described in the 
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cholera vignette was more often perceived as a severe and potentially fatal health problem in 
both communities. This finding is consistent with another study comparing the two conditions; 
unaffected community residents, confirmed shigellosis patients and health care providers in 
Bangladesh considered cholera to be more severe than shigellosis [26].  
 
Although a variety of causes were acknowledged, respondents clearly regarded the condition 
depicted in the cholera vignette as a disease linked to a dirty environment and to ingesting 
microbiologically contaminated water and food. The relevance of this concept of dirtiness and of 
sanitation and hygiene in connection with diarrhea was also found in a qualitative study of 
childhood diarrhea among mothers living in Chake-Chake district on Pemba [27]. The role of a 
dirty environment as a cause of cholera was especially highlighted by periurban residents living 
in an area with better water supply and sanitation. While it can be expected that better water 
supply and sanitation would result in less importance of dirty environment, the periurban 
emphasis in this study may be explained by the 19 times higher population density and the 
higher number of persons living in the average Chumbuni household. Most people reported 
magico-religious causes, but the relative priority was higher in the rural site. Other causes 
unrelated to the biomedical basis of cholera (i.e. worms and malaria) were less frequently 
mentioned in both sites and were also more prominent in the rural site. These findings are 
consistent with the lack of knowledge of cholera causes in the rural community, which was 
especially prominent among the women there. 
 
Besides using various allopathic and traditional home remedies, respondents also recommended 
immediate hospital treatment when queried about what they would do at home with someone 
like the person described in the cholera vignette. Periurban community responses emphasized 
rehydration; rural community responses emphasized herbal treatment and use of antibiotics 
and other drugs. Certain herbs and plants, most of which were also reported as herbal treatment 
in the childhood diarrhea study from Chake-Chake [27], were frequently recommended as 
home-based treatment. Reasons for that may include their availability to people, who collect 
them freely in the bush and woods, and their beneficial effect against cholera and other bacterial 
gastrointestinal diseases [28-30]. Periurban recommendations for self-treatment more 
frequently referred to health education and awareness, which probably results from exposure to 
public health activities. Periurban respondents also more frequently considered the value of 
immediate hospital treatment for the condition in the cholera vignette. Rural respondents, on 
the other hand, emphasized magico-religious and other unrelated causes of cholera.  
 
In both sites, help seeking outside the household for the person described in the cholera vignette 
essentially meant going to public health care facilities, with little mention of traditional healers 
and faith healers. This finding of reliance on hospital treatment is remarkable compared with 
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other studies from low- and middle-income countries, which emphasize traditional treatment 
for childhood and adult diarrhea [31-33]. Several factors may help explain this priority: Many 
people in these communities have experience and a high regard for cholera treatment camps, 
which have been established when needed for outbreaks by the district administration and 
provide free treatment. Traditional health care providers, on the other hand, charge for their 
services. These communities have also been exposed to health education from public health 
action of the MoHSW and international non-governmental organizations in the wake of cholera 
outbreaks. Ethnographic field study also indicates that traditional healers in the study 
communities support hospital treatment (A. Pach, unpublished data). 
 
The analysis of disagreement showed illness concepts for the two conditions were distinct with 
respect to reported patterns of distress, perceived causes and self treatment. For outside help 
seeking, however, reference to the value of hospital treatment was the same for both conditions. 
Differentiation of the two conditions may be explained by community and personal experience 
with cholera and shigellosis, resulting in the awareness of particular features of the two 
conditions. Both conditions occur with similar rates in the study communities (Table 3-1).  
 
Health educational activities for cholera, in response to the priority arising from outbreaks 
making heavy demands on the health system in Zanzibar, are more extensive than for 
shigellosis. Less emphasis on shigellosis control may account for the finding that fewer 
respondents could explain the cause of shigellosis (23% reporting cannot say) compared with 
cholera (7.3%). The finding that fewer respondents identified houseflies as a cause of shigellosis 
may also result from the lower priority of public health action for shigellosis control, inasmuch 
as houseflies are recognized agents of transmission for shigellosis [34]. Dehydration and 
contagiousness are two other features of both conditions that community respondents identified 
more with cholera only. Dehydration is also an important feature of shigellosis, and shigellosis is 
more contagious than cholera [35].  
 
The differentiation of the two conditions is reflected by appropriate differences in treatment 
recommended by respondents. Community self-treatment priorities emphasized rehydration for 
cholera and herbal and antibiotic treatment for shigellosis.  
3.4.1 Strengths and limitations 
This study shows how EMIC interviews can be used to assess explanatory models of diarrheal 
illnesses among unaffected community residents and how to compare them among sub-groups. 
The specific approach employed in this cultural epidemiological study to comparing prominence 
allowed the ranking of categories according to their relative priority and not just according to 
their reported frequency. This weighted approach represents a more sensitive method to clarify 
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differences between groups and has implications for explaining cultural priorities and potential 
effects on health behavior.  
 
The findings presented here are specific for cholera and shigellosis in one culture and focus on 
variation between periurban and rural areas. Thus, any generalizations made to countries 
outside the target populations have to be examined cautiously as the results presented here are 
inherently linked to the context. Some may argue that the differences in community views are 
due to education rather than to residence. However, analysis of the patterns of distress, 
perceived causes, self treatment and help seeking, stratified by educational status, showed that 
the cross-site differences reported here were not confounded by education.  
 
It should also be noted that findings reported here are cross-sectional and may change over 
time, possibly in response to access to health services, a vaccine campaign or other social 
changes. Furthermore, the data are based on respondents’ ideas about the condition of a clinical 
vignette, representing community views of illness experience, meaning and behavior, but not 
necessarily an account of personal or family history.  
 
The sampling included only community residents who were at home when the field teams 
visited. The study could be biased if the views of the respondents available for interviews at 
home and persons unavailable because of other responsibilities differed. The age distribution at 
both sites, however, mitigates this concern, inasmuch as all age groups were represented in the 
sample.   
3.5 Conclusions  
This study has clarified local periurban and rural views of cholera among the general population 
with practical significance for cholera control in Zanzibar. Cholera was recognized as a serious 
and potentially fatal condition, a priority that makes such communities receptive to community 
health education programs. The overwhelming preference for public health care facilities to 
treat cholera and shigellosis indicates the importance of strengthening health systems to ensure 
they are capable of fulfilling expectations. Notwithstanding this appropriate community 
preference for hospital treatment, this study also suggests that better health education is needed 
for cholera in rural areas and for shigellosis in general. The finding that rural women were more 
likely than men to be unable to specify a cause of cholera indicates the need to ensure a gender-
sensitive approach to control.  
 
Although sanitation, hygiene and safe water are critical issues for diarrheal disease control, 
recent consideration of vaccines in endemic areas suggest an appealing complementary 
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intervention. It is an approach that has been of considerable interest to policy makers in 
Zanzibar, where a cholera vaccine campaign was implemented in January and February 2009. 
Research is needed to identify not only health system capacities to deliver vaccines but also 
social and cultural factors affecting community acceptance of vaccines. Factors influencing the 
willingness and enthusiasm of communities for a recommended vaccine can be expected to 
affect the success of a vaccine intervention program. The interests and findings of this study are 
likely to inform such efforts to clarify social and cultural features of vaccine acceptance and 
demand. 
 
Although not used in planning the cholera vaccine campaign in Zanzibar, findings from this 
study identified variables for a subsequent analysis of social and cultural determinants of 
vaccine acceptance and demand. Further analysis is also needed to explain the impact of the 
vaccine campaign on community views of cholera and risk-related behavior. This study indicates 
directions and enables further research, and it has also clarified important issues for cholera 
control. 
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Abstract 
Despite improvements in sanitation and water supply, cholera remains a serious public health 
burden. Vaccination is included among recommendations for cholera control. Cultural concepts 
of illness are likely to affect vaccine acceptance. This study examined social and cultural 
determinants of anticipated acceptance of an oral cholera vaccine (OCV) prior to a mass 
vaccination campaign in Zanzibar. Using a cultural epidemiological approach, 356 unaffected 
adult residents were studied with vignette-based semi-structured interviews. Anticipated 
acceptance was high for a free OCV (94%), but declined with increasing price. Logistic 
regression models examined social and cultural determinants of anticipated acceptance at low 
(USD 0.9), medium (USD 4.5) and high (USD 9) price. Models including somatic symptoms 
(low and high price), social impact (low and medium) and perceived causes (medium and high) 
explained anticipated OCV acceptance better than models containing only sociodemographic 
characteristics. Identifying thirst with cholera was positively associated with anticipated 
acceptance of the low-priced OCV, but acknowledging the value of home-based rehydration was 
negatively associated. Concern about spreading the infection to others was positively associated 
at low price among rural respondents. Confidence in the health system response to cholera 
outbreaks was negatively associated at medium price among periurban respondents. Identifying 
witchcraft as cause of cholera was negatively associated at medium and high price. Anticipated 
acceptance of free OCVs is nearly universal in cholera-endemic areas of Zanzibar; pre-
intervention assessments of community demand for OCV should not only consider the social 
epidemiology, but also examine local sociocultural features of cholera-like illness that explain 
vaccine acceptance. 
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4.1 Introduction 
Despite improvements in infrastructure, cholera remains a serious public health burden in 
Africa and South Asia [1,2]. The World Health Organization (WHO) recommends vaccination as 
a supplement to improved sanitation, supply of safe water and hygiene education for the 
prevention of cholera in populations at risk [3]. Recent studies have assessed the use of oral 
cholera vaccines (OCV) in endemic areas and in emergency situations, with a focus on vaccine 
characteristics, herd protection and economic aspects [4]. 
 
To maximize the public health impact of immunization, however, more than a safe and 
efficacious vaccine is needed. In addition to an effective health system optimizing access to 
immunization, it is also crucial to better understand local cultural concepts of illness among 
potential vaccine recipients as these are likely to affect vaccine acceptance [5-7]. The bulk of 
literature on determinants of vaccine acceptance, however, has mainly considered 
sociodemographic characteristics, with an emphasis on vaccines for human papillomavirus, and 
seasonal or pandemic influenza [8-10]. In industrialized countries, acceptance of these vaccines 
by health care workers has also been a focus of research [11]. Despite the need to assess local 
community views of illness and their relationship with vaccine acceptance, only few studies have 
been conducted in low- and middle-income countries. A series of studies on social and cultural 
determinants of cholera vaccine acceptance was conducted by the International Vaccine 
Institute in cholera-endemic Asian countries [12-14], but no such studies have been published 
for Africa. 
 
Cultural epidemiological studies using vignette-based semi-structured interviews have been 
employed to empirically describe community views of illness among general populations [15,16]. 
Cultural epidemiology [17], which is an integrated methods approach based on Arthur 
Kleinman’s concept of illness explanatory models [18], is using qualitative and quantitative 
methods to clarify locally valid sociocultural features of illness experience with reference to 
patterns of distress, meaning with reference to perceived causes, and behavior with reference to 
help seeking. These three areas of interest are examined through study of the distribution of 
categories of distress (which include signs, symptoms and other features of illness experience), 
perceived causes (a feature of illness meaning of particular interest) and self treatment at home 
and outside help seeking for health problems. Cultural epidemiological studies have been 
particularly useful in examining the link between the distribution of sociocultural features of 
illness and designated outcomes of importance for disease control and public health for 
infectious and chronic illnesses [19-22]. 
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This study was performed in Zanzibar within a project managed by the WHO. The project’s 
main objective was to vaccinate community residents in selected cholera hotspots on both 
islands of Zanzibar to assess the effectiveness of OCV under real-life conditions. Complementary 
research studies examined additional epidemiological, sociobehavioral and economic aspects 
regarding the use of OCV in endemic settings in Africa. A mass vaccination campaign, which was 
implemented in early 2009 by the Ministry of Health and Social Welfare of Zanzibar (MoHSW) 
with assistance from the WHO, offered an OCV without cost to a target population of ~50,000 
people living in periurban and rural communities. The campaign used Dukoral®, a recombinant 
cholera toxin B subunit, killed whole-cell OCV that has to be administered in a buffer solution in 
two doses at least one week apart; it should not be given to children younger than two years and 
to pregnant women [3]. Dukoral® is currently the only OCV that is prequalified by the WHO; 
thus it is the sole OCV that can be used for cholera control in countries that have no capacity or 
limited resources to license vaccines. Another OCV, ShancholTM, is a simpler variant of 
Dukoral® that is being produced in India and likely to be cheaper and thus more attractive for 
use in low- and middle-income countries, but it is still pending WHO prequalification [3,4]. 
 
The results presented here are based on descriptive findings from a previous report that clarified 
similarities and differences of community views of cholera in the periurban and rural target 
populations in Zanzibar [23]. 
 
This study aimed to assess social and cultural determinants of anticipated oral cholera vaccine 
acceptance prior to a mass vaccination campaign in a periurban and a rural community of 
Zanzibar. Because of the reported high awareness of cholera in the study communities [23], it 
was hypothesized that anticipated acceptance of the free vaccine would also be high, and that 
determinants of anticipated acceptance would not only include sociodemographic and economic 
characteristics, especially for high-priced vaccines [24-26], but also sociocultural features of 
illness. Social and cultural determinants of anticipated OCV acceptance were investigated with 
regard to the OCV at no cost, and at three distinct price levels. The latter were defined on the 
basis of pragmatic considerations of using vaccines as a public health tool to improve cholera 
control. 
4.2 Methods 
4.2.1 Setting and study design  
This cross-sectional survey took place from June to August 2008 in two communities selected 
for the 2009 cholera mass vaccination campaign in Zanzibar. The community of Chumbuni, 
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located on the outskirts of the capital Stonetown on Unguja island, was selected as the 
periurban, and the community of Mwambe, located on the southeastern tip of Pemba island, as 
the rural study site. In both sites only a basic sanitation infrastructure and a sporadic water 
supply exist. Monthly mean per capita expenditure for all goods amounted to USD 28.3 in the 
periurban and to USD 20.1 in the rural site in 2004/2005 [30]. Further details of both study 
sites have been presented elsewhere [23]. 
 
A simple random sample of 180 houses per site was drawn from existing geographic information 
system data in the periurban site and from census information in the rural site. Eligible 
participants who were selected from households identified in the sampled houses needed to be 
18 years or older and capable to stand an interview of approximately one hour duration. An 
equal number of men and women were approached for the interviews. 
4.2.2 Instrument 
Semi-structured illness explanatory model interviews are the principal tool for cultural 
epidemiological research. These EMIC (Explanatory Model Interview Catalogue) interviews 
enable assessment of locally valid features of illness-related experience, meaning and behavior, 
operationalized as categories of distress, perceived causes, and help seeking [35]. Since this 
study’s objective was to examine the influence of community views of cholera illness on 
anticipated vaccine acceptance, only residents without an apparent diarrheal illness at the time 
of the study were interviewed.  
 
Interviews were introduced with clinical vignettes describing a person with cardinal somatic 
symptoms of cholera. Categories of somatic symptoms (in addition to the ones mentioned in the 
vignette), social impact, perceived causes, self treatment at home and outside sources of help 
seeking were elicited first with open questions followed by explicit probing of remaining 
categories. After each section, a summary question was asked to identify the most troubling 
category of distress, the most important category of perceived causes and the most helpful 
category of help seeking. Further details about interview development and the vignettes used in 
this study have been presented elsewhere [23]. 
 
The interview also inquired whether respondents would swallow a vaccine against cholera if it 
was made available at no cost, since Dukoral® was administered for free during the subsequent 
mass vaccination campaign. However, since a vaccine for free might have been considered less 
useful by respondents, interviews also asked about acceptance of the OCV at a low price of TZS 
1,000 (~USD 0.9), a medium price of TZS 5,000 (~USD 4.5) and a high price of TZS 10,000 
(~USD 9). The low price level was chosen to be close to the threshold of USD 1 reported by Asian 
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policy makers as “the maximum acceptable price the government would pay for new-generation 
enteric vaccines.” [13] The high price level approximated the manufacturing costs of Dukoral® 
at the time of the study; the medium level represented 50% of it.  
4.2.3 Data management and analysis 
Explanatory variables 
Explanatory variables for the analysis of anticipated OCV acceptance included categories of 
distress, perceived causes, and help seeking. Categories mentioned spontaneously were assigned 
a value of 2. After screening for remaining categories, those that were reported affirmatively 
were assigned a value of 1. Categories identified as most troubling, most important or most 
helpful were assigned an additional value of 3. The cumulative prominence by respondent 
(range 0-5) was then used to calculate the mean prominence for each category. This 
prominence-based approach enabled examination of the relative significance of each category in 
the local cultural concepts of cholera. The distribution and prominence of these categories with 
reference to their similarities and differences in the periurban and the rural study community 
has been presented extensively in the baseline study [23]. Sociodemographic characteristics 
were also recorded and, if needed, categorized for regression analysis.  
Outcome variables 
Anticipated acceptance of the OCV for free, at low, medium and high price was elicited with a 
series of four questions at the end of the interview. Respondents’ positive answers were coded 
with “yes” or “possibly” in the event of a qualified answer and with “no” and “uncertain,” 
respectively, for a negative answer. These variables were then dichotomized into outcome 
variables denoting acceptance or non-acceptance of the OCV for logistic regression analysis 
using SAS 9.2 (SAS Institute, Cary, NC, USA). 
Focal and comprehensive models of anticipated OCV acceptance 
Only explanatory variables reported by 5-95% were considered for analysis. Second, only 
variables whose crude association with the outcome had a p value less than 0.2 were retained for 
subsequent multivariable models. Third, focal multivariable logistic regression models were run 
for each subset of categories related to somatic symptoms, social impact, perceived causes, self 
treatment at home and outside sources of help seeking, while adjustment was made for 
sociodemographic characteristics. Focal models addressed the question of how specific subsets 
of sociocultural features of cholera-like illness are associated with anticipated OCV acceptance. 
Fourth, to examine which factors affect anticipated OCV acceptance from an exclusively social 
epidemiological standpoint [31], additional focal models were calculated that considered only 
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sociodemographic characteristics. Among these focal models, consideration of the difference (∆) 
in the Akaike Information Criterion corrected for sample size (AICc) between each model and 
the model with the lowest AICc helped to examine which of these models explain anticipated 
OCV acceptance better. Models of sociocultural features of cholera-like illness were considered 
better than the sociodemographic model if their ∆(AICc) value was noticeably below the latter’s 
value. Finally, comprehensive multivariable models examined determinants of anticipated OCV 
acceptance, taking into account only variables with p<0.2 from focal models. Respondents’ 
residence (rural vs. periurban site at baseline) was assessed as an effect modifier. Interaction 
between each explanatory variable and site was initially tested in focal models and interaction 
terms only retained in final focal and comprehensive models if p<0.1. Models report regression 
coefficients and their 95% confidence intervals and p values. In case of significant effect 
modification by site, site-specific estimates are presented. This staged variable reduction 
strategy ensured that the final models were not overfitted. 
Qualitative data for integrated analysis 
Qualitative data were used to help explain quantitative associations found in adjusted analyses. 
Narratives written down in Kiswahili during the interview were translated into English and 
typed in word processor software using a pre-coded structure that reflected interview items. 
Deductive coding of themes was done based on open-ended questions and probing in the 
interview. Transcripts were imported into MAXQDA 10 (VERBI Software, Consult. 
Sozialforschung. GmbH, Marburg, Germany) together with explanatory and outcome variables. 
This enabled selective retrieval of narrative segments based on analytically relevant 
relationships. Further themes were coded inductively based on additional relevant issues 
emerging from analysis. 
4.2.4 Ethics 
Written informed consent was obtained from all study participants and no incentives were 
provided to them. The protocol of this study was cleared by the WHO Research Ethics Review 
Committee and the MoHSW Ethics Committee [36]. Interviews were recorded without names 
and all data were handled with strict confidentiality and anonymized for analysis. 
4.3 Results 
Of the 356 interviews that were conducted in total, 179 took place in the periurban and 177 in 
the rural site. The sample consisted of 50.3% women. Mean age was 35.5 years (median 33 
years) and the majority of respondents was married (76.4%). Mean household size was 6.8 
persons (median 7 persons) and major occupations were farming (30.6%), being a housewife 
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(21.4%) and working in the informal economy (17.1%). More than half (55.9%) reported a 
regular and dependable household income. All respondents were Muslims, except one Christian 
woman.  
4.3.1 Anticipated acceptance of OCV 
Figure 4-1 presents the anticipated acceptance rates for the OCV at no cost and at the three 
designated price levels.  
Figure 4-1: Anticipated oral cholera vaccine acceptance at different prices in Zanzibar, stratified by 
site 
Low price: TZS 1,000 (~USD 0.9), medium price: TZS 5,000 (~USD 4.5), high price: TZS 10,000 (~USD 9). 
Approximate exchange rate of TZS 1,140 per USD 1 as of August 1, 2008 (www.oanda.com); *p<0.05 
 
Anticipated acceptance of the free vaccine was greater than 93% for the pooled sample of 
periurban and rural sites. These acceptance rates dropped with increasing price level to a 
minimum of 15%. Differences between sites were significant at the no cost and high price level.  
 
In addition to a high demand for free vaccination, respondents also stated the importance of 
other preventive measures for cholera control when asked for advice at the end of the interview. 
The following narrative of a 47-year-old man from the rural site represents these community-
perceived needs:  
“The ministry of health should provide health education. They should also tell us how to build and 
use latrines. The provision of safe water is also important, especially during the rainy season. The 
ministry of health should give us vaccines and inform the community about the importance of using 
vaccines that ought to be provided free of charge.” 
 
Because intention to take the free OCV was almost 95%, subsequent statistical analysis of 
determinants of anticipated OCV acceptance considered only low, medium and high price as 
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outcome variables. Tables 4-1 to 4-6 present explanatory variables that were identified in crude 
analyses together with the respective focal and comprehensive models. Focal models analyzed 
specific subsets of explanatory variables to examine the influence of categories of distress, 
perceived causes, self treatment at home and outside help seeking on anticipated OCV 
acceptance. Each of these models was adjusted for sociodemographic characteristics and 
compared to the respective model containing only sociodemographic characteristics by using the 
Akaike Information Criterion corrected for sample size (AICc). Focal models were also used to 
select explanatory variables for analysis of social and cultural determinants of anticipated OCV 
acceptance in comprehensive models. 
4.3.2 Determinants of anticipated OCV acceptance at low price 
Two categories of distress—being very thirsty and being concerned about spreading the infection 
to others—were positively associated with anticipated OCV acceptance, though the former with 
borderline significance (p=0.056) and the latter only at the rural site (Table 4-1). 
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Table 4-1: Crude and adjusted analysis (focal models) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at low price in Zanzibar, n=356 
 Crude analysisa  Adjusted analysisb    
 
Coefficient (95% CI)c 
p 
valued Coefficient (95% CI)c 
p 
valued Inte ∆(AICc)f 
Categories of distress: somatic symptoms      0.34 
Very thirsty 0.31 (-0.05; 0.68) 0.09 0.37 (-0.01; 0.75) 0.06   
Categories of distress: social impact      0 
Fear of infecting others 0.22 (-0.02; 0.46) 0.07     
Fear of infecting others (periurban site)   -0.14 (-0.54; 0.26) 0.49   
Fear of infecting others (rural site)   0.41 (0.07; 0.75) 0.02 **  
Perceived causes      5.91 
Unprotected/spoiled food 0.29 (0.04; 0.54) 0.03 0.16 (-0.11; 0.43) 0.23   
Not washing hands 0.40 (0.02; 0.77) 0.04 0.11 (-0.28; 0.50) 0.59   
Witchcraft -0.45 (-0.85; -0.05) 0.03 -0.25 (-0.68; 0.19) 0.27   
God's will -0.14 (-0.30; 0.03) 0.10 -0.03 (-0.22; 0.15) 0.73   
Cannot say -0.49 (-0.90; -0.08) 0.02 -0.40 (-0.85; 0.05) 0.09   
Self treatment at home      2.12 
Drinking more water or liquids -0.10 (-0.24; 0.05) 0.19 -0.18 (-0.34; -0.02) 0.03   
Oral rehydration therapy 0.11 (-0.02; 0.25) 0.10 0.04 (-0.10; 0.18) 0.56   
Prayers -0.21 (-0.41; -0.01) 0.05 -0.13 (-0.35; 0.09) 0.23   
Outside help seeking      2.98 
Faith healers -0.35 (-0.76; 0.07) 0.10 -0.31 (-0.75; 0.13) 0.17   
Sociodemographic characteristicsg      2.25 
Gender (male vs. female) 0.31 (-0.12; 0.74) 0.15 0.36 (-0.11; 0.83) 0.14   
Site (rural vs. periurban) -0.25 (-0.68; 0.17) 0.24 -0.43 (-1.11; 0.24) 0.21   
Age -0.02 (-0.04; -0.01) 0.01 -0.01 (-0.03; 0.00) 0.11   
Primary school vs. no education 0.67 (0.12; 1.23) 0.02h 0.54 (-0.06; 1.14) 0.08   
Secondary school and above vs. no education 1.18 (0.65; 1.70) <0.01h 1.05 (0.42; 1.68) <0.01   
Regular and dependable household income 0.59 (0.16; 1.02) 0.01     
Regular and dependable household 
income (periurban site)   0.11 (-0.55; 0.78) 0.74   
Regular and dependable household 
income (rural site)   0.91 (0.27; 1.56) 0.01 *  
aOnly variables with univariable association (p<0.2) listed, except for site; bFocal models adjusted for 
sociodemographic characteristics (see footnote g). Effects of adjustment variables not presented since similar to 
model containing only sociodemographic characteristics (bottom block); cLogistic regression coefficient with 95% 
confidence interval; dFigures in bold if p<0.05; eInteraction of rural with periurban site (baseline) considered if p<0.1 
for interaction term (*p<0.1, **p<0.05); fDifference of corrected Akaike Information Criterion (AICc) between each 
model and the best model, designated with ∆(AICc)=0. Bold figures indicate models that are better than the model 
containing only sociodemographic characteristics (bottom block); gVariables used for adjusting each focal model. 
Figures reported in adjusted analysis refer to model containing only sociodemographic characteristics; hVariable with 
three categories, overall p<0.01 
 
In crude analysis, categories of perceived causes related to biomedical risk factors for cholera 
were significantly positively associated; attribution of cholera to witchcraft or inability to 
identify a cause was negatively associated. These effects, however, were reduced in the focal 
model probably because they were partly explained by sociodemographic factors. Rehydration 
as self treatment at home was negatively associated with anticipated OCV acceptance. Among 
sociodemographic characteristics, having completed at least secondary school, and reporting a 
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regular and dependable household income in the rural site, were highly significant determinants 
of anticipated OCV acceptance. According to their ∆(AICc) values, both models related to 
categories of distress explained anticipated acceptance better than the model containing only 
sociodemographic characteristics.  
 
All variables that showed a significant association with anticipated acceptance of the low-priced 
OCV in the focal models were also present in the comprehensive model (Table 4-2). Effects were 
similar, but very thirsty turned significant (p=0.034) and the interaction with rural site was no 
longer present for regular and dependable household income. 
Table 4-2: Adjusted analysis (comprehensive model) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at low price in Zanzibar, n=356 
 Adjusted analysisa 
 Coefficient (95% CI)b p valuec Intd 
Categories of distress: somatic symptoms    
Very thirsty 0.41 (0.03; 0.80) 0.03  
Categories of distress: social impact    
Fear of infecting others (periurban site) -0.20 (-0.60; 0.20) 0.33  
Fear of infecting others (rural site) 0.38 (0.02; 0.74) 0.04 * 
Perceived causes    
Cannot say -0.34 (-0.81; 0.14) 0.16  
Self treatment at home    
Drinking more water or liquids -0.22 (-0.38; -0.05) 0.01  
Outside help seeking    
Faith healers -0.19 (-0.64; 0.26) 0.41  
Sociodemographic characteristics    
Gender (male vs. female) 0.32 (-0.16; 0.81) 0.19  
Site (rural vs. periurban) -0.70 (-1.49; 0.10) 0.09  
Age -0.02 (-0.03; 0.00) 0.11  
Primary school vs. no education 0.59 (-0.03; 1.21) 0.06  
Secondary school and above vs. no education 0.97 (0.34; 1.61) <0.01  
Regular and dependable household income 0.57 (0.10; 1.05) 0.02  
aOnly variables identified in focal models (p<0.2) included in comprehensive model; bLogistic regression coefficient 
with 95% confidence interval; cFigures in bold if p<0.05; dInteraction of rural with periurban site (baseline) 
considered if p<0.1 for interaction term (*p<0.05) 
4.3.3 Determinants of anticipated OCV acceptance at medium price 
In the periurban site, disruption of health services was negatively associated with anticipated 
OCV acceptance at medium price (Table 4-3).  
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Table 4-3: Crude and adjusted analysis (focal models) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at medium price in Zanzibar, n=356 
 Crude analysisa  Adjusted analysisb    
 
Coefficient (95% CI)c 
p 
valued Coefficient (95% CI)c 
p 
valued Inte ∆(AICc)f 
Categories of distress: somatic symptoms      4.90 
Abdominal pain/discomfort -0.31 (-0.67; 0.05) 0.09 -0.30 (-0.71; 0.10) 0.14   
Pus in stool 0.43 (-0.15; 1.00) 0.14 0.55 (-0.11; 1.21) 0.10   
Categories of distress: social impact      0 
Fear of infecting others 0.18 (-0.07; 0.44) 0.16 0.19 (-0.08; 0.47) 0.16   
Disruption of health services -0.33 (-0.79; 0.13) 0.16     
Disruption of health services (periurban site)   -1.11 (-2.02; -0.20) 0.02   
Disruption of health services (rural site)   0.28 (-0.44; 0.99) 0.45 **  
Interference with social relationships -0.27 (-0.58; 0.04) 0.08 -0.22 (-0.56; 0.12) 0.20   
Perceived causes      1.51 
Witchcraft -0.60 (-1.19; -0.01) 0.05 -0.79 (-1.45; -0.14) 0.02   
Self treatment at home      6.22 
Prayers -0.21 (-0.51; 0.09) 0.17 -0.19 (-0.50; 0.12) 0.24   
Outside help seeking      6.00 
Pharmacy/Over-the-counter drugs -0.39 (-0.94; 0.16) 0.17 -0.37 (-0.93; 0.20) 0.20   
Sociodemographic characteristicsg      4.80 
Household size -0.06 (-0.15; 0.03) 0.19     
Household size (periurban site)   -0.20 (-0.34; -0.06) 0.01   
Household size (rural site)   0.08 (-0.06; 0.23) 0.26 ***  
Marital status (married vs. not married) 1.37 (0.49; 2.24) <0.01 1.26 (0.36; 2.17) 0.01   
Site (rural vs. periurban) 0.12 (-0.40; 0.65) 0.65 -1.05 (-2.74; 0.65) 0.23   
Regular and dependable household income 0.98 (0.39; 1.56) <0.01     
Regular and dependable household income 
(periurban site)   1.67 (0.63; 2.70) <0.01   
Regular and dependable household income 
(rural site)   0.56 (-0.21; 1.34) 0.15 *  
aOnly variables with univariable association (p<0.2) listed, except for site; bFocal models adjusted for 
sociodemographic characteristics (see footnote g). Effects of adjustment variables not presented since similar to 
model containing only sociodemographic characteristics (bottom block); cLogistic regression coefficient with 95% 
confidence interval; dFigures in bold if p<0.05; eInteraction of rural with periurban site (baseline) considered if p<0.1 
for interaction term (*p<0.1, **p<0.05, ***p<0.01); fDifference of corrected Akaike Information Criterion (AICc) 
between each model and the best model, designated with ∆(AICc)=0. Bold figures indicate models that are better than 
the model containing only sociodemographic characteristics (bottom block); gVariables used for adjusting each focal 
model. Figures reported in adjusted analysis refer to model containing only sociodemographic characteristics 
 
Narratives among acceptors and non-acceptors, however, did not differ and acknowledged the 
impact of outbreaks on the primary health care system:  
“Yes, health services can stop because health workers will deal only with the outbreak for that time.” 
(Male student, 21 years)  
A 39-year-old jobless man even gave a reason why health care services would be interrupted:  
“Yes, if the primary health care unit provides treatment for cholera patients, other patients will not 
be treated there to avoid infection.”  
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Attribution of witchcraft as a cause of cholera was identified as negative determinant in both the 
crude and adjusted analysis. The larger the household was in the periurban site, the lower the 
willingness for buying medium-priced OCV. A statement by a male, 33-year-old carpenter 
represents a likely reason behind this:  
“It is hard because what we earn is not enough to pay for a vaccine for the fifteen people who are 
living in this house.”  
Being married and reporting a regular and dependable household income in the periurban site 
were positively related sociodemographic factors. Focal models of social impact and perceived 
causes explained anticipated OCV acceptance better than the sociodemographic model. 
 
All variables from the focal models, except witchcraft, were retained as significant determinants 
with similar effects in the comprehensive model (Table 4-4). 
Table 4-4: Adjusted analysis (comprehensive model) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at medium price in Zanzibar, n=356 
 Adjusted analysisa   
 Coefficient (95% CI)b p valuec Intd 
Categories of distress: somatic symptoms    
Abdominal pain/discomfort -0.27 (-0.69; 0.15) 0.21  
Pus in stool 0.54 (-0.14; 1.22) 0.12  
Categories of distress: social impact    
Fear of infecting others 0.15 (-0.13; 0.43) 0.30  
Disruption of health services (periurban site) -1.14 (-2.07; -0.22) 0.02  
Disruption of health services (rural site) 0.26 (-0.50; 1.01) 0.51 ** 
Perceived causes    
Witchcraft -0.63 (-1.31; 0.05) 0.07  
Outside help seeking    
Pharmacy/Over-the-counter drugs -0.16 (-0.71; 0.39) 0.58  
Sociodemographic characteristics    
Household size (periurban site) -0.22 (-0.37; -0.07) <0.01  
Household size (rural site) 0.08 (-0.07; 0.24) 0.28 *** 
Marital status (married vs. not married) 1.40 (0.47; 2.33) <0.01  
Site (rural vs. periurban) -1.89 (-3.88; 0.11) 0.06  
Regular and dependable household income (periurban site) 1.66 (0.58; 2.75) <0.01  
Regular and dependable household income (rural site) 0.45 (-0.35; 1.25) 0.27 * 
aOnly variables identified in focal models (p<0.2) included in comprehensive model; bLogistic regression coefficient 
with 95% confidence interval; cFigures in bold if p<0.05; dInteraction of rural with periurban site (baseline) 
considered if p<0.1 for interaction term (*p<0.1, **p<0.05, ***p<0.01) 
4.3.4 Determinants of anticipated OCV acceptance at high price 
In the focal models for high price, no interactions with site were present (Table 4-5).  
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Table 4-5: Crude and adjusted analysis (focal models) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at high price in Zanzibar, n=356 
 Crude analysisa  Adjusted analysisb   
 
Coefficient (95% CI)c 
p 
valued Coefficient (95% CI)c 
p 
valued ∆(AICc)e 
Categories of distress: somatic symptoms     0.38 
Abdominal pain/discomfort -0.40 (-0.81; 0.02) 0.06 -0.29 (-0.76; 0.17) 0.22  
Pus in stool 0.75 (0.15; 1.36) 0.02 0.68 (-0.00; 1.36) 0.05  
Categories of distress: social impact     1.01 
Fear of infecting others 0.23 (-0.04; 0.50) 0.10 0.23 (-0.05; 0.52) 0.11  
Perceived causes     0 
Eating soil 0.41 (-0.16; 0.98) 0.16 0.36 (-0.26; 0.98) 0.25  
Malaria 0.42 (-0.15; 1.00) 0.15 0.43 (-0.26; 1.13) 0.22  
Witchcraft -0.52 (-1.17; 0.13) 0.11 -0.90 (-1.66; -0.14) 0.02  
Self treatment at home     2.29 
Prayers -0.24 (-0.58; 0.11) 0.18 -0.19 (-0.56; 0.17) 0.30  
Sociodemographic characteristicsf     1.40 
Site (rural vs. periurban) 0.64 (0.04; 1.23) 0.04 0.80 (0.12; 1.48) 0.02  
Marital status (married vs. not married) 1.51 (0.46; 2.56) <0.01 1.41 (0.33; 2.49) 0.01  
Primary school vs. no education 0.79 (-0.00; 1.57) 0.05g 0.82 (-0.00; 1.64) 0.05  
Secondary school and above vs. no education 0.37 (-0.40; 1.15) 0.34g 0.87 (0.00; 1.74) 0.05  
Regular and dependable household income 0.94 (0.30; 1.59) <0.01 0.98 (0.30; 1.66) 0.01  
aOnly variables with univariable association (p<0.2) listed; bFocal models adjusted for sociodemographic 
characteristics (see footnote f). Effects of adjustment variables not presented since similar to model containing only 
sociodemographic characteristics (bottom block); cLogistic regression coefficient with 95% confidence interval; 
dFigures in bold if p<0.05; eDifference of corrected Akaike Information Criterion (AICc) between each model and the 
best model, designated with ∆(AICc)=0. Bold figures indicate models that are better than the model containing only 
sociodemographic characteristics (bottom block); fVariables used for adjusting each focal model. Figures reported in 
adjusted analysis refer to model containing only sociodemographic characteristics; gVariable with three categories, 
overall p=0.14 
 
But site itself was a confounding factor, indicating that rural respondents were more likely to 
accept the vaccine. Besides marital status, education and regular and dependable household 
income, which were all positively associated, attribution of cholera to witchcraft, similar to the 
medium price focal model, was a negative determinant of anticipated OCV acceptance. Another 
positive determinant was pus in stool, an unrelated symptom of cholera, which was probed for 
in the interview to compare community views of cholera and shigellosis [23]. Perceived causes 
and somatic symptoms explained anticipated OCV acceptance better than the sociodemographic 
model. 
 
The only significant variables in the comprehensive model at high price were sociodemographic 
characteristics: being married and depending on a regular household income were positive 
determinants of anticipated OCV acceptance (Table 4-6). Belonging to rural site (p=0.052) and 
having attained primary school education (p=0.057) were also positive predictors, though with 
borderline significance. 
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Table 4-6: Adjusted analysis (comprehensive model) of social and cultural determinants of 
anticipated oral cholera vaccine acceptance at high price in Zanzibar, n=356 
 Adjusted analysisa  
 Coefficient (95% CI)b p valuec 
Categories of distress: somatic symptoms   
Pus in stool 0.64 (-0.06; 1.33) 0.07 
Categories of distress: social impact   
Fear of infecting others 0.16 (-0.14; 0.45) 0.29 
Perceived causes   
Witchcraft -0.69 (-1.43; 0.05) 0.07 
Sociodemographic characteristics   
Site (rural vs. periurban) 0.73 (-0.01; 1.47) 0.05 
Marital status (married vs. not married) 1.44 (0.36; 2.53) <0.01 
Primary school vs. no education 0.82 (-0.02; 1.67) 0.06 
Secondary school and above vs. no education 0.73 (-0.17; 1.63) 0.11 
Regular and dependable household income 0.91 (0.22; 1.60) 0.01 
aOnly variables identified in focal models (p<0.2) included in comprehensive model; bLogistic regression coefficient 
with 95% confidence interval; cFigures in bold if p<0.05 
4.4 Discussion 
This cross-sectional study using the cultural epidemiological framework clarified social and 
cultural determinants of anticipated OCV acceptance before a mass vaccination campaign in 
Zanzibar. Reported anticipated acceptance of a free OCV was very high (94%). Fewer were 
willing to pay for it: 61% at low, 19% at medium and 15% at high price. Sociocultural features of 
cholera-like illness—that is, how people perceive and understand the acute watery diarrhea 
described to them in a clinical vignette—were identified as determinants of anticipated 
acceptance if the OCV was offered at some cost. Individual features of respondents, i.e., their 
sociodemographic and economic status, were also important determinants, and they became 
more influential as prices increased. 
 
This study examined willingness to accept a free vaccine for cholera, or to pay for the vaccine, 
which may be regarded as a surrogate for demand. Anticipated acceptance of the free OCV was 
at the upper end of the range of 60-99% reported by studies that have assessed people’s 
intention to receive vaccines for shigellosis, other dysentery and typhoid fever in several Asian 
countries [27-29]. High levels of intention to receive free vaccination against cholera in Zanzibar 
may be explained by high levels of reported severity and fatality in the sample [23]. The fact that 
60% of respondents willing to spend more for the low-priced OCV than the mean monthly per 
capita out-of-pocket expenditure on health (~USD 0.44 in 2004/2005) [30] indicates the 
priority of cholera. The finding that less than 20% would pay for the medium- or high-priced 
OCV indicates that despite this priority the cost was insurmountable. Other studies highlight the 
problem of cost as a barrier to use of desired OCVs [24-26]. If free vaccination becomes possible 
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for cholera control in Zanzibar, findings from this study of high community demand for a free 
OCV suggest it will be effective. This demand for an accessible vaccine complemented demand 
for classical preventive interventions, such as improved infrastructure, better services and 
health education from the government.  
 
The positive association of sociodemographic and economic factors with anticipated acceptance 
if the OCV was offered at some cost was represented by respondents who reported a regular and 
dependable income, which was used as a proxy for economic status, who had attained a good 
educational level and were married. The effects of income, present throughout all models, and 
education, present at low and high price, are supported by Lucas et al. who studied private 
demand for Dukoral® in the city of Beira, Mozambique [26]. In contrast to findings from Beira, 
increasing household size was identified as a negative determinant of willingness to pay for 
medium-priced OCV in the periurban community, probably reflecting limited financial 
capabilities there.  
 
As hypothesized, sociocultural features of illness, i.e., somatic symptoms (at low and high price), 
categories of social impact (at low and medium price) and perceived causes (at medium and 
high price), explained anticipated vaccine acceptance better than models containing only 
sociodemographic and economic characteristics. This finding demonstrates the explanatory 
power of sociocultural features of cholera-like illness as determinants of anticipated OCV 
acceptance. It shows that to enhance effectiveness of mass vaccination programs for cholera, 
pre-intervention assessments of community demand for OCV should not only consider the 
social epidemiology [31], but also examine local concepts of cholera-like experience, meaning 
and behavior. With particular reference to Zanzibar, consideration of social and cultural 
determinants of OCV acceptance may be especially important if the vaccine is offered at some 
cost. Even though overwhelming willingness to receive the free OCV made it impossible to study 
determinants, in settings where anticipated acceptance is lower, sociocultural features of illness 
are also likely to be important. 
 
The use of cultural epidemiological methods enabled the identification of explanatory variables 
based on empirical associations, rather than just relationships based on the insight of 
respondents. The finding that thirst was associated with anticipated acceptance of the low-
priced vaccine suggests a relationship between an important feature of dehydration from 
cholera, and the perceived value of a vaccine to prevent it, even though respondents did not 
explain it that way explicitly. Community solidarity to prevent spread of the infection to others—
though it was only identified in the rural site—also increased priority of the low-priced vaccine. 
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On the other hand, an alternative intervention to vaccination—rehydrating the patient with 
cheap liquids at home—was preferred to spending even a little money on vaccines.  
 
Although a disruption of local health care services was identified as the least prominent problem 
in both communities [23], this factor was a significant determinant of non-acceptance at 
medium price, but only among periurban respondents. This finding might indicate that 
periurban villagers who reported adequate government response to cholera outbreaks were less 
willing to spend money on a vaccine to prevent an illness that, in their eyes, can be dealt with in 
treatment camps. Such camps, where patients are treated at no cost in Zanzibar, are usually set 
up in primary health care facilities by district health authorities. These facilities were identified 
by everybody as the preferred place to seek help for cholera patients; and they were perceived as 
more helpful in the periurban community [23]. 
 
The appeal of perceived causes that compete with biomedical explanations of cholera made 
respondents less willing to buy an OCV at medium and high price. This suggests the relevance of 
people’s beliefs in witchcraft be taken into account as a factor if mass vaccinations are planned 
that require recipients to contribute fees that exceed ~USD 1.  
 
Based on the variation of the distribution of sociocultural features of cholera-like illness in both 
communities, interaction with site (rural vs. periurban site at baseline) was tested in all models. 
The only sociocultural feature that interacted with site at low price was fear of infection; at 
medium price, the only interacting factor was disruption of health services. At high price, no 
interaction terms remained in the models, implying that a financial level was reached that 
canceled out any community-specific characteristics. However, site itself was a main factor at 
this price level; it predicted higher anticipated OCV acceptance among rural respondents who 
also expressed higher willingness than their periurban counterparts to purchase the vaccine at 
its manufacturing costs of ~USD 9. 
 
Previous experience of illness episodes was positively associated with vaccine acceptance for 
cholera in Vietnam [25], and negatively for dysentery in six Asian countries [29]. Owing to the 
fact that personal or household episodes of the condition described in the cholera vignette were 
reported by 15.5% of the sample, crude analysis also examined previous experience as an 
additional explanatory variable. But since no suggestive relationship with any of the outcome 
variables was found (p>0.2), previous experience was not included as independent variable in 
subsequent adjusted analyses. Similarly, no statistically relevant relationship between previous 
experience of cholera and vaccine demand was reported in the private demand study from 
Mozambique [26]. 
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Although anticipated that research as presented here should guide future cholera immunization 
campaigns, recommendations that may follow from this prevaccination survey were not part of 
the design for the 2009 mass vaccination campaign in Zanzibar since analyses were only 
completed after the campaign had been implemented.  
 
It should also be noted that findings reported here indicate people’s intention to vaccinate but 
not necessarily their actual behavior. Study of determinants of actual acceptance is required to 
explain what actually influenced vaccine uptake. Recognizing this as a limitation of any pre-
intervention research, an additional study following the mass vaccination campaign in Zanzibar 
was conducted to retrospectively examine social and cultural determinants of uptake. 
Preliminary findings from that study, which is currently being written up, confirm the 
importance of considering sociocultural features of illness vis-à-vis a solely social 
epidemiological approach to explain vaccine acceptance. 
 
It may be regarded as another limitation that this study assessed the influence of illness 
explanatory models on vaccine acceptance. Another approach might also have considered how 
perceived features of OCVs, such as their effectiveness, duration of protection and/or side 
effects, affect acceptance [25,32]. Studying vaccine-related barriers to acceptance might thus 
also be required to explain their impact on immunization campaigns. A separate postvaccination 
study was conducted to analyze barriers of actual acceptance; details of these findings will be 
reported in a subsequent paper. Investigation of other factors that likely influence vaccine 
acceptance (e.g., national and regional policy contexts [33], other political–macroeconomic 
factors, access and equity issues, client–health care provider communication and geographical 
features [12,34]) might also warrant attention, but consideration of these factors was beyond the 
scope of this study. 
 
In conclusion, findings of this prevaccination survey suggest that anticipated acceptance of a 
free OCV is nearly universal in cholera-endemic areas of periurban and rural Zanzibar, and the 
vaccine also appears acceptable at an affordable price of ~USD 1. This study indicates the 
salience of considering not only sociodemographic characteristics but also locally valid 
sociocultural features of cholera-like illness as potentially relevant determinants of anticipated 
OCV acceptance. When planning mass vaccination campaigns, knowing more about local ideas 
of illness and how they may influence vaccination behavior is likely to be useful to increase 
participation for maximum community effectiveness. 
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Abstract 
Introduction 
Improving mass vaccination campaigns for cholera control requires not only consideration of 
technical and financial feasibility, but also consideration of social and cultural factors of vaccine 
acceptance in target populations. This study empirically examined how local community views 
of cholera influenced oral cholera vaccine (OCV) uptake in the 2009 mass vaccination campaign 
in Zanzibar. 
 
Methods 
Data from a baseline study that had elicited local community views of cholera with semi-
structured interviews was used. Uni- and multivariable logistic regression models identified 
social and cultural determinants of OCV uptake. 
 
Results 
Less than half of the 356 interviewed adult respondents (49.7%) drank two doses of OCV. 
Nonspecific features of cholera related to malaise were negative determinants. Recognition of 
unconsciousness as a serious sign of dehydration and concern that cholera outbreaks could 
negatively impact the local health care system in the rural area were positive determinants of 
acceptance. Female gender, rural residence and older age were also positive determinants of 
OCV uptake. 
 
Conclusions 
OCV uptake in a mass vaccination campaign in periurban and rural Zanzibar was lower than 
reported anticipated acceptance. Consideration of sociocultural features of cholera-like illness 
explained uptake better than a purely social epidemiological analysis. Planning of future cholera 
mass vaccination and sensitization campaigns in Zanzibar may directly benefit from findings 
presented here. The likely potential of cholera as a cause of severe dehydration should be 
emphasized vis-à-vis nonspecific symptoms of diarrheal illness. Rural recognition of the 
cholera-related burden on the local health care system was reflected by a priority for oral 
cholera vaccination. This indicates community appreciation of vaccination for cholera control 
and a perceived need to strengthen health care services in Zanzibar, particularly in rural areas. 
Findings recommend particular efforts to increase cholera immunization coverage among young 
adults, in periurban areas and for men. 
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5.1 Introduction 
In 2009, 45 countries mainly from Africa and Asia reported a global total of 221,226 cases and 
4,946 deaths attributable to cholera [1]. Recognizing difficulties with limited surveillance and 
under-reporting, the World Health Organization (WHO) estimates annual morbidity and 
mortality to be in excess of 3 million cases and 100,000 deaths [2].  
 
Besides timely rehydration and administration of antibiotics to patients who suffer from acute 
watery diarrhea caused by Vibrio cholerae O1 or O139, cholera control also involves preventive 
activities that center on the provision of safe water in sufficient quantities, sanitation and health 
education (WASH). Using oral cholera vaccines (OCV) has also been recommended to 
supplement WASH in an integrated strategy to reduce the public health burden of cholera in 
affected countries [3]. In endemic settings, community-based mass vaccination campaigns in 
selected hotspot areas have been the preferred route for efficient deployment of OCV.  
 
Following research examining key epidemiological parameters and characteristics of available 
OCVs in different populations and contexts [4-7], studies have investigated the practical 
feasibility and economic aspects of using OCVs in vulnerable populations that are at risk of 
recurrent cholera outbreaks [8-13]. Effective use of OCVs for maximum impact on morbidity 
and mortality depends on a variety of factors: in addition to the availability of a safe and 
efficacious vaccine and a well-functioning health system with sufficient capacity to implement 
mass immunizations, local views of potential respondents about cholera, and how these affect 
whether or not they would accept a vaccine, have to be considered for maximum coverage, but 
have often been neglected [14].  
 
Recently published studies addressing the relationship between local perceptions of severe 
enteric diarrheal illness and willingness or desire to receive vaccines have mainly focused on 
shigellosis and typhoid fever [15-21]. Studies on cholera have assessed social factors of vaccine 
acceptance [22] or have considered policy makers’ views [23], but empirical study of cultural 
factors of cholera and how they affect OCV uptake is lacking. 
 
Research reported in this paper took advantage of a mass vaccination campaign that was 
conducted in cholera-endemic areas of periurban and rural Zanzibar in 2009. Approximately 
50,000 inhabitants were targeted for vaccination with Dukoral®, which was the only OCV 
prequalified by the WHO at that time. This two-dose vaccine was offered without charge in two 
rounds in January and February 2009 [24]. Nine temporary vaccination posts were set up on 
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each island in the target communities; posts were open daily for at least eight hours and staffed 
with local health personnel and villagers. 
 
A baseline survey, which was conducted six months before the mass vaccination campaign, 
examined social and cultural determinants of anticipated OCV acceptance [25]. Findings from 
that study showed that 93.5% of the interviewed adults intended to take a vaccine if offered 
without charge. However, when offered at three different prices levels—approximately USD 0.9, 
USD 4.5 and USD 9—acceptance rates dropped to 60.7%, 19.4% and 15.2%, respectively. 
Multivariable models examining factors that affect vaccine acceptance if the OCV was offered at 
various levels of cost showed that sociocultural features of illness explain anticipated acceptance 
better than social epidemiological models [26] containing only sociodemographic 
characteristics. 
 
Since intention to be vaccinated does not always predict vaccination [27-29], examination of 
how cultural concepts of cholera determine actual OCV acceptance (or uptake) is much-needed. 
Findings from such research may contribute essential information to increase coverage of OCV 
in future mass vaccination campaigns for the benefit of cholera control in Zanzibar. 
 
This study used the integrated methods framework of cultural epidemiology [30]. This research 
approach has been valuable in determining how local cultural concepts of illness—i.e., how 
people experience an illness, what causes they attribute it to and what they do for help seeking—
affect health-related behavior [31-33]. The aim of this work was to identify social and cultural 
determinants of OCV uptake based on a random sample of adults that was interviewed before 
the 2009 mass vaccination campaign in Zanzibar [34]. 
5.2 Methods 
5.2.1 Setting and study participants 
Zanzibar belongs to the United Republic of Tanzania and consists of two major islands, Unguja 
and Pemba, just off the coast between Dar-Es-Salaam in the south and the Kenyan border in the 
north. Zanzibar has been regularly affected by cholera since the 1970s, and the government 
therefore recently decided to vaccinate major hotspots on both islands with assistance from the 
WHO. Two out of the six cholera-endemic communities that had been identified as mass 
vaccination targets were visited six months before the campaign was conducted in January and 
February 2009. The periurban community of Chumbuni on Unguja and the rural community of 
Mwambe on Pemba, both representing core areas of the campaign, were chosen for this baseline 
survey. Diarrhea-free adults aged 18 years or older were randomly selected for interviews. An 
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equal number of men and women were approached at each study site. A detailed description of 
both sites and more information on sampling has been presented elsewhere [34]. 
5.2.2 Instrument 
Semi-structured interviews based on the Explanatory Model Interview Catalogue (EMIC) are the 
principal instrument of inquiry in cultural epidemiological research [35]. EMIC interviews 
enable empirical clarification of how locally valid features of illness-related experience, meaning 
and behavior are distributed in a population [36-38]. Since adults who were apparently 
unaffected by cholera were the focus of this study, the EMIC interview began with the 
presentation of a clinical vignette that described a local person with cardinal somatic symptoms 
of cholera [34]. The interview also recorded sociodemographic characteristics and asked about 
anticipated acceptance of the OCV if it was offered without charge and at three different levels of 
cost.  
5.2.3 Data management and analysis 
Explanatory variables for analysis of actual determinants of OCV acceptance were obtained from 
the baseline study [34]. These included sociodemographic characteristics and sociocultural 
features of cholera-like illness, operationalized as patterns of distress referring to categories of 
somatic symptoms and social, emotional and financial impact, categories of perceived causes, 
self treatment at home and help seeking outside households of affected persons. The outcome 
variable, respondents’ vaccination status, was obtained from the mass vaccination database that 
had been compiled with the use of personal digital assistants by the International Vaccine 
Institute, Seoul [24]. Receipt of two complete doses of OCV was coded with a value of 1 and 
receipt of one or zero doses with a value of 0.  
 
Determinants of uptake were identified in a staged process that involved uni- and multivariable 
logistic regressions in SAS 9.2 (SAS Institute, Cary, NC, USA). Crude analysis examined 
associations between OCV and explanatory variables that were reported by 5-95% of 
respondents. Only variables with p<0.2 were retained for multivariable analyses to calculate 
focal models of sociocultural features of illness, adjusted for sociodemographics. Variables 
identified in focal models with p<0.2 were then used for calculating a comprehensive model. 
Assessment of which focal model explained vaccine uptake better than the focal model 
containing only sociodemographic characteristics was based on the corrected Akaike 
Information Criterion (AICc). The difference (∆) of AICc between each model and the model 
with the lowest AICc was calculated; any focal model with a ∆(AICc) noticeably lower than the 
one containing sociodemographics only was considered better. Interaction of rural or periurban 
site with each variable was tested individually in focal models; interaction terms were only 
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retained if their p values were below 0.1. Only interaction terms present in the focal models were 
assessed for inclusion in the comprehensive model based on the same threshold of p<0.1.  
 
Anticipated acceptance if the OCV was offered without charge, and at low, medium and high 
price, respectively, were also considered as potential explanatory variables; however, only 
acceptance for free was included in models because crude analysis showed no associations 
between intention to buy an OCV and uptake in the campaign (p>0.2). Because 15.5% of the 
sample had reported a personal or household episode of cholera [25], previous illness 
experience was also considered as potential explanatory variable, but not included in further 
analyses since crude analysis showed no suggestive association (p=0.44). 
 
This study was approved by the Research Ethics Review Committee of the World Health 
Organization and the Ethics Committee of the Ministry of Health and Social Welfare of 
Zanzibar. All study participants gave written consent before being interviewed. No 
compensation was offered to them. 
5.3 Results 
5.3.1 Sample characteristics 
A total of 356 interviews were completed, 179 in the periurban and 177 in the rural site. Slightly 
more than half of the study participants were women (50.3%). Mean age was 35.5 years, 76.4% 
were married and the mean household size was 6.8 persons. Major occupations were farming 
(30.6%), being housewife (21.4%) and working in the informal economy (17.1%). The sample 
consisted of Muslims, with the exception of one Christian woman. A majority (55.9%) reported a 
regular and dependable household income. Further details of sample characteristics have been 
described elsewhere [34]. 
5.3.2 OCV uptake 
Less than half of the respondents (49.7%) actually drank two doses of OCV, as documented in 
the mass vaccination database. More rural than periurban respondents drank the vaccine 
(58.8% vs. 40.8%, p<0.01, Chi2 test); and more women than men (54.8% vs. 44.6%), though 
with borderline statistical significance (p=0.056, Chi2 test). 
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5.3.3 Social and cultural determinants of OCV uptake 
Crude analysis and focal models 
Table 5-1 presents all variables that were identified in crude analysis together with focal models 
of sociocultural features of illness (i.e., patterns of distress, perceived causes and self treatment 
at home), of intention to receive the OCV and of sociodemographic characteristics.  
Table 5-1: Crude analysis and focal models of social and cultural determinants of oral cholera vaccine 
uptake in a community mass vaccination campaign in Zanzibar, 2009, n=356 
 Crude analysisa  Focal modelsb    
 Coefficient (95% CI)c 
p 
valued Coefficient (95% CI)c 
p 
valued Inte ∆(AICc)f 
Categories of distress: somatic symptoms      0 
Loss of appetite -0.34 (-0.70; 0.02) 0.07     
Loss of appetite (periurban site)   0.15 (-0.33; 0.62) 0.54   
Loss of appetite (rural site)   -0.58 (-1.22; 0.06) 0.08 *  
Nausea -0.49 (-0.99; 0.02) 0.06 -0.65 (-1.22; -0.08) 0.03   
Palpitations -0.19 (-0.44; 0.06) 0.14 -0.03 (-0.31; 0.24) 0.81   
Unconsciousness 0.11 (-0.05; 0.27) 0.18 0.21 (0.04; 0.38) 0.02   
Categories of distress: social impact      3.06 
Fear of isolation from others -0.11 (-0.27; 0.05) 0.18 -0.12 (-0.29; 0.05) 0.16   
Disruption of healthcare services 0.36 (0.01; 0.70) 0.04     
Disruption of healthcare services 
(periurban site)   -0.07 (-0.53; 0.38) 0.75   
Disruption of healthcare services 
(rural site)   1.01 (0.15; 1.87) 0.02 **  
Perceived causes      10.77 
Unprotected/spoiled food -0.15 (-0.38; 0.07) 0.18 -0.02 (-0.26; 0.22) 0.86   
Contact with contaminated water 0.19 (-0.03; 0.41) 0.08 0.13 (-0.11; 0.37) 0.28   
Witchcraft 0.50 (0.08; 0.91) 0.02 0.26 (-0.18; 0.69) 0.25   
Cannot say 0.35 (-0.07; 0.77) 0.10 0.21 (-0.24: 0.66) 0.36   
Self treatment at home      5.83 
Drinking more water or liquids -0.16 (-0.30; -0.01) 0.04 -0.12 (-0.28; 0.03) 0.12   
Intention to receive OCV      4.44 
Anticipated acceptance of a free OCV 0.87 (-0.05; 1.78) 0.06 0.91 (-0.06; 1.87) 0.07   
Sociodemographic characteristicsg      6.05 
Gender (male vs. female) -0.41 (-0.82; 0.01) 0.06 -0.48 (-0.97; 0.01) 0.05   
Site (rural vs. periurban) 0.73 (0.31; 1.15) <0.01 0.73 (0.15; 1.31) 0.01   
Age 0.02 (0.00; 0.03) 0.01 0.02 (0.01; 0.04) 0.01   
Marital status (married vs. not married) 0.68 (0.18; 1.19) <0.01 0.31 (-0.25; 0.88) 0.27   
Main occupation (housewife/student/retired 
vs. farmer/fisherman) -0.58 (-1.07; -0.09) 0.02
h -0.02 (-0.70; 0.66) 0.96   
Main occupation (informal business/formally 
employed vs. farmer/fisherman) -0.56 (-1.09; -0.03) 0.04
h -0.04 (-0.70; 0.61) 0.90   
aOnly variables with univariable association at p<0.2 listed; bEach model adjusted for sociodemographic 
characteristics, see footnote g; cLogistic regression coefficient with 95% confidence interval; dFigures in bold if 
p<0.05; eInteraction of rural with periurban site (baseline) considered if p value of interaction term less than 0.1 
(*p<0.1, **p<0.05); fDifference of corrected Akaike Information Criterion (AICc) between each model and the best 
model, designated with ∆(AICc)=0. Bold figures indicate models that explain vaccine acceptance better than the 
sociodemographic model only; gVariables used for adjusting. Figures reported in adjusted analysis refer to model with 
sociodemographic characteristics alone; hVariable is nominal with 3 categories, overall p=0.04 
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According to their ∆(AICc) values, focal models of somatic symptoms and social impact and the 
model containing the intention-to-vaccinate variable explained uptake better than the model 
containing only sociodemographic characteristics. Respondents who identified unconsciousness 
as a priority symptom and those among the rural respondents who strongly believed that 
cholera patients may cause a disruption in the local health care services were more likely to 
drink the OCV. Rural respondents and older respondents were also more likely to become 
vaccinated; and women tended to accept it more than men, though with borderline significance 
(p=0.053). Nausea was the only negative determinant of OCV uptake identified in any focal 
model. 
Comprehensive model 
All sociocultural features of illness identified as significant determinants of OCV uptake in the 
focal models (Table 5-1) were retained with similar effects in the comprehensive model that 
includes interactions with site (Table 5-2). An additional somatic symptom, loss of appetite, 
showed a negative association, but only in the rural site. Sociodemographic characteristics were 
also the same as in the focal model, with female gender clearly a significant positive determinant 
of OCV uptake (p=0.03). Anticipated acceptance for a free OCV appears to influence uptake; the 
adjusted regression coefficient is 0.91, but only marginally significant (p=0.078). 
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Table 5-2: Comprehensive model of social and cultural determinants of oral cholera vaccine uptake 
in a community mass vaccination campaign in Zanzibar, 2009, n=356 
 Comprehensive modela  
  Coefficient (95% CI)b p valuec Intd 
Categories of distress: somatic symptoms    
Loss of appetite (periurban site) 0.12 (-0.36; 0.59) 0.63  
Loss of appetite (rural site) -0.67 (-1.34; -0.00) 0.05 * 
Nausea -0.64 (-1.21; -0.08) 0.03  
Unconsciousness 0.19 (0.02; 0.37) 0.03  
Categories of distress: social impact    
Fear of isolation from others -0.08 (-0.26; 0.09) 0.35  
Disruption of healthcare services (periurban site) -0.06 (-0.52; 0.39) 0.79  
Disruption of healthcare services (rural site) 0.91 (0.00; 1.81) 0.05 * 
Self treatment at home    
Drinking more water or liquids -0.13 (-0.29; 0.03) 0.12  
Intention to receive OCV    
Anticipated acceptance of a free OCV 0.91 (-0.10; 1.92) 0.08  
Sociodemographic characteristics    
Gender (male vs. female) -0.51 (-0.97; -0.05) 0.03  
Site (rural vs. periurban) 0.83 (-0.41; 2.07) 0.19  
Age 0.03 (0.01; 0.04) <0.01  
aOnly variables identified in focal models at p<0.2 included in comprehensive adjusted model; bLogistic regression 
coefficient with 95% confidence interval; cFigures in bold if p<0.05; dInteraction of rural with periurban site 
(baseline) considered if p value of interaction term less than 0.1 (*p<0.1) 
 
The overall effect of site (adjusted regression coefficient: 0.94, 95% confidence interval: 0.47 to 
1.42, p<0.01) showed that rural respondents were more likely to accept the OCV (main effects 
model, not shown). 
5.3.4 Comparing social and cultural determinants of intention and 
uptake for a free OCV 
Because intention to be vaccinated with a free OCV was almost 95%, a multivariable logistic 
regression of determinants of this outcome would be inappropriate. Nevertheless, to address the 
question of whether determinants of intention and of uptake are similar or different, univariable 
logistic regression was conducted to compare results for each outcome. Table 5-3 shows the 
variables that were associated in crude analysis (p<0.05) with respondents’ intention to 
vaccinate themselves with a free OCV, including borderline results for gender and site.  
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Table 5-3: Crude analysis of social and cultural determinants of intention to vaccinate with a free oral 
cholera vaccine in Zanzibar, n=356 
  Crude analysisa 
  Coefficient (95% CI)b p value 
Categories of distress: social impact   
Fear of infecting others 0.86 (0.19; 1.54) 0.01 
Disruption of healthcare services 0.89 (0.06; 1.72) 0.04 
Perceived causes   
God's will -0.37 (-0.64; -0.10) <0.01 
Self treatment at home   
Drinking more water or liquids 0.55 (0.05; 1.04) 0.03 
Sociodemographic characteristics   
Gender (male vs. female) -0.89 (-1.81; 0.02) 0.06 
Site (rural vs. periurban) -0.89 (-1.81; 0.02) 0.06 
Regular and dependable household income 1.14 (0.22; 2.05) 0.02 
aOnly variables listed with univariable association with anticipated acceptance for a free OCV at p<0.05, except 
gender and site; bLogistic regression coefficient with 95% confidence interval 
 
Similar to the crude analysis of uptake (Table 5-1), categories related to social impact, perceived 
causes, self treatment at home and sociodemographic variables were identified as significant 
determinants. Reported disruption of health care services was a positive determinant in both 
analyses, and fear of infecting others was another positive factor, but only in the intention 
analysis. Among perceived causes, instead of witchcraft as positive determinant of uptake, God’s 
will was related to intention, but negatively. Rehydration at home featured as positive 
determinant in the intention-to-vaccinate analysis, but was a negative determinant of uptake. 
Among sociodemographics, only women and site were identified in both analyses, but periurban 
site was positively associated with intention and rural site with uptake. Increasing age, being 
married and being a farmer/fisherman were only positively associated with uptake. Although 
the vaccine was offered for free, regular and dependable income was a positive determinant of 
intention to be vaccinated. 
5.4 Discussion 
To improve the use of vaccines in endemic communities, public health planners need not only 
know coverage rates of vaccination campaigns, but also what social and cultural factors may 
have contributed to the achieved coverage [39]. By empirically examining the relationship 
between cultural concepts of illness and OCV uptake, a connection which has rarely been 
considered by classical epidemiologists and public health officials [40], this study developed an 
approach for contributing relevant information to help local decision makers to improve cholera 
control. 
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Prevaccination study results showed a high rate of anticipated acceptance (94%) across both 
islands. Despite this and the local organization and implementation of the 2009 mass 
vaccination campaign that attempted to minimize other access-related issues, uptake of the OCV 
was notably lower (50%). This uptake rate was between rates of two recent mass vaccination 
campaigns conducted in Africa and Asia. The 2003/2004 campaign using Dukoral® in an 
urban endemic neighborhood in the coastal town of Beira, Mozambique, estimated coverage of 
~41% for people 15 years and older [8]. Coverage with a locally produced two-dose OCV in a 
campaign conducted in 1998 in 13 communes of coastal Hue City, Vietnam, amounted to 74% 
for people aged 20 and above, and with significantly higher coverage among women [13].  
 
Demotivating factors for OCV uptake were related to symptoms of malaise: priority for getting a 
vaccine was reduced when people associated cholera with nausea and loss of appetite, which are 
not cholera-specific symptoms.  
 
Higher OCV uptake in the rural site was further reinforced by the fact that concern about the 
detrimental impact of cholera outbreaks on local health care services was a positive determinant 
of uptake among rural respondents only. Rural villagers feared that the local health care system 
would be overburdened with cholera cases; this might explain their preference for vaccination, 
although supplementary WASH activities were also frequently demanded [25]. This finding and 
the previously reported higher rural than periurban willingness to buy the OCV at a price of 
almost USD 10 [25] suggest a higher priority for using OCV in rural Zanzibar.  
 
Perceived severity of illness may influence desire for enteric vaccines [15-17]. Because cholera 
was almost universally reported in both communities as “very serious” (97%) and “usually or 
sometimes fatal without treatment” (96%) (not shown), the influence of illness-related severity 
and fatality could not directly be analyzed as potential determinants of OCV uptake. Perceptions 
regarding severity and potential fatality were nevertheless related to vaccine acceptance in these 
communities because unconsciousness, a feature of dehydration and thus an advanced stage of 
cholera, was not only reported as one of the most prominent somatic problems [34], but it was 
also identified as positive determinant of OCV uptake. 
 
Increasing age and female gender were further positive determinants of OCV uptake. In 
contrast, Ali et al., who studied how sociodemographic and spatial variables influenced 
participation in a cholera vaccination trial in Kolkata, India, found that younger age was 
positively related [22]. Although previous personal or household illness experience was not 
associated with OCV uptake, older people might have drunk the vaccine more often because of 
their higher likelihood to have witnessed the grave consequences of cholera. In line with the 
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Kolkata study [22] and the 1998 mass vaccination campaign in Vietnam [13], men were less 
likely to accept oral cholera vaccination. As in Zanzibar, it is not clear whether this reflects more 
responsibility or self-perceived vulnerability among women. 
 
In addition to focusing on sociocultural features of cholera, anticipated acceptance of the free 
OCV was also assessed and found to be a tentative positive predictor of uptake. However, 
evidence that intention to vaccinate is directly related to vaccination behavior is still 
inconclusive [28,29,41]; because of this and because no studies have yet firmly established such 
an association for cholera, further research is warranted to investigate this relationship. 
 
Social and cultural determinants of anticipated acceptance and uptake of an OCV in a mass 
vaccination campaign in Zanzibar were not directly comparable because of almost universal 
willingness for free immunization. Recognizing this statistical limitation, comparison of crude 
associations nevertheless showed that categories related to social impact, perceived causes, self 
treatment at home and sociodemographics are relevant determinants for both intention to be 
vaccinated and actual behavior. 
5.4.1 Conclusions 
Uptake of a free OCV in the 2009 mass vaccination campaign in a periurban and a rural 
endemic area of Zanzibar was lower than anticipated acceptance. This study showed that 
consideration of sociodemographic and economic factors is necessary but not sufficient to 
explain coverage, because sociocultural features of cholera-like illness determined vaccine 
acceptance better than purely social epidemiological models. 
 
Planning of future cholera mass vaccination and sensitization campaigns in Zanzibar should 
benefit from findings presented here. Cholera as a cause of severe dehydration should be 
emphasized vis-à-vis its moderate malaise-related symptoms. Rural recognition of the cholera-
related burden on the local health care system was reflected by a priority for oral cholera 
vaccination; this shows not only the importance of vaccination for cholera control but also the 
need to strengthen health care services in Zanzibar, particularly in rural areas. Inasmuch as 
resources for public health are generally scarce in Zanzibar, findings recommend particular 
efforts to increase cholera immunization coverage among young adults, in periurban areas and 
for men. 
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Abstract 
Background 
Recent research in two cholera-endemic communities of Zanzibar has shown that a majority 
(~94%) of the adult population was willing to receive free oral cholera vaccines (OCVs). Since 
OCV uptake in the 2009 campaign reached only ~50% in these communities, an evaluation of 
social and cultural factors and of barriers was conducted to understand this difference for future 
cholera control planning. 
 
Methodology/Principal Findings 
A random sample of 367 adult periurban and rural community residents (46.6% immunized vs. 
53.4% unimmunized) was studied with a semi-structured interview that inquired about social 
and cultural features of cholera depicted in a vignette and barriers to OCV uptake. Symptoms 
(rectal pain, loose skin only in rural community) and perceived causes (uncovered food, contact 
with contaminated water) specific for severe diarrhea were associated with uptake. Purchasing 
drugs from pharmacies to stop diarrhea and vomiting was negatively associated with uptake. 
Increasing household size, age and previous enteric illness episode were positively related to 
uptake, the latter only at the rural site. The most prominent barrier to uptake was competing 
obligations or priorities (reported by 74.5%, identified as most important barrier by 49.5%). 
Next most prominent barriers were lacking information about the campaign (29.6%, 12.2%), 
sickness (14.3%, 13.3%) and fear of possible vaccine side effects (15.3%, 5.6%). The majority of 
unvaccinated respondents requested repetition of the vaccination with free OCVs. 
 
Conclusions/Significance 
Factors associated with uptake indicated a positive impact of the vaccination campaign and of 
sensitization activities on vaccine acceptance behavior. Unlike communities opposed to cholera 
control or settings where public confidence in vaccines is lacking, identified barriers to uptake 
indicated a good campaign implementation and trust in the health system. Despite prospects 
and demand for repeating the vaccination, local decision makers should reconsider how careful 
logistical arrangements may improve community coverage and thus effectiveness of vaccination 
campaigns. 
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6.1 Introduction 
Cholera control in populations living at risk of recurrent cholera outbreaks is based on timely 
treatment and a preventive strategy, mainly promoting supply of safe water in sufficient 
quantities, improved sanitation, and health education (WASH) [1]. Despite these 
recommendations, cholera has remained a global public health concern; the World Health 
Organization (WHO) assumes that annual estimates for morbidity and mortality exceed 3 
million cases and 100,000 deaths [2]. The WHO also recommends the use of mass oral cholera 
vaccination as a supplementary prevention measure to WASH [3].  
 
Cholera is an enteric bacterial disease caused by Vibrio cholerae serogroup O1 or O139. People 
living in unsanitary conditions without access to safe drinking water and sanitation are at 
greatest risk of becoming infected with V. cholerae, which is mainly transmitted through the 
fecal-oral route. Major clinical features, which usually start abruptly after an incubation period 
of a few hours to five days, include profuse watery diarrhea and vomiting [4]. Without 
treatment, case-fatality rates may rise to 50% or above. Rehydration is the mainstay for 
treatment and includes administration of oral rehydration solution (ORS) to patients with mild 
to moderate symptoms and intravenous fluids to severely dehydrated cases. Antibiotics should 
also be administered to severe cases to shorten episodes, diminish the amount of intravenous 
fluids required and reduce shedding of V. cholerae [2]. Some studies suggest that antibiotics 
should also be used for moderate cases [5]. 
 
While recent research on the use of oral cholera vaccines (OCVs) in mass vaccination campaigns 
in endemic communities has focused on epidemiologic parameters [6,7] and economic aspects 
[8-13], relatively little is known about local perceptions of cholera, intentions to accept OCVs 
and how such factors are associated with uptake. Even though detailed knowledge of 
epidemiologic and economic aspects is indispensable for a successful introduction of vaccines, 
social and cultural factors should also be examined to improve and sustain vaccination coverage 
[14,15]. In the past, a lack of attention to community views of illness and prevention has proven 
to be fatal not only for disease control in certain populations but also for national or 
international public health goals, e.g., to eradicate polio in Africa [16,17]. 
 
Up to date, only articles on policy makers’ views of cholera [18,19] and on social factors of oral 
cholera vaccine uptake [20] have been published, and studies on the feasibility and costs of 
community mass vaccination campaigns have examined why people might not have taken the 
OCV [8,21,22]. However, an assessment of mass vaccination campaigns to more systematically 
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evaluate social and cultural factors associated with OCV uptake and to identify potential barriers 
is still missing, but likely to be very useful for the benefit of local (and even international) 
vaccination campaign planning. 
 
Recent research in two cholera-endemic communities of Zanzibar, conducted within the 
framework of a WHO study to evaluate the use of OCV in endemic settings, has shown that a 
vast majority (~94%) of the population targeted for the campaign was in principle willing to 
receive free vaccines against cholera [23]. Since actual OCV acceptance (or uptake) reached only 
~50% in this prevaccination sample, an evaluation of social and cultural factors and of barriers 
to OCV uptake was needed to understand this difference for future cholera control planning in 
Zanzibar. 
 
Findings reported here are based on the research approach of cultural epidemiology, which was 
used in prevaccination studies to examine social and cultural determinants of anticipated and 
actual OCV acceptance [23,24]. Cultural epidemiology is a research approach in health social 
sciences that integrates quantitative and qualitative data [25] to study community views of 
illness [26-30] and how these influence health-related behavior [31-33].  
 
This study examined data from a periurban and a rural community targeted in the 2009 OCV 
mass vaccination campaign in Zanzibar. It aimed to evaluate the influence of social and cultural 
factors on OCV uptake and to identify logistical, medical, social and system-related barriers to 
uptake. 
6.2 Methods 
6.2.1 Ethics statement 
The Research Ethics Review Committee of the World Health Organization and the Ethics 
Committee of the Ministry of Health and Social Welfare of Zanzibar approved this study. 
Participants were informed orally about this study and also given a detailed information sheet. 
Only those who gave written consent were interviewed. No compensation was offered for the 
interview. Interview data sheets did not bear the names of respondents and all data were 
anonymized before analysis. 
6.2.2 Setting 
The east African archipelago of Zanzibar belongs to the United Republic of Tanzania and is 
inhabited by ~1.2 million people who are predominantly Muslim. Kiswahili is the main 
language, but English is also widely used. The archipelago is located ~60 km off the coast of 
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mainland Tanzania and consists of two major islands—Unguja in the south and Pemba in the 
north—and several islets; it can be reached from the coast by ferry or air within 20 minutes to 2 
hours. Zanzibar has been regularly affected by cholera; the first cases in recent times were 
detected in 1978 [34,35]. 
 
This study was conducted in the periurban Shehia of Chumbuni (population ~11,000) in Unguja 
and the rural Shehia of Mwambe (~8,000) in Pemba. Both Shehias (administrative term for 
community in Zanzibar) were among the core areas of a mass vaccination campaign that was 
conducted in early 2009 by the Ministry of Health and Social Welfare of Zanzibar (MoHSW) 
with support from the WHO. The sample for this study was drawn from these two Shehias 
because they had been studied in a prevaccination survey in 2008 [23,24].  
6.2.3 Mass vaccination campaign 
The mass vaccination campaign aimed to vaccinate ~50,000 inhabitants with Dukoral®, a two-
dose OCV containing killed V. cholerae O1 bacteria and recombinant cholera toxin B subunit 
protein [36]. Dukoral® was the only OCV prequalified by the WHO at the time of vaccination. It 
requires a cold chain for storage and safe water (~1.5 dl per dose) for its administration. It was 
offered without charge in two rounds from January 17 to 26 and February 7 to 16, 2009, to 
residents aged two years or older from six Shehias from Unguja and Pemba that had been 
identified as recent cholera hotspots. Nine vaccination posts were set up on each island that 
operated daily for at least eight hours and were staffed with local health care workers and 
villagers.  
 
Information activities for the campaign started with a meeting with district officials on 
December 23, 2008 followed by three meetings to inform leaders, Shehia committee members 
and mobilizers from each community (January 5 and 10, 2009) and general community 
residents (January 15, 2009) (MoHSW, Health Promotion Unit, OCV Social Mobilization 
Report, February 20, 2009). A refresher meeting in the communities followed shortly before the 
second round on February 5, 2009. Social mobilization used posters, leaflets, street banners and 
T-shirts to disseminate information on the OCV campaign and to reinforce general hygiene and 
sanitation messages in the six Shehias. Messages were continuously broadcast on national TV 
and radio from the first until the last day of the campaign. The local press was also briefed and 
newspaper articles reported from the campaign to promote participation. The campaign was 
officially launched by the Minister of Health who drank the vaccine publicly at the Chumbuni 
Primary Health Care Unit (Zanzibar Today, January 18, 2009). Mobilizer teams were formed 
for each Shehia and delivered information from house to house and by megaphone. Each team 
consisted of five to six community residents representing also women’s groups, youth, religious 
102 
groups and members of the opposition party. Key messages highlighted not only the importance 
of vaccination for cholera prevention, but also promoted hygiene messages to prevent other 
diarrheal diseases, and explained administration of the OCV, its characteristic features and 
potential for mild side effects.   
6.2.4 Design and sampling 
This was a cross-sectional survey designed as a case-control study. Data were collected in June 
and July 2009 from vaccinated and unvaccinated community residents, six months after the 
mass vaccination campaign. The sampling frame for this study was derived from the census 
database that had been compiled by the International Vaccine Institute shortly before the mass 
vaccination campaign implementation in early 2009 [37]. Names, age, sex, OCV vaccination 
status and a unique house identification number were extracted for both study Shehias. 
Respondents’ houses in Chumbuni were located with the help of aerial photographs indicating 
house numbers; houses in Mwambe were located with the help of local assistants. 
 
Approximately 380 adults, based on a sample size of 330 [38] with 15% compensation for 
missing data, were identified following a stratified random sampling procedure. After exclusion 
of respondents who had been interviewed before the vaccination for the baseline study [24], all 
respondents aged 18 years and older were selected. Second, periurban and rural respondents 
were separated and groups of women and men created among them. Third, of the ~95 women 
and 95 men required per site, 50% were selected from those who had received two doses of the 
OCV, 40% from those who had not received a single dose and 10% from those with one dose 
only. Only residents who were physically and mentally fit to stand an interview of approximately 
one hour duration were included in the sample. Women who had not taken the vaccine because 
of pregnancy during the mass vaccination campaign were not interviewed.  
6.2.5 Instrument 
Semi-structured interviews based on the Explanatory Model Interview Catalogue (EMIC) are the 
principal instrument for cultural epidemiological studies and elicit locally valid representations 
of illness-related experience, meaning and behavior [25,39]. An EMIC interview for study of 
diarrhea-free community residents was developed based on the prevaccination survey [24]. A 
ten-day workshop was conducted shortly before the survey to train field workers and pilot the 
EMIC interview in Shehias adjacent to the study communities. 
 
After recording relevant sociodemographic characteristics, interviews began with the telling of a 
brief story in easily understandable terms, making use of a clinical vignette that described a 
cholera patient with cardinal somatic symptoms. To study sociocultural features of cholera-like 
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illness, respondents were asked a series of open and closed questions. These elicited 
respondents’ opinions on (i) what additional physical symptoms the cholera patient described in 
the vignette might suffer from, (ii) how the illness might impact him/her socially, emotionally 
and financially, (iii) what causes the illness may be attributed to and (iv) what would usually be 
done at the patient’s home for self treatment and (v) what sources of help would be consulted 
outside the household. 
 
Respondents who did not swallow two doses of the OCV during the mass vaccination campaign 
were queried about their reasons against vaccination by specifically inquiring about barriers 
related to logistical, social and system-relevant and medical aspects. 
6.2.6 Data management and analysis 
Data entry 
Quantitative data were recorded by interviewers on data sheets, double entered in Epi Info 3.5.1 
(CDC, Atlanta, GA, USA) by data entry clerks and cleaned for statistical analysis in SAS 9.2 (SAS 
Institute, Cary, NC, USA). Qualitative data, i.e. narratives from selected items of the interview, 
were written down during the interview by note takers in Kiswahili (or in English in a few cases). 
Narratives were typed in a pre-coded word processor template after translation into English. 
This enabled automatic importation of entire interviews with codes into the qualitative data 
analysis software MAXQDA 10 (VERBI Software, Consult. Sozialforschung. GmbH, Marburg, 
Germany). For integrated analysis of quantitative and qualitative data, relevant quantitative 
variables were imported into MAXQDA 10; this made it possible to retrieve narrative segments 
based on analytically relevant findings or statistical relationships.  
Multivariable analysis of factors of uptake 
Sociodemographic characteristics were coded as numeric or categorical variables and, if needed, 
dichotomized for logistic regression analysis. Categories of sociocultural features of cholera-like 
illness were assigned a value of 2 if they were mentioned spontaneously and a value of 1 if they 
were mentioned only after probing. Those among the reported categories that were identified as 
single most troubling (among patterns of distress), most important (perceived cause) or most 
helpful (help seeking) were given an additional value of 3. A cumulative prominence was then 
calculated for each category ranging from 0 to 5. This approach based on the ranked 
prominence of responses has been widely used in analytic cultural epidemiological studies, 
which have examined how sociocultural features of illness affect health behavior [31,33].  
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To identify social and cultural factors explaining OCV uptake, a multivariable logistic regression 
model was calculated. OCV uptake was obtained from mass vaccination campaign data that had 
been compiled electronically during the campaign [37]; fully immunized respondents were 
coded as 1 and those who had received only one or no dose were coded as 0. The regression 
analysis included interaction with site as suggested by site-specific findings from the 
prevaccination survey [24] and because OCV uptake was higher in the rural than in the 
periurban site (58.8% vs. 40.8%, p=0.001).  
 
Only explanatory variables reported by 5-95% were considered for analysis. First, variables were 
identified whose univariable association with OCV uptake had a p<0.2. Second, multivariable 
regression models were run for each subset of categories related to patterns of distress, 
perceived causes and help seeking, and each of these models was adjusted for sociodemographic 
characteristics. To calculate the final model, only those variables which were retained with a 
p<0.2 in these sub-models were considered. Interaction between each explanatory variable and 
site (rural vs. periurban site at baseline) was tested in sub-models; only interaction terms 
retained with a p<0.1 in sub-models were used in the final model. The final model reports 
logistic regression coefficients with 95% confidence intervals and p values. In case of significant 
interaction with site, site-specific estimates are presented. 
Descriptive analysis of barriers to uptake 
Coding and calculation of variables related to barriers followed the approach used for 
sociocultural features of illness. Unvaccinated respondents’ spontaneous and probed answers 
for each barrier and the barrier they identified as most important were recorded. Thematically 
similar barriers were subsumed under groups of logistical, medical and social/system-related 
barriers. The nonparametric Wilcoxon test was used for identifying statistically significant 
differences of prominence between both sites and between genders. 
6.3 Results 
6.3.1 Sample characteristics 
A total of 378 respondents were interviewed. Eleven interviews were excluded from analysis due 
to pregnancy. Of the remaining 367 respondents, 46.6% were vaccinated with two doses, 9.3% 
with one dose only and 44.1% had not drunk any dose of OCV. Their characteristics are 
presented in Table 6-1. All respondents were Muslims and of Tanzanian nationality. 
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Table 6-1: Sociodemographic characteristics and vaccination status of a sample interviewed after a 
community mass vaccination campaign in Zanzibar, stratified by site and gender 
 Total  Periurban site Rural site   Women Men   
Number (%) 367 (100)  189 (51.5) 178 (48.5)   180 (49.0) 187 (51.0)  
Age (years)          
Mean (SD) 35.4 (14.6)  33.1 (13.5) 37.8 (15.4) **  35.7 (13.8) 35.1 (15.4)  
Median (range) 32 (18-90)  28 (18-75) 36.5 (18-90) **  33 (18-90) 30 (18-80)  
Marital status (%)          
Never married 30.5  42.9 17.4 ***  21.1 39.6 *** 
Married 59.4  49.7 69.7 ***  61.1 57.8  
Separated 0.5  0.0 1.1   0.0 1.1  
Divorced 6.5  6.9 6.2   12.2 1.1 *** 
Widowed 3.0  0.5 5.6 **  5.6 0.5 ** 
Household size (number of persons)         
Mean (SD) 6.9 (3.0)  7.6 (3.2) 6.3 (2.6) ***  6.8 (3.0) 7.1 (2.9)  
Median (range) 7 (1-15)  7 (1-15) 6 (1-13) ***  7 (1-14) 7 (1-15)  
Main occupation (%)          
Agriculture 30.8  3.2 60.1 ***  35.0 26.7  
Fishing 6.0  0.0 12.4 ***  0.0 11.8 *** 
Self-employment 23.7  36.0 10.7 ***  18.3 28.9 * 
Formal employment 8.2  13.2 2.8 ***  3.3 12.8 *** 
Housewife 12.3  18.0 6.2 ***  25.0 0.0 *** 
Casual laborer 0.8  1.1 0.6   0.0 1.6  
Student 12.5  18.0 6.7 **  12.2 12.8  
Not active/retired 5.7  10.6 0.6 ***  6.1 5.3  
Highest education (%)          
No education 8.4  4.8 12.4 *  10.6 6.4  
Koranic school 23.7  10.1 38.2 ***  30.6 17.1 ** 
Primary school 26.4  21.2 32.0 *  19.4 33.2 ** 
Secondary school 36.8  56.1 16.3 ***  35.6 38.0  
Above secondary school 4.6  7.9 1.1 **  3.9 5.3  
Vocational school 1.4  1.6 1.1   0.6 2.1  
Higher education 3.3  6.3 0.0 ***  3.3 3.2  
Household income (%)          
More regular and dependable 39.8  54.0 24.7 ***  41.1 38.5  
Less regular and dependable 60.2  46.0 75.3   58.9 61.5  
Vaccination status         
Receipt of 2 doses, number (%) 171 (46.6)  86 (45.5) 85 (47.8)   85 (47.2) 86 (46.0)  
Receipt of 1 dose, number (%) 34 (9.3)  18 (9.5) 16 (9.0)   17 (9.4) 17 (9.1)  
Receipt of 0 doses, number (%) 162 (44.1)  85 (45.0) 77 (43.3)   78 (43.3) 84 (44.9)   
SD: Standard deviation, t test used for comparing means, Wilcoxon test used for comparing medians, Fisher’s exact 
test used for comparing proportions (*p<0.05, **p<0.01, ***p<0.001) 
6.3.2 Social and cultural factors associated with OCV uptake 
Multivariable logistic regression analysis identified sociocultural features of cholera-like illness 
associated with OCV uptake, adjusted for sociodemographic characteristics (Table 6-2).  
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Table 6-2: Social and cultural factors associated with oral cholera vaccine uptake in a community 
mass vaccination campaign in Zanzibar, n=367 
 Adjusted analysisa   
 Coefficient (95% CI)b p valuec Intd 
Categories of distress: somatic symptoms      
Pus in stool 0.30 (-0.14; 0.75) 0.18  
Rectal pain 0.60 (0.16; 1.05) 0.01  
Sunken eyes 0.18 (-0.15; 0.51) 0.29  
Loose skin (periurban site) -0.48 (-1.15; 0.18) 0.16  
Loose skin (rural site) 0.70 (0.17; 1.22) 0.01 ** 
Perceived causes    
Unprotected/spoiled food 0.22 (0.00; 0.43) 0.05  
Contact with contaminated water 0.36 (0.06; 0.65) 0.02  
Outside help seeking    
Pharmacy/Over-the-counter drugs -0.61 (-1.08; -0.13) 0.01  
Sociodemographics and previous illness episode    
Age 0.03 (0.01; 0.04) <0.01  
Household size 0.09 (0.01; 0.17) 0.03  
Site (rural vs. periurban) -1.29 (-2.32; -0.26) 0.01  
Previous enteric illness episode (periurban site) -0.38 (-1.73; 0.98) 0.59  
Previous enteric illness episode (rural site) 1.11 (0.13; 2.09) 0.03 * 
aList of variables with univariable association at p<0.2 that were included in adjusted models; bLogistic regression 
coefficient with 95% confidence interval; cFigures in bold if p<0.05; dInteraction of rural with periurban site 
(baseline) considered if p value of interaction term less than 0.1 (*p<0.1, **p<0.01) 
 
Among categories of distress, two of the somatic symptoms that were mentioned in connection 
with the cholera vignette were positively associated with OCV uptake: rectal pain and loose or 
shriveled skin, which is a sign of dehydration. Rectal pain was spontaneously reported by 1.9% 
and mentioned by 68.7% upon probing. Vaccinated and unvaccinated respondents explained 
that this symptom meant that frequent passing of stool may be painful to the person described 
in the vignette. Loose or shriveled skin was only associated with vaccine uptake among rural 
respondents. It was reported by 86.6% of the total sample; 88.8% reported it in the rural and 
84.7% in the periurban site and more rural respondents mentioned it spontaneously (33.1%) 
compared to periurban respondents (5.8%). Accounts from vaccinated and unvaccinated 
respondents were similar, saying that frequent diarrhea leads to loss of water in the body, which 
in turn was seen as the reason for dehydration manifested by the sign of loose skin. 
 
Among categories of perceived causes, two categories were positively associated with OCV 
uptake: eating food that has not been covered properly and contact with contaminated water. 
The first category was mentioned by 89.4% of the total sample and identified by 8.2% as most 
important cause for cholera. Among those who reported this category, the majority said that if 
food is not covered properly, flies or other insects that carry germs may contaminate it. A 22-
year-old farmer from Pemba, who had ingested both doses, explained it this way:  
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“Yes, this is the area where one can get it [the illness described in the vignette], because the flies are 
carrying feces and land with it on the food.”  
Such explanations were not only typical for the vaccinated group because narratives from 
unvaccinated respondents also frequently showed flies as main disease vector. 
 
Fewer respondents (69.2%) reported that contact with contaminated water was a cause for 
cholera, and only 1.9% identified it as most important cause. Both vaccinated and unvaccinated 
respondents referred to dirty water as a potential cause because it contains bacteria or other 
disease-causing organisms that can be transmitted through the fecal-oral route. The following 
example from a 19-year-old fully immunized male student from Unguja illustrates this 
reasoning:  
“Yes, because it is already contaminated with bacteria. If you have touched the water and not 
washed your hands with soap and then you eat food you will get the disease.”  
 
Among categories of help seeking outside the home, consulting pharmacies was negatively 
associated with OCV uptake. While everybody reported spontaneously that a patient with 
cholera-like illness should be sent to professional health facilities, 32.4% of the sample also 
reported getting drugs from the pharmacy as a means to stop diarrhea and vomiting, though 
none of them identified this category as most helpful. Primarily antibiotics like tetracycline or 
septrine were mentioned among both vaccinated and unvaccinated groups. 
 
Among sociodemographic characteristics, increasing household size and increasing age was 
positively related to OCV uptake. A total of 9.5% reported a household episode of the illness 
described in the cholera vignette. No gender differences were found, but rural respondents 
reported more such episodes than their periurban counterparts (13.5% vs. 5.8%, p=0.013). This 
variable was also positively associated with OCV uptake, but only at the rural site. 
6.3.3 Barriers to OCV uptake 
All 196 respondents who were not completely immunized were asked the following open 
question: “Can you tell us the reasons why you did not swallow two doses of the cholera 
vaccine?” Individual and grouped barriers are presented for the overall sub-sample of 
unvaccinated respondents (Table 6-3), and stratified by site (Table 6-4) and by gender (Table 
6-5).  
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Most prominent barriers 
Logistical factors were reported as paramount barriers, followed by medical issues; social and 
system-related factors were the least prominent barriers (Table 6-3).  
Table 6-3: Barriers to uptake of an oral cholera vaccine in a community mass vaccination campaign 
in Zanzibar 
  Pooled sample, n=196 
 How reported?  
Barriers to uptakea   
Totalb 
% 
Spon.c 
% 
Most 
importantd 
% 
Mean 
prom.e 
Logistical barriers 76.5 71.4 63.3 3.38 
Competing obligations/priorities 74.5 69.4 49.5 2.92 
Lacking information about campaign 29.6 9.7 12.2 0.76 
Vaccination post open days/hours limited 13.8 3.1 1.5 0.21 
Costs apart from vaccine 3.6 0.5 0.0 0.04 
Organizational problems at vaccination post 0.5 0.0 0.0 0.01 
Medical barriers 31.1 23.5 23.5 1.25 
I was sick (not due to vaccine) 14.3 14.3 13.3 0.68 
Fear of possible side effects from vaccine 15.3 6.1 5.6 0.38 
Doubted effectiveness of vaccine 9.2 5.6 4.6 0.29 
Social/system-related barriers 12.2 4.1 3.6 0.27 
Vaccine free of charge (useless medicine) 5.6 2.6 1.0 0.11 
Fear of infertility 3.1 0.0 1.5 0.08 
Mistrust motives of campaign 5.1 2.0 0.0 0.07 
Social pressure against taking vaccine 3.1 1.0 0.5 0.06 
Lacking confidence in government 2.6 1.0 0.5 0.05 
Prior bad experience with health system 0.5 0.0 0.0 0.01 
Miscellaneous 8.7 8.7 6.6 0.37 
Other barriers 7.1 7.1 5.6 0.31 
Cannot say/Nothing 1.5 1.5 1.0 0.06 
aBarriers ordered according to descending mean prominence (see footnote e), grouped barriers in bold; bPercentage 
of barriers reported spontaneously and after probing; cPercentage of barriers reported spontaneously only; 
dPercentage of barriers that were identified as single most important among all the reported barriers. Six respondents 
who only received one dose identified barriers that were not among the ones listed as most important: four 
respondents reported “Experience of side effects from first dose of vaccine,” two respondents reported “Did not have 
information about timing of second dose;” eMean prominence based on values assigned for each barrier (3=identified 
as most important, 2=reported spontaneously, 1=reported after probing, 0=not reported) 
 
The most prominent individual barrier to OCV uptake, i.e., the one having the highest mean 
prominence, was competing obligations or priorities, which was reported by almost three-
quarters (74.5%) of the unvaccinated respondents and identified by nearly half (49.5%) as the 
most important barrier. Analysis of qualitative data from these respondents indicated that they 
had mostly been away for a longer time on the mainland or another island and thus were less 
able to reach the vaccination posts. Activities included working in farms, going on month-long 
fishing trips and some visited their relatives or were away from home for study or exams. 
 
The second most prominent barrier was lacking information about the campaign, reported by 
29.6% and identified as most important barrier by 12.2%. Almost everyone who did not have 
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information about the campaign also reported his/her absence because of other activities. The 
following accounts illustrate how lacking information and being away together prevented 
vaccine uptake. Respondents were either away during both rounds, as illustrated by the account 
of a 36-year-old man from Chumbuni:  
“I was not here during the campaign and I didn’t know when the campaign started and finished. I 
am a seaman. My wife informed me that all the people in the house got the vaccine. The day I 
arrived here I was advised to take the vaccine but I didn’t take it because I was tight with other 
activities. And on the second day my boss asked me to go to Mombasa.”  
Or they were only in their village during the second round, but not given the vaccine:  
“I was not around because I had traveled to Wete. And when I came back I went to the vaccination 
post and the workers told me that I cannot get it because I missed the first dose.” (Housewife from 
Mwambe, 50 years old) 
 
Sickness, which was reported by 14.3% of unvaccinated respondents in total and identified by 
13.3% as the single most important reason, was the third most prominent barrier to uptake. 
Respondents who reported a sickness were either uncomfortable to take the vaccine, concerned 
about a potential negative impact of vaccination on their health, or simply not able to access 
vaccination posts because of a physical handicap or a recent delivery or surgery.  
 
Fear of possible side effects was the fourth most prominent barrier against vaccination, reported 
by 15.3% in total and identified by 5.6% as most important. People were afraid of side effects 
such as diarrhea, vomiting, nausea, skin reactions after injection, and exacerbations of 
underlying diseases due to interaction with the vaccine. Also, something free of charge was 
believed to cause problems. Three respondents were afraid of side effects if the vaccine was 
administered concurrently with other drugs—they were also among those who reported being 
sick as main barrier to vaccination. 
 
Besides fear of side effects, doubted effectiveness of the vaccine was reported by 9.2% as another 
vaccine-related barrier; and for 4.6% this category was the main reason against taking the OCV. 
Respondents were not sure about the benefit for their own health or the effectiveness of the 
vaccine. 
Least prominent barriers 
The four least prominent barriers to OCV uptake were related to lacking confidence in the 
government (reported in total by 2.6% of the unvaccinated sub-sample), costs apart from the 
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vaccine (3.6%), prior bad experience with health system (0.5%), and organizational problems 
at vaccination post (0.5%) (Table 6-3).  
 
Other barriers related to social issues were reported by 5% or less: mistrust motives of the 
campaign were reported by 5.1% and social pressure against vaccination and fear of infertility 
by 3.1%. Nobody reported that discouragement by authoritative persons made them refuse 
vaccination. 
Site- and gender-specific barriers  
Among the most prominent barriers, lacking information about the campaign was more often 
reported and identified as most important barrier among rural than periurban respondents 
(p=0.012) (Table 6-4). Narratives indicated that rural respondents were away from their homes 
for longer times and several went fishing for months, which made it difficult for them to be 
home at the right time slot needed for the vaccination:  
“I had traveled to Unguja for fishing for a period of one month and fifteen days. And I had no 
information about the vaccine campaign.” (Unvaccinated rural fisherman, 35 years old) 
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Table 6-4: Barriers to uptake of an oral cholera vaccine in a community mass vaccination campaign 
in Zanzibar, stratified by site 
  Periurban site, n=103   Rural site, n=93  
 How reported?   How reported?   
Barriers to uptakea    
Totalb 
% 
Spon.c 
% 
Most 
importantd 
% 
Mean 
prom.e   
Totalb 
% 
Spon.c 
% 
Most 
importantd 
% 
Mean 
prom.e  
Logistical barriers 79.6 75.7 68.0 3.59  73.1 66.7 58.1 3.14  
Competing obligations/priorities 76.7 73.8 55.3 3.17  72.0 64.5 43.0 2.66  
Lacking information about campaign 20.4 8.7 11.7 0.64  39.8 10.8 12.9 0.89 * 
Vaccination post open days/hours limited 8.7 4.9 1.0 0.17  19.4 1.1 2.2 0.27 * 
Costs apart from vaccine 2.9 0.0 0.0 0.03  4.3 1.1 0.0 0.05  
Organizational problems at vaccination post 0.0 0.0 0.0 0.00  1.1 0.0 0.0 0.01  
Medical barriers 27.2 22.3 23.3 1.19  35.5 24.7 23.7 1.31  
I was sick (not due to vaccine) 15.5 15.5 14.6 0.75  12.9 12.9 11.8 0.61  
Fear of possible side effects from vaccine 10.7 4.9 5.8 0.33  20.4 7.5 5.4 0.44  
Doubted effectiveness of vaccine 5.8 3.9 2.9 0.18  12.9 7.5 6.5 0.40  
Social/system-related barriers 8.7 2.9 1.0 0.15  16.1 5.4 6.5 0.41  
Vaccine free of charge (useless medicine) 1.9 1.0 0.0 0.03  9.7 4.3 2.2 0.20 * 
Fear of infertility 1.9 0.0 0.0 0.02  4.3 0.0 3.2 0.14  
Mistrust motives of campaign 1.9 1.0 0.0 0.03  8.6 3.2 0.0 0.12 * 
Social pressure against taking vaccine 3.9 1.9 1.0 0.09  2.2 0.0 0.0 0.02  
Lacking confidence in government 0.0 0.0 0.0 0.00  5.4 2.2 1.1 0.11 * 
Prior bad experience with health system 0.0 0.0 0.0 0.00  1.1 0.0 0.0 0.01  
Miscellaneous 6.8 6.8 5.8 0.31  10.8 10.8 7.5 0.44  
Other barriers 5.8 5.8 4.9 0.26  8.6 8.6 6.5 0.37  
Cannot say/Nothing 1.0 1.0 1.0 0.05  2.2 2.2 1.1 0.08  
aBarriers ordered according to descending mean prominence for the pooled sample (see Table 6-3), grouped barriers 
in bold; bPercentage of barriers reported spontaneously and after probing; cPercentage of barriers reported 
spontaneously only; dPercentage of barriers that were identified as single most important among all the reported 
barriers; eMean prominence based on values assigned for each barrier (3=identified as most important, 2=reported 
spontaneously, 1=reported after probing, 0=not reported), *p<0.05 (Wilcoxon test for comparison of mean 
prominence between site) 
 
Four more barriers were more prominent in the rural area: limited open days/hours of 
vaccination post (p=0.045), vaccine free of charge is useless (p=0.020), mistrust motives of the 
campaign (p=0.037) and lacking confidence in government (p=0.019). Three out of these five 
rural barriers were also reported with more prominence by men (in the total sub-sample): 
Limited open days/hours of vaccination post (p=0.032), vaccine free of charge is useless 
(p=0.008) and lacking confidence in government (p=0.030).  
 
The analysis of grouped categories showed that men reported significantly more logistical, social 
and system-related barriers than women (Table 6-5). Narratives indicated that men had their 
business or were committed to fishing and farming and mostly away during the daytime or for 
months. These commitments limited access to vaccination posts because open hours were too 
limited or because the duration of the campaign itself was not long enough. Even though women 
reported fewer such problems, they also explained their absence as being too busy with work 
and thus unable to reach the posts in time. Mostly rural men, compared to only one woman 
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from the periurban site, complained about why the vaccine was offered free of charge despite the 
fact that other drugs require purchase. This and the finding that only rural men were not 
confident about the government’s intentions is illustrated by the account of a 40-year-old man 
from Pemba:  
“I did not drink the medicine because I felt it does not help and drugs are not given free. Also when 
they give it to you free of charge there is some reason for doing that.” 
Table 6-5: Barriers to uptake of an oral cholera vaccine in a community mass vaccination campaign 
in Zanzibar, stratified by gender 
  Women, n=95   Men, n=101  
 How reported?   How reported?   
Barriers to uptakea     
Totalb 
% 
Spon.c 
% 
Most 
importantd 
% 
Mean 
prom.e   
Totalb 
% 
Spon.c 
% 
Most 
importantd 
% 
Mean 
prom.e  
Logistical barriers 66.3 62.1 56.8 2.99  86.1 80.2 69.3 3.74 * 
Competing obligations/priorities 65.3 61.1 47.4 2.68  83.2 77.2 51.5 3.15  
Lacking information about campaign 26.3 7.4 8.4 0.59  32.7 11.9 15.8 0.92  
Vaccination post open days/hours limited 8.4 1.1 1.1 0.13  18.8 5.0 2.0 0.30 * 
Costs apart from vaccine 2.1 0.0 0.0 0.02  5.0 1.0 0.0 0.06  
Organizational problems at vaccination post 0.0 0.0 0.0 0.00  1.0 0.0 0.0 0.01  
Medical barriers 38.9 32.6 32.6 1.69  23.8 14.9 14.9 0.83 ** 
I was sick (not due to vaccine) 26.3 26.3 24.2 1.25  3.0 3.0 3.0 0.15 *** 
Fear of possible side effects from vaccine 15.8 6.3 5.3 0.38  14.9 5.9 5.9 0.39  
Doubted effectiveness of vaccine 5.3 3.2 3.2 0.18  12.9 7.9 5.9 0.39  
Social/system-related barriers 7.4 0.0 1.1 0.11  16.8 7.9 5.9 0.43 * 
Vaccine free of charge (useless medicine) 1.1 0.0 0.0 0.01  9.9 5.0 2.0 0.21 ** 
Fear of infertility 2.1 0.0 1.1 0.05  4.0 0.0 2.0 0.10  
Mistrust motives of campaign 2.1 0.0 0.0 0.02  7.9 4.0 0.0 0.12  
Social pressure against taking vaccine 3.2 0.0 0.0 0.03  3.0 2.0 1.0 0.08  
Lacking confidence in government 0.0 0.0 0.0 0.00  5.0 2.0 1.0 0.10 * 
Prior bad experience with health system 0.0 0.0 0.0 0.00  1.0 0.0 0.0 0.01  
Miscellaneous 9.5 9.5 7.4 0.41  7.9 7.9 5.9 0.34  
Other barriers 8.4 8.4 6.3 0.36  5.9 5.9 5.0 0.27  
Cannot say/Nothing 1.1 1.1 1.1 0.05  2.0 2.0 1.0 0.07  
aBarriers ordered according to descending mean prominence for the pooled sample (see Table 6-3), grouped barriers 
in bold; bPercentage of barriers reported spontaneously and after probing; cPercentage of barriers reported 
spontaneously only; dPercentage of barriers that were identified as single most important among all the reported 
barriers; eMean prominence based on values assigned for each barrier (3=identified as most important, 2=reported 
spontaneously, 1=reported after probing, 0=not reported), *p<0.05, **p<0.01, ***p<0.001 (Wilcoxon test for 
comparison of mean prominence between gender) 
 
Sickness was equally prominent in both sites, but the majority who reported this barrier were 
women (26.3% vs. 3.0%, p<0.001). Qualitative data showed that many of those women had 
actually been eager to receive the vaccine, but could not because of troubling symptoms or 
because they were afraid that the vaccine could make their present condition worse. A 30-year-
old housewife from Chumbuni explained why she could not take the vaccine because of her 
severe fever:  
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“I came home during the vaccination days but I had severe fever and I left soon after the campaign. 
While I was there I heard an announcement about the vaccination on the radio. But because of my 
condition—I was still sick—I was unable to come and take the vaccine.”  
 
Three men only reported sickness, but identified it as the most important barrier; they 
exclusively referred to a perceived harmful interaction between drugs and the OCV:  
“I was sick with severe fever. And they told me it was [high blood] pressure. I was using many drugs 
and therefore I was told not to mix drugs because of harmful effects.” (50-year-old farmer in 
Mwambe) 
 
Since the majority of respondents (76.5%) had missed the vaccination due to logistical 
constraints (Table 6-3), further analysis of their views was deemed necessary. At the end of the 
interview, respondents were encouraged to share any additional comments, advice or 
suggestions about the health problems and vaccines that had been discussed or needed to be 
emphasized. Based on the assumption that these respondents did not object to receiving the 
OCV in principle, thematic analysis of their concluding statements was done. 
 
Most of the respondents who missed the complete course of vaccination because of logistical 
barriers requested the government repeat the vaccination to make them fully immunized and to 
vaccinate those people who did not get the vaccine during the campaign. They also emphasized 
the need to make the vaccine available free of charge and frequently demanded more health 
education in the communities. Even though men reported logistical barriers more prominently 
(Table 6-5), themes identified in male and female narratives were very similar. A businessman 
from Chumbuni, aged 28 years, gave the following advice:  
“I would like to advise the Ministry of Health and Social Welfare to provide free vaccines. They 
should also sensitize the community by providing health education. This will make the community 
aware of the importance of vaccines.”  
A female student from Mwambe, aged 18 years, also suggested how to improve the campaign: 
“The vaccination should be repeated so that I can also make it. But I suggest that we should be 
better informed about the real date of the second dose.” 
6.4 Discussion 
This postvaccination survey clarified social and cultural factors of uptake of an oral cholera 
vaccine in a periurban and a rural community of Zanzibar. Sociocultural features of cholera-like 
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illness and sociodemographic factors were identified, and logistical, medical and social and 
system-related barriers were examined among unvaccinated community residents. 
6.4.1 Influence of social and cultural factors on uptake 
Compared to the prevaccination analysis of determinants of OCV uptake where nonspecific 
symptoms of cholera determined uptake negatively, rectal pain was positively associated with 
OCV uptake in this survey. Even though cholera-related purging is usually painless [4], this 
finding may indicate a priority for vaccines not only for cholera but also for severe diarrhea in 
general. Features of dehydration were identified as promoting factors for vaccination in both 
pre- and postvaccination surveys. However, while unconsciousness determined uptake 
positively in the prevaccination study in both sites, reporting a loose or shriveled skin influenced 
only rural respondents to take the OCV. 
 
Recognizing biomedical risk factors for cholera, i.e., the potential risk for infection with germs 
when leaving food uncovered or when coming into contact with contaminated water, prompted 
respondents to take the OCV. This may reflect the positive impact of the mass vaccination 
campaign on people’s ideas and behavior. Neither biomedical nor alternative factors that had 
been perceived to cause cholera were identified as determinants of OCV uptake in the 
prevaccination survey.  
 
Despite offering the OCV for free and despite no significant direct costs were likely to be 
incurred in accessing the vaccination posts, purchasing drugs to stop vomiting and diarrhea in 
pharmacies competed with vaccines. This finding may indicate that the idea of treating cholera 
with drugs seemed to be more attractive than prevention with vaccination, or that the appeal of 
well-known powerful antibiotics was so valued that they overrode vaccination as a new and 
more uncertain intervention for cholera in Zanzibar.  
 
Reporting a previous enteric illness episode at the rural site was positively associated with 
uptake. This confirms results from a study in Vietnam [11], but contrasts the prevaccination 
study in Zanzibar, where reporting of such episodes did not determine vaccine uptake. This 
finding nevertheless suggests a higher perceived need for vaccination in the rural area, which is 
supported by the higher OCV uptake among rural respondents and the finding from the 
prevaccination study that fear of disruptions of health care services during cholera outbreaks 
was a positive determinant of OCV uptake in the rural area. Consistent with the prevaccination 
study is the finding that older people were more likely to drink the OCV. A higher household 
size, which had made people less willing to pay for an OCV before the campaign, was positively 
Chapter 6 | Improving OCV community coverage: lessons learned in Zanzibar 115 
associated with uptake; this might demonstrate the higher perceived need for vaccines if no 
costs are attached to it. 
6.4.2 Assessment of barriers to uptake 
Logistical issues were paramount barriers against taking the vaccine. Issues around social 
pressure or mistrust in the government or the vaccine, which have been identified as major 
factors against cholera control [40] or vaccination in other developing countries [17,41], did 
influence campaign coverage in Zanzibar only slightly. The importance of logistical issues 
confirms findings from a mass vaccination campaign in the cholera-endemic city of Beira, 
Mozambique, where main reason against OCV uptake were traveling (mentioned by 58% of non-
acceptors) and being busy (26%), while the rest reported pregnancy (5.2%), refusal (3.7%), long 
waiting time (3.1%) and taking medication (2.6%) [8].  
 
People’s own busy daily schedules and obligations, which made it also less likely for them to 
receive timely information about the planned mass vaccination campaign, were limiting factors 
to receive vaccines. Qualitative data clearly indicate that those residents who had been away 
during the campaign still wished to receive the vaccine. Thus, it can be expected that an earlier 
start of the mobilization—media broadcasts and meetings with community leaders started only 
shortly before the campaign in January 2009—is likely to increase coverage because people 
would have more time to plan their activities around the campaign. Alternative ways to 
administer the vaccine may have to be considered as well to better reach those population 
groups that are in principal willing to get vaccinated but whose daily schedules or professional 
activities make it difficult to receive vaccines. 
 
Fears about possible side effects were a substantive barrier to uptake; this needs to be addressed 
in future campaigns. The usually mild and transient side effects of Dukoral® (or other OCVs) 
[7,36] should be explained more properly versus the benefit of protection against cholera. Such 
information may also re-emphasize that the vaccine is administered orally and not through 
injections.  
 
Rumors about sterility have been reported in many immunization campaigns in Africa [42]. 
However, contrary to studies reporting that Muslims believe vaccines might cause infertility or 
could have been adulterated with anti-fertility agents [41-43], issues around fertility were not an 
important barrier to vaccine uptake. This suggests that future cholera campaigns in Zanzibar are 
somewhat less likely to suffer from such potentially sensitive issues. 
 
116 
The site and gender analysis of barriers to uptake showed that logistical challenges to access 
vaccination posts, and a tendency to question the value of vaccination against cholera, were 
primarily prominent among rural men. Despite differing logistical challenges, a clear demand 
for OCVs or a repetition of the mass vaccination campaign was reported among both genders, 
highlighting the local priority and demand for vaccination for cholera control in endemic areas 
of Zanzibar. Because sickness prevented more than one-fourth of women (regardless of site) 
from accessing posts or accepting the vaccine, further study may be needed to examine whether 
women are in general more often sick than men in Zanzibar, or whether this gender difference 
occurred by chance.  
 
Study limitations may include a potential selection bias because respondents were chosen from 
only two instead of all the six villages of the mass vaccination campaign. It should also be borne 
in mind that this was a cross-sectional survey, where only associations and no causal 
relationships could be examined.  
6.4.3 Lessons learned and recommendations 
Despite a high willingness to receive free vaccines, coverage was less than satisfying in the 2009 
oral cholera mass vaccination campaign in Zanzibar. Complementing a prevaccination 
community survey that identified predisposing social and cultural factors as determinants of 
OCV uptake, this postvaccination survey examined which social and cultural factors were 
associated with uptake and assessed barriers to uptake among unvaccinated community 
residents.  
 
Factors associated with uptake indicated a positive impact of the mass vaccination campaign 
and of community sensitization activities on vaccine acceptance behavior. Unlike in other 
circumstances, where communities opposed cholera control or where public trust of vaccines 
was damaged, the evaluation of barriers to uptake also indicated a good implementation of the 
mass vaccination campaign and trust in the health system.  
 
High community awareness of cholera and a positive attitude towards receiving OCVs, 
especially if they are provided without charge, suggest little opposition to vaccination as a 
supplementary means to cholera control in Zanzibar. Despite such encouraging prospects and 
demand for repeating vaccination in cholera-endemic populations, local policy makers and 
public health officials still need to know how community coverage of mass campaigns could be 
improved. Even though the following recommendations are in principle limited to cholera-
endemic communities in Zanzibar, national and international cholera control experts may also 
benefit from them. 
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First, campaigns should be announced earlier, at least a few months before vaccination posts 
open, with repeated reminders in the target communities. Second, campaign planners may also 
consider an extension of daily open hours or numbers of days for the vaccination especially in 
rural areas. Third, information about the campaign should not only cover dates and venues, 
specific requirements and inclusion criteria, but, fourth, also reinforce again more general 
health education on hygiene and diarrhea to interrupt fecal-oral transmission and, fifth, 
particularly point out the value of vaccination versus treatment of cholera with antibiotics. 
Sixth, although side effects of OCVs are usually mild, they should not only be specified, but also 
explained versus the benefit of vaccination. Finally, identification of alternative solutions to 
mass vaccination campaigns may be needed for population groups that recognize the value of 
vaccination in principal but are harder to reach due to their daily or professional activities. 
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Abstract 
Background 
Despite efforts to improve water supply and sanitation, cholera still represents a serious public 
health burden in low- and middle-income countries. The World Health Organization (WHO) 
recommends oral cholera vaccines (OCVs) as a supplementary public health tool to conventional 
prevention and treatment in endemic and epidemic settings. Dukoral®, a killed whole-cell two-
dose OCV was used in a mass vaccination campaign in 2009 in Zanzibar. This study estimated 
public and private costs of illness (COI) due to endemic cholera and costs of the 2009 mass 
vaccination campaign to assess the cost-effectiveness (CE) of OCVs in Zanzibar from both the 
health care provider and the societal perspective. 
 
Methodology/Principal Findings 
Estimates for public COI were obtained from interviews with local experts and patients and 
from reports and record review. Cost data for the mass vaccination campaign were collected 
based on real expenditure and planned budget data. Private direct and indirect costs were 
collected through patient interviews from three outbreaks. A static cohort of 50,000 individuals 
was examined. Primary outcome measures were incremental cost-effectiveness ratios (ICERs) 
per death, per case and per disability-adjusted life-year (DALY) averted. One-way sensitivity and 
threshold analyses were conducted and the ICER evaluated with regard to widely used WHO 
criteria for CE. Base-case ICERs were USD 1,878,142 per death averted, USD 16,171 per case 
averted and USD 119,339 per DALY averted, with negligible differences between the health care 
provider and the societal perspective. Threshold analyses using ShancholTM, the second OCV 
that is currently prequalified by the WHO for public use, indicated that the purchase price per 
course would have to be as low as USD 1.10 to render the mass vaccination campaign cost-
effective from a health care provider perspective (or USD 1.15 from a societal perspective). 
 
Conclusions/Significance 
The 2009 mass oral cholera vaccination campaign with Dukoral® was not cost-effective mainly 
due to the expensive OCV and the low incidence. However, mass vaccination campaigns in 
Zanzibar to control endemic cholera may meet WHO criteria for CE under certain 
circumstances, especially in high-incidence areas and when OCV prices are reduced to levels at 
USD 1.10 to 1.15. 
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7.1 Introduction 
Despite efforts to improve water supply and sanitation, cholera still represents a serious public 
health burden in low- and middle-income countries. In 2009, more than 220,000 cases and 
almost 5,000 deaths were reported to the World Health Organization (WHO) [1]. Due to 
underreporting and difficulties with surveillance, however, the true burden is likely to exceed 3 
million cases and 100,000 deaths per year [2]. A recent review of official cholera-related 
morbidity and mortality data from the WHO Africa region also indicated a potential economic 
burden of cholera for families and the health sector [3]. 
 
Cholera is an enteric bacterial disease caused by Vibrio cholerae serogroup O1 or O139 that 
usually occurs in sudden epidemics. Main features include acute, profuse watery diarrhea and 
vomiting that may lead to dehydration with concurrent electrolyte loss and eventually death if 
timely treatment is unavailable. Even though case-fatality rates (CFRs) may reach 50%, a rate 
below 1% has been realistic with proper case management [2,4]. Treatment is based on prompt 
rehydration with oral rehydration solution (ORS) for mild to moderate cases and intravenous 
(IV) fluids for severe cases [2]. Antibiotics are recommended for severe, and also moderate 
cases, to reduce the duration of episodes and shedding of infectious V. cholerae [2,5]. 
 
Traditionally, cholera control has been based on prevention, i.e., adequate water supply, 
improved sanitation and health education, and timely treatment. The role of vaccination for 
cholera control has recently received increased attention from public health officials; the WHO 
recommends oral cholera vaccines (OCVs) as a supplementary public health tool to traditional 
prevention and treatment in endemic and epidemic settings [6]. 
 
A series of research studies, done as part of the Diseases of the Most Impoverished (DOMI) 
project coordinated by the International Vaccine Institute (IVI), evaluated the use of OCVs in 
Asia and Africa for control of endemic cholera. Private demand for cholera vaccines was 
examined through willingness-to-pay studies [7-10], costs of illness (COI) and mass vaccination 
data were collected [11-13], and cost-effectiveness and cost-benefit analyses were performed 
[14,15]. Besides the recent article by Poulos et al. [12], published information about COI due to 
cholera is lacking even though patient-level data is needed for economic evaluations to improve 
local planning of cholera control. 
 
A joint initiative between the WHO, the IVI and the Ministry of Health and Social Welfare of 
Zanzibar (MoHSW) implemented a mass vaccination campaign with an OCV in two selected 
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cholera-endemic areas of Zanzibar in 2009. This intervention-cum-research project provided 
the opportunity to assess costs of immunization in an endemic setting. Public COI were 
estimated from three outbreaks that happened in 2009 outside the mass vaccination target 
communities. Private direct and indirect COI (borne by patients and their families) were elicited 
from a sample of patients admitted to cholera treatment centers during these outbreaks.  
 
This study aims to estimate (i) public and private COI due to cholera, (ii) costs of an oral cholera 
mass vaccination campaign, and (iii) the cost-effectiveness (CE) of using OCVs in endemic 
regions of Zanzibar from a health care provider and a societal perspective. 
7.2 Methods 
7.2.1 Study setting 
Zanzibar consists of two major islands, Unguja (also named Zanzibar) and Pemba, which are 
situated in the Indian Ocean about 40-60 km off the coast of Tanzania. Zanzibar, a 
semiautonomous entity within the United Republic of Tanzania, consists of five regions, which 
are subdivided into ten districts, 50 constituencies and 296 Shehias, the latter being the smallest 
administrative unit. The main islands cover ~2,557 km2 (Unguja: ~1,651 km2, Pemba ~906 
km2). The archipelago is inhabited by a fast-growing population of ~1.2 million Kiswahili-
speaking Muslim people. Monthly mean per capita expenditure for all goods and services was 
TZS 21,000 (~USD 18) in 2004/5 with a 2.1% share for health-related expenditures [16]. Life 
expectancy at birth has risen from 47 years in 1988 to 57 years in 2002 [17]. The economy of the 
islands depends on agriculture (primarily cloves, coconuts/copra and seaweed), fishing and 
tourism. 
 
The public health care delivery structure in Zanzibar comprises two zones, Unguja and Pemba, 
each with three levels: the primary, the secondary and the tertiary level. Each zone is headed by 
a zonal medical officer. Most of the health care services are provided at the primary level 
through Primary Health Care Units (PHCU) (n=124). The majority of these units is open during 
the day to outpatients and provides basic services. Primary Health Care Centers (PHCC) (n=4) 
are additional facilities on the primary level; they operate on a 24-hours basis and can admit up 
to 30 patients. At the secondary level, three district hospitals (only in Pemba) are operational 
while the country’s only tertiary level hospital (Mnazi Mmoja) is located in the capital 
Stonetown in Unguja. The top causes of primary- and secondary-level outpatient visits in 2008 
were upper respiratory tract infections (23%), pneumonia (10%), malaria (10%) and diarrhea 
(9%) [18]. 
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In recent times, the first cholera outbreak with 411 cases and 51 deaths was reported in 1978 
from two fishermen villages in Zanzibar [19]. More than a dozen outbreaks followed since then 
with almost annual episodes since the year 2000. Reyburn et al. reported an annual incidence of 
0.5 cases per 1,000 population based on a review of routine surveillance data for the years 1997 
to 2007 [20]. A seasonal pattern can be observed that follows the rainy seasons (usually from 
March to June and from October to December) during which widespread flooding occurs. Such 
deteriorating environmental conditions subsequently expose the majority of inhabitants on both 
islands to an increased risk of waterborne diseases due to the scarcity of safe drinking water 
supplies and a generally poor or lacking sanitation infrastructure in periurban and rural areas. 
 
Based on a consideration of areas of recent cholera activity, three Shehias per island, adjacent to 
each other, were selected as sites for the mass vaccination campaign. In Unguja, the Shehias of 
Chumbuni and Karakana in Urban district and Mtopepo in West district were targeted for the 
campaign; in Pemba, the Shehias of Kengeja, Mwambe and Shamiani, all located in the rural 
southeastern Mkoani district, were chosen. 
 
Dukoral®, the only OCV that was prequalified by the WHO in 2009, was used in the mass 
vaccination campaign. Dukoral® is a V. cholerae serogroup O1 whole-cell, killed vaccine 
containing recombinant cholera toxin (CT) B subunit protein; it has to be administered in two 
doses at least one week apart and requires a cold chain (2-8°C) [21]. This OCV was originally 
designed for immunologically naïve travelers from the north to tropical countries; it is licensed 
for use from two years of age and above and was shown to be 60-90% protective for up to three 
years [22-24]. One 3-ml vial of Dukoral® contains 1x1011 killed V. cholerae O1 (biotype classical 
and El Tor) and 1 mg of the CT B subunit protein in a suspension. Because the CT B subunit 
protein is not gastric acid-fast, the suspension has to be mixed with 1.5 dl of drinking water and 
a buffer sachet containing effervescent granules of sodium bicarbonate for ingestion. Recipients 
need to fast one hour before and after ingestion. 
7.2.2 Cost data collection 
Table 7-1 describes cost components (and sources) of data collected for this study. Estimates for 
public COI were obtained from interviews with local experts and patients and from reports and 
record review. Cost data for the mass vaccination campaign were collected based on real 
expenditure and planned budget data. Private direct and indirect costs were collected through 
patient interviews done on Pemba. All costs are reported in 2009 USD from an economic 
perspective, based on mid-year exchange rates obtained from http://www.oanda.com. 
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Table 7-1: Cost components for cholera collected in Zanzibar, 2009 
Cost components Description Source 
Public COI     
Fixed costs CTC set up and running including top up 
payments and personnel opportunity costs 
Questionnaire for zonal and district 
medical officers, MoHSW, NGOs, reports, 
record review 
Variable costs Treatment costs including drugs and 
material 
Interview with laboratory-confirmed cases 
and health care personnel, questionnaire 
for zonal and district medical officers, chief 
pharmacist, NGOs 
Private COI      
Direct Medical, non-medical costs Interview with laboratory-confirmed cases  
Indirect Loss of income Interview with laboratory-confirmed cases  
Mass vaccination campaign costs   
Material Purchase, transport and storage of 
vaccine, water and cups 
Reports and documents from WHO HQ, 
WHO consultants, EPI 
WHO consultants Compensation, travel Communication from WHO HQ 
Training of vaccinators and social 
mobilizers 
Staff compensation, transport, material, 
refreshment, venue 
Reports and documents from WHO 
consultants, EPI 
Implementation Staff compensation, transport, material, 
communication 
Reports and documents from WHO 
consultants, EPI 
COI: Costs of illness, CTC: Cholera treatment center, MoHSW: Ministry of Health and Social Welfare of Zanzibar, 
NGO: Non-governmental organization, WHO HQ: World Health Organization headquarters, EPI: Expanded program 
on immunization in Zanzibar 
Public COI 
Usually, cholera treatment centers (CTCs) are set up in Zanzibar once a cholera outbreak has 
been declared. Any person with acute watery diarrhea will be admitted and treated with IV 
fluids (Ringer’s lactate, Hartmann’s solution) and/or ORS, antibiotics and other drugs (Zinc for 
children) depending on the dehydration level. Community help-seeking behavior for cholera in 
peri-urban and rural Zanzibar also favors professional treatment in public health care facilities 
[25]. Thus, assuming that the majority of cases that occur during outbreaks are treated in CTCs, 
this study collected treatment costs incurred at CTCs to estimate public COI. 
 
Public COI data from three outbreaks (one from Unguja and two from Pemba) that happened 
after the mass vaccination campaign were collected prospectively and retrospectively from local 
health care personnel and experts. All three centers were visited for an overview of how they 
were set up and being run. Fixed COI related to set up and running of centers, but considered 
independent of the number of cholera cases, included permanent material, consumables, 
transportation and personnel, i.e., extra payments for personnel and opportunity costs due to 
personnel diverted from other health services. Variable COI incurred for cholera cases included 
drugs (resource use obtained from patient interviews) and material used for patient treatment. 
Current unit costs for drugs and material were provided by the chief pharmacist and the medical 
store department. 
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In Unguja, a CTC was opened on September 22, 2009, in PHCU Chumbuni after a cholera 
outbreak had been declared in one of the districts where the mass vaccination was conducted. A 
total of 161 patients were admitted over the course of 63 days before the CTC was closed on 
November, 29, 2009. Patients were treated in military tents (at the beginning of the outbreak) 
and in premises belonging to the PHCU. During the period while the CTC was operational, only 
suspected cholera cases were treated; patients with other illnesses were sent to adjacent clinics. 
 
The first outbreak on Pemba occurred in Wete district, which is located between Micheweni 
district in the north and the Pemban capital Chake-Chake in the center of the island; the PHCU 
in Kiuyu Minungwini was turned into a CTC during 88 days from May 11 until August 7, 2009, 
when 88 patients were admitted and treated. The second outbreak on Pemba happened in 
Micheweni district in the northeast of the island. A school adjacent to PHCC Micheweni was 
turned into a CTC with male and female and pediatric wards. This center was first open from 
June 18 until August 11, 2009, to admit 349 patients over the course of 54 days. After another 
surge in cholera cases, the center was reopened on August 30, 2009, and run for an additional 
31 days to treat another 32 patients until it was closed on September 30, 2009. 
Private COI 
Private COI data were collected with questionnaires from laboratory-confirmed cholera 
patients. A convenience sample of ~100 respondents was selected based on a list of positive 
cases from outbreaks kept at the Public Health Laboratory (PHL) in Chake-Chake, Pemba. 
Health care providers were then contacted at the respective CTC where the patients had been 
admitted to confirm details and to contact the patient or the caregiver for an interview. 
 
Based on WHO guidelines [26], a questionnaire was constructed in an adult and a child version 
to elicit out-of-pocket costs for cholera cases borne by patients and affected households. After 
pretesting, the questionnaire was administered in face-to-face interviews to inquire about direct 
medical and non-medical costs and indirect costs, i.e., productivity losses to the patient or 
caregiver and other household members. Patients aged 18 years or older were directly 
interviewed while caregivers were interviewed if the patient was younger than 18 years. 
Questionnaires were administered between July and November 2009, predominantly at 
respondents’ homes. Questionnaire data were entered into Microsoft Excel for analysis. 
Mass vaccination campaign costs 
The mass vaccination campaign with Dukoral® was implemented in the six selected Shehias in 
two rounds from January 17 to 26, 2009, and from February 7 to 16, 2009. Vaccination posts 
were erected within easy reach for the targeted population. Posts were run by local health care 
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workers and villagers and open daily for at least eight hours. For each round, a total of 21 teams 
were needed to run the nine vaccination posts on each island. Each team consisted of six 
vaccinators. In addition, eight supervisors were deployed to Unguja and five to Pemba. The 
campaign was planned and implemented by the local Expanded Program on Immunization 
(EPI) team and international consultants deployed by the WHO. Social mobilization was done 
before and during both rounds by the MoHSW Health Promotion Unit. 
 
Cost data on material (purchase, transport and storage of vaccines, cups and water), training 
and implementation required for the campaign were obtained locally from consultants and EPI. 
Because the campaign was planned and implemented within the scope of the research project, 
raw data were adjusted to exclude costs related to research. These costs were mostly incurred to 
train and compensate people at vaccination posts collecting data with electronic devices for 
parallel and subsequent epidemiological studies [27].  
7.2.3 Cost-effectiveness analysis 
Based on a previous study for Bangladesh [28], a model was developed in Microsoft Excel to 
estimate the costs and health effects of a mass vaccination campaign program compared to 
standard treatment in CTCs in Zanzibar. A static cohort of 50,000 individuals, reflecting the 
target population of the 2009 mass vaccination campaign in Zanzibar, was examined from a 
health care provider and a societal perspective considering input parameters related to vaccine 
characteristics and vaccination costs, burden and impact of cholera, and public and private COI. 
Private providers were not considered since the majority of patients would visit public facilities 
in case of an outbreak [25]. The base-case model considered costs and effects of a one-time 
vaccination program over the duration of protection, i.e., three years. Annual number of cases 
without vaccination was obtained by multiplying the population size times the mean annual 
cholera incidence obtained from a review of cases per Shehia. The number of annual deaths was 
calculated by multiplying the CFR with the annual number of cases. The annual number of cases 
under the vaccination program was calculated by multiplying the annual number of cases 
without vaccination with (1 – protective efficacy). The number of deaths with vaccination was 
calculated similarly by using the same CFR. 
 
Incremental cost-effectiveness ratios (ICER) calculated as incremental costs per death, per case 
and per disability-adjusted life-year (DALY) averted were used as outcome measures. 
Incremental costs were calculated as the difference between costs of the vaccination program 
and public COI saved due to the vaccination from the health care provider perspective. Private 
direct COI saved were added in the base-case model adopting the societal perspective. Private 
indirect COI saved were not included in the base-case model [29]. The number of deaths, cases 
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or DALYs averted was equal to the difference in numbers with and without the vaccination 
program. DALYs, which are an aggregate measure combining morbidity (i.e., years of life lived 
with disability) and mortality (years of life lost), were calculated according to Jeuland et al. [14], 
assuming no age weighing and a disability weight of 0.105 for diarrheal diseases [30]. Life 
expectancy at average age of onset based on patient data was obtained from WHO life tables for 
Tanzania [31]. The vaccine was directly purchased from the manufacturer at a UN rate. Future 
effects were discounted at a rate of 3% for the base case. Costs were not discounted since the 
mass campaign happened over one single year. 
 
Cost-effectiveness was examined according to widely-used WHO criteria that define an 
intervention as cost-effective if the ICER is less than three times per capita gross domestic 
product (GDP) per DALY averted and as highly cost-effective if the ICER is less than per capita 
GDP per DALY averted [32]. 
 
One-way sensitivity analyses were done to estimate the influence of changes in potentially 
influential input parameters on model outcomes. Such key parameters included vaccine 
purchase price and delivery costs, protective efficacy (PE), duration of protection, incidence, 
CFR and so forth [14]. Plausible ranges were based on public health considerations (for vaccine 
purchase price and delivery costs, incidence), guidelines (discount rate) and variation for local 
data (PE, CFR, coverage, number of ill days, public and private COI). Base-case values and 
plausible ranges are presented in Table 7-2. Threshold analyses examined at which vaccine 
purchase price the intervention would become cost-effective. 
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Table 7-2: Model input parameters with plausible ranges 
Parameters Base case Minimum Maximum Assumptions, References 
Vaccine costs and characteristics        
Vaccine purchase price, 2009 USD per 2 doses 10.28 2.06 12.34 Base case: this study; range: 20-
120% of base case based on 
policymaker and expert data [33,34] 
Vaccine delivery, 2009 USD per 2 doses a 2.66 1.06 3.19 Base case: this study; range: from 
USD 0.5 per dose to 120% of base 
case [14,34] 
Protective efficacy of vaccine, % 77.0 30.0 93.0 Base case and range (95% CI): this 
study (Khatib et al., unpublished 
manuscript) 
Campaign coverage, % 57.9 53.5 66.8 Base case: this study; range: 
minimum and maximum among the 
6 targeted Shehias 
Duration of protection, years 3 2 4 Jeuland et al. [14] 
Discount rate, % 3 0 5 Constant, for effects [35], no 
discounting of costs 
Life expectancy at average age of onset, years 44.9 36.4 55.5 Life tables for WHO member states 
[31]; base case: based on mean 
age of onset (18 years) from patient 
data; range: based on life 
expectancy [31] at IQR of age of 
onset from patient data 
Risk for cholera        
Cholera incidence, annual cases/1,000 population 0.65 0.5 4.0 Base case: mean from review of 
surveillance reports from Unguja for 
2002-2010; range: minimum (Beira), 
maximum (Jakarta) (Deen et al. 
[36]) 
Impact of illness on patients        
Case-fatality rate, % 0.86 0.52 1.86 Base case: 14 deaths/1626 cases 
treated in CTCs in Unguja and 
Pemba during three outbreaks 
between June 2009 and April 2010; 
range: minimum and maximum 
(ZMO Unguja); same rate assumed 
for vaccinated and unvaccinated 
cases  
Duration of illness episode, days 5 4 6 Base case: median illness duration 
from patient data; range: IQR from 
patient data 
Costs of illness, 2009 USD        
Public fixed costs of treatment per episode 51.41 20.64 88.00 Base case: mean from this study 
(seeTable 7-3); range: minimum 
and maximum from this study (see 
Table 7-3) 
Public variable costs of treatment per episode 9.15 4.57 18.29 Base case: mean from this study 
(see Table 7-3); range: 50-200% of 
base case [14] 
Private direct costs per episodeb 11.39 4.23 16.50 Base case: mean from this study 
(see Table 7-4); range: based on 
IQR from patient data 
Private indirect costs per episodeb 31.46 4.44 46.32 Base case: mean from this study 
(see Table 7-4); range: based on 
IQR from patient data 
aExcluding costs for international consultants (see Table 7-5); bEstimates only used in analysis from societal 
perspective; CI: Confidence intervals, IQR: Interquartile range, ZMO: Zonal medical officer 
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7.2.4 Ethics 
Written informed consent was obtained from all study participants interviewed for private COI. 
No incentives were provided to them. The protocol of this study was cleared by the WHO 
Research Ethics Review Committee and the MoHSW Ethics Committee. All data were handled 
confidentially and made anonymous before analysis. 
7.3 Results 
7.3.1 Public COI 
Table 7-3 presents the fixed and variable mean public COI at the three CTC sites. Fixed costs of 
USD 51.41 accounted for 84.9% of public COI, with mean fixed costs ranging from USD 20.64 to 
USD 88.00. Direct and indirect human resources costs accounted for the majority of fixed costs; 
they were highest in Kiuyu Minungwini (86.3%), medium in Micheweni (84.9%) and lowest in 
Chumbuni (80.0%). The remaining fixed costs were used for setting up and running the centers. 
Health care personnel working in Unguja received higher top up payments than in Pemba, but 
the latter were given food to cater for themselves while on shift. Variable costs of USD 9.15 were 
mainly driven by IV fluid use as patients were administered on average 8.8 liters, which cost 
USD 7.08. Further details on public variable costs for treatment can be found as supporting 
information in Table 9-1. 
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Table 7-3: Public costs of illness for cholera, Zanzibar, 2009 
 Description   2009 USD % 
Fixed costsa     51.41 84.9 
CTC at PHCU Chumbuni (Unguja)   88.00 100.0 
Permanent material Beds, canvas, ropes, basins, buckets, further utensils 6.37 7.2 
Consumables Water, detergent, kerosene 2.54 2.9 
Transport Fuel for DHMT cars  8.67 9.9 
Personnel Top up payments  27.28 31.0 
Personnel diverted from other health care 
services 
Opportunity costs based on functions and official salaries 43.13 49.0 
CTC at PHCC Micheweni (Pemba)   20.64 100.0 
Permanent material Water drum  0.01 0.0 
Consumables Detergent, kerosene  1.15 5.6 
Transport Fuel for DHMT cars  1.94 9.4 
Personnel Top up payments and food allowance 6.01 29.1 
Personnel diverted from other health care 
services 
Opportunity costs based on functions and official salaries 11.52 55.8 
CTC at PHCU Kiuyu Minungwini (Pemba)   45.59 100.0 
Permanent material Water tank, cooking utensils etc 1.88 4.1 
Consumables Chlorinated lime  1.71 3.8 
Transport Car use  2.64 5.8 
Personnel Top up payments and food allowance 13.46 29.5 
Personnel diverted from other health care 
services 
Opportunity costs based on functions and official salaries 25.89 56.8 
Variable costsb     9.15 15.1 
Total     60.56 100.0 
aMean costs per treated patient at each CTC; bMean costs per treated patient from patient interviews (n=95), 
including drugs and material, see supporting information (Table 9-1) for more details; CTC: Cholera treatment center, 
PHCU: Primary health care unit, PHCC: Primary health care center, DHMT: District health management team   
7.3.2 Private COI 
A total of 95 individuals were interviewed. All but one of the interviewed patients had been 
admitted at the CTC at Micheweni PHCC. Total direct and indirect mean private COI amounted 
to USD 42.85, with almost three-fourth (USD 31.46) being indirect costs, i.e., productivity losses 
to the patient or caregiver and other household members (Table 7-4). Among direct costs, which 
amounted to USD 11.39, feeding the patient at the CTC accounted for the biggest share (USD 
8.29, 19.4% of total costs). Other direct costs, incurred for treatment (mainly for plastic sheets 
needed to cover cots), transport and communication, were reported by less than 3%.  
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Table 7-4: Private direct and indirect costs of illness for cholera, Zanzibar, 2009 
 2009 USD* % 
Direct costs 11.39 (9.13) 26.6 
Medical 1.21 (1.6) 2.8 
Food 8.29 (6.64) 19.4 
Transport 1.23 (2.66) 2.9 
Communication 0.65 (1.36) 1.5 
Indirect costs (i.e., lost productivity) 31.46 (34.97) 73.4 
Total 42.85 (40.08) 100.0 
* Mean costs (standard deviation in brackets) per treated patient from patient interviews (n=95) 
7.3.3 Mass vaccination campaign costs 
Total mass vaccination campaign costs amounted to USD 755,192, with USD 513,901 (68.0%) 
spent on vaccine purchase and USD 241,291 (32.0%) on delivery (Table 7-5). The vaccine was 
purchased from SBL Vaccin AB, Sweden, at a price of USD 10.28 per course (2 doses). Delivery 
costs comprised transport of the vaccine from Stockholm to Zanzibar and procurement of cups 
and water required for the buffer solution (6.0% of campaign costs), the work of two 
experienced international consultants (14.4%), training of locally recruited implementers (1.3%) 
and the implementation (social mobilization and vaccination) itself (10.4%). More details on 
delivery costs are presented as supporting information in Table 9-2. 
Table 7-5: Costs of a mass oral cholera vaccination campaign, Zanzibar, 2009 
  Totala Meanb % 
Vaccine (purchase price USD 10.28 per 2 doses) 513,901 17.73 68.0 
Deliveryc 241,291 8.32 32.0 
Vaccine transport, storage, water and cups 45,128 1.56 6.0 
International consultants 108,432 3.74 14.4 
Training 9,461 0.33 1.3 
Implementation 78,270 2.70 10.4 
Total 755,192 26.05 100.0 
aTotal costs (2009 USD) to vaccinate a target population of 49,980 people; bMean costs (2009 USD) per fully 
immunized individual based on actual coverage (58.0%); cBased on real expenditure or planned budget data from 
2009 mass vaccination campaign, see supporting information (Table 9-2) for more details 
 
At a vaccine purchase price of USD 10.28 per course, the estimated total costs per fully 
immunized individual amounted to USD 26.05, with mean costs per vaccine course of USD 
17.73 and mean costs for delivery of USD 8.32. Mean costs were adjusted for actual coverage of 
58.0%, relating to 29,666 fully immunized individuals out of 51,151 targeted during the mass 
vaccination campaign (Khatib et al., unpublished manuscript).  
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7.3.4 Cost-effectiveness analysis 
Base-case results 
Table 7-6 presents the results of the cost-effectiveness analysis (CEA) from the health care 
provider perspective using base-case parameter estimates obtained from primary and secondary 
data sources from Zanzibar. Annual costs to immunize 50,000 people, if the OCVs cost USD 
10.28 per course, were USD 371,850, assuming one campaign per three years at a cost of USD 
1,115,549. Annual public COI averted by vaccination amounted to USD 1,515. Incremental costs, 
the difference between total annual costs (i.e., vaccination program and public COI) with and 
without vaccination, amounted to USD 370,334. ICERs were USD 1,878,142 per death averted, 
USD 16,171 per case averted and USD 119,339 per DALY averted.  
Table 7-6: Key outcomes from model of mass oral cholera vaccination (health care provider 
perspective) in Zanzibar, 2009a 
  No vaccination Vaccination Difference 
Effects 
Annual number of cases  30 7 23 
Annual number of deaths 0.26 0.06 0.20 
Annual number of YLD averted   0.02 
Annual number of YLL averted   3.08 
Annual number of DALY averted   3.10 
Total number of DALY averted over duration of protection     8.78 
Costs of outcome indicators, 2009 USD 
Annual costs of vaccination programb 0 371,850 -371,850 
Annual public costs of illness 1,968 453 1,515 
Annual costs of treatment and vaccination program 1,968 372,302 -370,334 
Costs per death averted with vaccine  1,885,827  
Costs per case averted with vaccine  16,237  
Costs per DALY averted with vaccine  119,828  
Incremental costs and cost-effectiveness ratios (ICER), 2009 USD 
Incremental costsc   370,334 
ICER (death): Incremental costs/death averted   1,878,142 
ICER (case): Incremental costs/case averted   16,171 
ICER (DALY): Incremental costs/DALY averted     119,339 
aBase-case results from population of 50,000, with 3% annual discounting of effects; bCosts for international 
consultants excluded; cCosts of vaccination program minus public COI averted by vaccination (cost savings); YLD: 
Years of life lived with disability, YLL: Years of life lost, DALY: Disability-adjusted life-year, ICER: Incremental cost-
effectiveness ratio 
 
Logistical on-site support from the WHO headquarters was provided since the campaign was 
conducted within a research project that aimed to assess also epidemiological and 
sociobehavioral aspects of OCV use in endemic settings. Thus, costs incurred for international 
consultants were excluded from the analysis on the assumption that the campaign would also 
have been possible without intensive external help. 
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The predicted ICER was much greater than three times the per capita GDP for Tanzania (USD 
1,509 in 2009) per DALY averted [37], suggesting that mass immunization with OCV in 
Zanzibar was not cost-effective. Even if the OCV was offered at no cost, the vaccination would 
still cost more than the avoided public COI due to the delivery costs and the ICER would be USD 
24,127. 
 
Compared to the health care provider perspective, key outcomes of the CEA from the societal 
perspective (Table 9-3), which included private direct COI, differed only minimally. Annual 
private COI averted by vaccination amounted to USD 285; the ICER decreased to USD 119,247 
per DALY averted. With the OCV offered at no cost, the vaccination would still cost more than 
the avoided public and private COI and the ICER would be USD 24,035. 
Sensitivity analyses 
One-way sensitivity analyses were performed with all input parameters presented in Table 7-2 
from the health care provider perspective. This analysis does not account for the effects of non-
linearity and interactions between uncertain parameters as it varies parameters one at-a-time 
while keeping other parameters at base-case values, and the ranges specified for each parameter 
may not reflect equivalent ranges of uncertainty [38]. Varying base-case values over plausible 
ranges helped to estimate the influence of each parameter on the ICER per DALY averted (see 
supporting information, Figure 9-1), and per death (Figure 9-2) and case (Figure 9-3) averted. 
The most influential parameters on the ICER per DALY averted were PE, CFR, incidence, 
discount rate and vaccine purchase price. 
Threshold analyses 
Another two-dose OCV was licensed for use in India in 2009. ShancholTM (Shanta Biotechnics, 
Hyderabad, India) is a bivalent variant of Dukoral®, containing killed V. cholerae O1 and O139, 
but no CT B subunit. It has recently been prequalified by the WHO for UN use; at its current 
price of USD 1.85 per dose to the public sector, it may become an attractive alternative for future 
OCV campaigns [21]. Interim analysis from two-year follow-up of a randomized controlled trial 
from Kolkata, India, showed that ShancholTM is safe and has a PE of 67% across all age groups, 
which is similar to Dukoral® [39]. Repetition of the OCV campaign in Zanzibar with 
ShancholTM at USD 3.70 per course and PE=67% while keeping vaccine delivery with USD 1.06 
at the minimum level—and CFR (1.86%) and cholera incidence (4/1,000) as the most influential 
parameters at the maximum level—would reduce the ICER considerably to USD 3,600 per 
DALY averted from the health care provider perspective and to USD 3,557 per DALY averted 
from the societal perspective.  
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Based on these assumptions the purchase price of ShancholTM per course would have to be as 
low as USD 1.10 to render the mass vaccination campaign cost-effective from a health care 
provider perspective (or USD 1.15 from a societal perspective). 
7.4 Discussion 
This study estimated public and private COI due to endemic cholera in Zanzibar and costs of the 
2009 mass vaccination campaign to assess CE from a health care provider and a societal 
perspective. The analysis presented here suggests that COI averted by a mass vaccination 
campaign with an OCV were negligible to the public health sector and the society and that such 
an intervention was not cost-effective based on the stated assumptions. However, mass 
vaccination campaigns in Zanzibar to control endemic cholera may meet WHO criteria for CE 
under certain circumstances of highly optimistic assumptions about vaccine purchase price, 
delivery costs, incidence and CFR. 
 
Private cost were higher than in Beira, Mozambique [12], where Dukoral® had also been used 
in a mass campaign in endemic settings. Despite mean public and private COI of ~USD 104 per 
episode were higher than the ~USD 47 for hospitalized cases in Beira, the mass vaccination 
campaign was not cost-effective in Zanzibar. 
 
Relative costs for the vaccine and for delivery were comparable to findings from two campaigns 
in Vietnam with the bivalent Vietnamese OCV where this ratio was 25 vs. 75% in 1997 [40] and 
21 vs. 79% in 1998 [13], respectively. However, mean costs per fully immunized individual were 
much higher than previously reported costs of USD 0.5 to 10.0 from Sudanese refugee 
settlements in northern Uganda (1997) [41], USD 2.09 from Beira, Mozambique (2003), where 
the vaccine was provided free of charge [11], and USD 7.1 from Darfur, Sudan (2004), where the 
vaccine course cost USD 3.8 [42]. Mean costs per immunized individual of USD 17.6 for a mass 
immunization campaign in post-tsunami Aceh, Indonesia (2005), were also still lower than in 
Zanzibar, even though the vaccine had been purchased at a comparable rate of USD 9.4 per 
course [43]. 
 
ICERs were well above any results reported for cholera mass vaccination campaigns [14,28,44-
47]. The main reason why mass vaccination with Dukoral® was cost-ineffective in Zanzibar may 
be due to using an expensive OCV in a low incidence setting. Another reason may be that the 
present model used local data on costs of immunization. Other CE models that were not based 
on locally available data generally assumed much lower immunization costs, using (subsidized) 
vaccine prices of ~USD 1 and delivery costs of ~USD 1 per course; this made them propose 
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vaccination is economically more viable than standard treatment [14]. Threshold analyses 
indicated that mass vaccination may also become cost-effective in Zanzibar if OCVs were 
procured at prices of ~USD 1, a price level acceptable by many public health policy makers in 
Asia [33].  
 
This study has several limitations. First, even though uncertainty in input parameters was 
considered in one-way sensitivity analyses, an assessment of whether an intervention was cost-
effective or not should ideally be based on outcomes obtained from probabilistic sensitivity 
analysis that include confidence intervals and not only on point estimates [35]. Second, herd 
protection may play a considerable role in cholera vaccination [48] and was shown to make 
community-based programs in three Asian and one African setting cost-effective regarding the 
per capita GDP criterion [14]. Since relevant epidemiological data to model herd protection were 
not available for Zanzibar, indirect effects were not included in the model. Third, non-diarrhea 
patients were usually not treated or admitted by their local public health care facility during the 
time it operated as a CTC. Patients who need treatment, e.g., for malaria, will have to bear extra 
direct and indirect costs related to additional travel or potential serious complications due to 
delayed treatment. These additional costs have not yet been included in the CEA.  
7.4.1 Conclusions 
The analysis presented here suggests that costs averted by a mass vaccination campaign with an 
OCV in endemic areas of Zanzibar were negligible when compared to standard treatment in 
decentralized cholera treatment centers. Mass vaccination was not cost-effective based on the 
stated assumptions, mainly due to the high purchase price and the low cholera incidence in 
Zanzibar. However, mass vaccination campaigns in Zanzibar for endemic cholera control may 
meet WHO criteria for CE under certain circumstances, especially in high-incidence areas and 
when OCV prices are reduced to levels at USD 1.10 to 1.15. 
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 8  
GE N E R A L  D I S C U S S I O N  A N D  I M P L I C A T I O N S 
Cholera control is primarily a structural issue demanding a strong commitment and 
considerable investments by governments to overhaul and/or maintain a safe water supply and 
an appropriate sanitation infrastructure [1]. Even though great strides have been taken over the 
last two decades to increase the access of the global population to improved drinking-water 
sources, 40% of the people in sub-Saharan Africa still lived without safe water in the year 2008 
[2]. Recognizing that a reduction of the proportion of people without access to safe drinking 
water will remain a huge challenge, mainly because of the unprecedented population growth in 
low- and middle-income countries, which bear the brunt of the global cholera burden, 
developing and testing of complementary measures to protect peoples’ health from epidemic-
prone diarrheal diseases is crucial.  
 
Inasmuch as use of vaccines has been shown to reduce cholera-related morbidity and mortality 
in several settings [3], research presented in this thesis was conducted to provide practical 
information to local and international policy makers towards improving cholera control through 
vaccination in endemic settings.  
 
Findings and implications presented here come at a particularly appropriate time. They reiterate 
that the present public health burden due to cholera is still intolerable and that difficulties to 
tackle this disease have not been sufficiently addressed by the global community. On May 24, 
2011, the 64th World Health Assembly adopted a new resolution urging member states to more 
actively engage in the global fight against cholera and “to undertake planning for and give 
consideration to the administration of vaccines, where appropriate, in conjunction with other 
recommended prevention and control methods and not as a substitute for such methods.” [4]  
 
This thesis benefited greatly from the opportunity to conduct studies before and after a mass 
vaccination campaign in Zanzibar. Knowing whether the people of Zanzibar would like to take a 
vaccine against cholera, and what actually made them take it (or not take it), is likely to be 
relevant and represents important information to maximize the impact of future vaccination 
campaigns on cholera.  
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However, the decision to use oral cholera vaccines (OCVs) as a complementary measure for 
routine cholera control in endemic settings not only relies on community willingness for 
vaccination, but also on macroeconomic considerations. Such information is especially needed 
in settings where efforts and resources in the health sector have to be employed with utmost 
care and sensitivity to situation factors. In the effort toward achieving a sustainable cholera 
control strategy, policy makers and public health officials need to know whether health-related 
benefits and cost savings due to vaccinating their people is worth the monies invested.  
 
This thesis aimed to examine social and cultural features of OCV acceptance from a community 
perspective and to evaluate the cost-effectiveness (CE) of the 2009 OCV mass campaign in 
Zanzibar. In the following sections, major findings and methodological issues that are 
particularly relevant with reference to the research questions are discussed before overall 
conclusions are presented. Implications for local and global cholera control with OCVs and 
directions for future research follow. 
8.1 Discussion of major findings 
8.1.1 What are the social and cultural features of OCV acceptance in 
Zanzibar?  
The first research question was addressed from different angles in Chapters 3 to 6. Community 
views of cholera were clarified prior to examining rates and social and cultural determinants of 
anticipated and actual OCV acceptance and barriers to uptake were examined. 
Community-perceived burden and views of cholera 
Chapter 3 documents local perceptions of cholera in relation to shigellosis, another enteric 
diarrheal illness. It was shown that cholera was more often recognized as serious illness that 
may be fatal without appropriate treatment than shigellosis. Features of distress were primarily 
related to the negative social and financial impact cholera can have on a patient’s life. 
Interference with work- or income-related activities was the most prominent category of 
distress. The most prominent somatic symptoms were related to dehydration and to general 
gastrointestinal features. Cholera was mainly attributed to a dirty environment and 
microbiological contamination while causes unrelated to the biomedical basis were also 
identified, but with less prominence. Even though rehydration of the patient (primarily in the 
periurban community) and use of herbal treatment and antibiotics (rural community) were the 
preferred self-treatment options, professional health facilities were universally recommended at 
both sites. This survey showed that cholera represented a significant perceived illness burden in 
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periurban and rural Zanzibar. Because of community preference for professional treatment for 
cholera and shigellosis, the importance of strengthening local health systems to improve enteric 
disease control was highlighted; health education efforts for cholera were suggested particularly 
for rural areas and with a focus on women, and for shigellosis in general. 
Social and cultural features of OCV acceptance 
To date, no studies on social and cultural features of OCV acceptance in Africa have been 
published. Thus it was necessary to study whether and how community views of cholera, as 
presented in Chapter 3, determined anticipated OCV acceptance. The almost universal 
willingness (94%) to accept an OCV at no cost (Chapter 4) confirmed that the perceived high 
severity and fatality of cholera required preventive action in addition to existing treatment 
practices in endemic communities in Zanzibar. Fewer community residents, however, were 
willing to pay if the OCV was offered at some cost. The same pattern, but with a much less 
pronounced gradient, was found in studies using a similar EMIC interview in western Kenya 
and in southeastern Democratic Republic of Congo (DRC) (Figure 8-1).  
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Figure 8-1: Anticipated OCV acceptance in cholera-endemic communities in three African countries 
Low price: ~USD 1, medium price: ~USD 5, high price: ~USD 10. OCV: Oral Cholera Vaccine; DRC: Democratic 
Republic of Congo. Source: Zanzibar: Chapter 4, Kenya: Sundaram [5], DRC: Merten et al. [6] 
 
The influence of vaccine-related costs on reported and actual health behavior was reflected in 
the analysis of social and cultural determinants of anticipated OCV acceptance (Table 8-1): the 
higher the OCV price, the fewer categories of sociocultural features of illness determined 
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anticipated acceptance (Chapter 4). Economically more stable conditions, represented by 
households that depended on a regular budget or by married respondents, were the main 
drivers behind the willingness to buy the medium- and high-priced OCV. 
Table 8-1: Social and cultural features of anticipated and actual OCV acceptance (uptake) before and 
after a mass vaccination campaign in Zanzibar 
 Prevaccination  Postvaccination 
 Anticipated acceptance 
Categorya 
Low price, 
~USD 0.9 
Medium price, 
~USD 4.5 
High price, 
~USD 9 
Actual 
acceptance 
(uptake) 
 
Actual 
acceptance 
(uptake) 
Categories of distress:  
somatic symptoms     
  
Loose skin      (+)rural 
Loss of appetite    (–)rural   
Nausea    (–)   
Rectal pain      (+) 
Unconsciousness    (+)   
Very thirsty (+)      
Categories of distress:  
social impact     
  
Disruption of health services  (–)periurban  (+)rural   
Fear of infecting others (+)rural      
Perceived causes       
Contact with contaminated water      (+) 
Unprotected/spoiled food      (+) 
Self treatment at home       
Drinking more water or liquids (–)      
Outside help seeking       
Pharmacy/Over-the-counter drugs      (–) 
Sociodemographic characteristics/ 
previous illness episodes     
  
Age    (+)  (+) 
Gender (male vs. female)    (–)   
Household size  (–)periurban    (+) 
Married vs. not married  (+) (+)    
Previous illness episode      (+)rural 
Regular/dependable household 
income (+) (+)
periurban (+)    
Secondary school or above vs. no 
education (+)    
  
Siteb (rural vs. periurban)   (+) (+)   
aOnly significant positive and negative determinants (p≤0.05) listed that were identified in comprehensive models 
including interaction with periurban site as baseline if p(interaction term)<0.1. Superscript text refers to site at which 
effects were significant; bOverall effect of site assessed from main effects model. Source: Chapter 4 to 6. 
 
Because intention to accept a free vaccine was almost universal, only determinants of 
anticipated acceptance of the low-, medium- and high-priced OCV could be studied. Thus, 
subsequent study of determinants of vaccine uptake was needed (Chapter 5), which showed the 
influence of sociocultural features of illness on vaccine acceptance if no direct cost were 
attached. The decision to take preventive action against cholera was to a large extent influenced 
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by categories of distress, referring to illness experience. This supported the findings from 
analysis of focal models suggesting that categories of illness experience, meaning and behavior 
explained anticipated and actual OCV better than purely social epidemiological models (Chapter 
4 and 5). Postvaccination study of factors associated with OCV uptake also confirmed this 
relative importance of sociocultural features of illness (Chapter 6). While proxy variables for 
economic status had no effect on people’s decision to drink the free OCV, increasing age was a 
positive predictor to prevent cholera with vaccination. Contrary to the medium-price analysis, 
showing that a higher household was a negative determinant of anticipated acceptance in the 
periurban community, OCV uptake was not limited, but rather reinforced by a higher household 
size; this indicated the priority for free OCVs in both periurban and rural households. The 
finding that economic considerations are important in these poor communities was not 
surprising and confirmed contingent valuation exercises that studied private demand for 
cholera vaccines [7-9]. Studies presented in Chapter 4 to 6 showed the relevance of vaccine price 
on community willingness for cholera vaccination and highlighted the need to study 
sociocultural features of cholera-like illness in addition to sociodemographic and economic 
characteristics when assessing determinants of OCV acceptance.  
Passive acceptance rather than active resistance or refusal 
Despite a high willingness to receive free vaccines, the achieved coverage of 50% among 
prevaccination respondents (Chapter 5) was less than satisfying, even lower than community 
anticipation for a low-priced OCV. In the continuum from active resistance or refusal of 
vaccination to active demand [10-12], findings from the prevaccination studies did not suggest 
that there would be much active or passive resistance against cholera vaccination in Zanzibar. 
Also noteworthy with regard to the often reported allure of exotic reasons for refusal of 
vaccination was the complete absence of magico-religious causes as determinants of vaccine 
acceptance. Overall, these studies indicated passive community acceptance of OCVs, apparently 
uninfluenced by concepts of illness meaning. 
 
Retrospective study of determinants of uptake, and in particular analysis of barriers to uptake 
among unvaccinated community members (Chapter 6), confirmed this conclusion. Analysis of 
barriers revealed logistical issues as main reasons for the low coverage, with people’s own busy 
daily schedules as the most prominent feature. It is in principle possible that—under the pretext 
of “having a lot of things to do”—the real reasons why vaccination against cholera had a low 
priority for some people were confounded or not discernible by the approach taken. However, 
analysis of qualitative data indicated that those who did not drink the required two doses of 
Dukoral® did so because of daily commitments to either feed their families or support their 
households or because they were studying. Thus, despite the vaccine being offered at no cost 
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and mitigation of factors likely to limit access (e.g., travel distances), engagement in daily 
economic activities was identified as the major obstacle to getting immunized against cholera.  
 
One may ask, why were people apparently unwilling to sacrifice a few hours from mostly 
informal work to queue for the vaccine? Research on economic systems and behaviors in low- 
and middle-income countries may offer an explanation. In their recent book Poor Economics, 
Duflo and Banerjee [13] point out that even though many families run an informal business 
(e.g., petty trading, village shop, selling street food, etc.) in these countries, they earn almost 
nothing due to poor organization, lack of capital and limited entrepreneurship. Little diversity in 
the local informal economy—most of the village shops have the same goods in stock and women 
are virtually selling the same street food every day to passers-by and commuters—means that 
the return is meager even though investment in working time every day is high.  
 
Barriers related to concerns about the vaccine were much less prominently reported than 
logistical challenges. Nevertheless, fears about side effects or the doubted effectiveness of the 
vaccine should not be neglected in future campaign planning as rumors about allegedly 
adulterated vaccines may spread quickly with devastating consequences for immunization 
campaigns [14-16]. 
8.1.2 Does use of an OCV in a mass vaccination campaign in Zanzibar 
provide value for money?  
The study presented in Chapter 7 estimated public and private costs of illness (COI) due to 
cholera and costs of a mass vaccination campaign including the benefits in terms of cases and 
deaths prevented and disability-adjusted life-year (DALY) averted.  
 
Because the incremental cost-effectiveness ratio (ICER) of ~USD 119,000 per DALY averted 
exceeded three times the national per capita gross domestic product, use of OCVs was not 
considered a cost-effective strategy in comparison to the current practice of treatment in cholera 
treatment centers (CTCs). Mass vaccination costs were not offset by public and private COI in 
Zanzibar. In contrast, the Beira mass vaccination campaign was cost-effective, but only when 
herd protection was taken into account [17]. 
 
The main reason why mass vaccination was not found to be cost-effective in Zanzibar may be 
due to use of an expensive OCV in a relatively low incidence setting. Vaccine and delivery costs 
of ~USD 26 per fully immunized individual were higher than in any other published study on 
costs of immunization with OCVs. The high purchase price of Dukoral® accounted for 68% of 
these costs. The second-most costly item, hiring of international consultants (14%), was not 
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included in the CE model because a repetition of the campaign will likely be done without 
technical help from abroad. Despite this reduction to ~USD 22 per fully immunized individual, 
the mass vaccination was still not cost-effective. The impact of the vaccination campaign on 
morbidity and mortality, i.e., absolute reduction in numbers of cases and deaths, was limited 
because cholera incidence was too low and because the current case management was 
efficacious enough to keep the case-fatality rate (CFR) at ~1%.  
 
The vaccine purchase price is the only influential parameter policy makers or implementers can 
manipulate directly to improve the CE of vaccination. A threshold analysis with ShancholTM, the 
second OCV that is currently prequalified for use by UN agencies, indicated that only a 
substantial reduction in vaccine purchase price—from the USD 10.28 offered for Dukoral® for 
the 2009 campaign to USD 1.10—would make the intervention cost-effective (i.e., ICER<USD 
1,509 per DALY averted). This estimation was based on the health care provider perspective and 
maximum rates used in the CE model for incidence (4 per 1,000) and CFR (~1.9%) and 
minimum delivery costs of USD 1.06. 
 
Other short-term measures like chlorination of water kept at home or point-of-use water 
treatment may prove to be more cost-effective than use of OCVs [18], and long-term benefits of 
investments in water and sanitation were shown to be cost-beneficial [19]. While efforts at 
improving the sanitation infrastructure in Zanzibar are underway,1 repeating mass vaccination 
campaigns with OCVs may be considered as a supplement to current cholera control activities 
until improvements in the water and sanitation systems are realized. These proposed water and 
sanitation interventions, however, were beyond the scope of this thesis project. 
8.1.3 Is it affordable countrywide? 
In the following paragraphs, results presented in Chapter 7 are discussed to assess whether 
countrywide use of OCV mass campaigns may be an economical and affordable strategy for the 
government of Zanzibar.  
 
Cost-effectiveness is not the only criterion to decide whether OCV mass campaigns should be 
integrated into the national cholera control strategic plan. Affordability has to be considered as 
well to estimate whether the national health budget would be able to cover immunization 
expenses and/or whether and how much co-funding from international institutions is required.  
 
                                                        
1http://www.unhabitat.org/content.asp?cid=7728&catid=5&typeid=6&subMenuId=0  
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A basic budget impact analysis using data from Chapter 7 shows that if Dukoral® were used to 
vaccinate 50% of the population of Zanzibar at the current public price of USD 10.28, the annual 
cost to the government would be ~USD 2.6 million. This would translate into 14.8% of the 
annual Zanzibar health budget for 2008 [20] (Figure 8-2). Whether this level of the health 
budget is affordable and should be allocated to cholera vaccination has to be decided by 
Zanzibar decision makers. If ShancholTM were used at its current public price of USD 3.70, it 
would still cost the government between USD 1.1 and 1.2 million, equal to 6.6 and 6.9% of the 
annual health budget. 
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Figure 8-2: Estimation of the impact of subsidized and unsubsidized OCV purchase prices and 
delivery costs for countrywide mass vaccination on the 2008 health care budget for Zanzibar 
Assumptions: Duration of protection of three years; vaccination needed for people living at risk of recurrent cholera 
outbreaks (50% of the entire population of Zanzibar). Current price for use by UN agencies is USD 3.70 for one course 
of ShancholTM and USD 10.28 for one course of Dukoral®. Mean delivery costs for Dukoral® (USD 2.66) are higher 
than for ShancholTM (USD 2.38) because the latter does not require cups and drinking water for administration. 
 
Hence, international support for cholera vaccination may be needed if the government of 
Zanzibar decides to use vaccination for endemic cholera control. Co-funding from the GAVI 
Alliance2 and other donors like the Bill & Melinda Gates Foundation—and/or price negotiations 
through OCV bulk purchase by mechanisms such as the UNICEF procurement system3 and the 
PAHO Revolving Fund4—could improve the CE of OCVs in Zanzibar and make their use more 
affordable to the government.  
 
                                                        
2The GAVI alliance is not supporting cholera vaccination until 2013 [21], but recommendations may be revised given 
the renewed global interest in cholera control. 
3http://www.unicef.org/supply/index_immunization.html  
4http://new.paho.org/hq/index.php?option=com_content&task=view&id=1864&Itemid=2234&lang=en  
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The following two scenarios illustrate how cholera vaccination may become economically and 
financially attractive to the government of Zanzibar if external support or price negotiations are 
considered: first, if ShancholTM is sold at a reduced price of USD 1.10 to Zanzibar, and if delivery 
costs are also partly subsidized to make the intervention cost-effective, annual countrywide 
vaccination of hotspots would cost the government ~USD 374,000. This would be equal to 2.1% 
of the annual health budget for 2008 (Figure 8-2). Second, if ShancholTM would be fully 
subsidized, but delivery costs were borne by the government, immunization of hotspots would 
cost the government ~USD 420,000 to 475,000, or 2.4 to 2.7% of the annual health budget, 
depending on the annual incidence.  
 
Local health policy makers may also decide to continue with the current practice of reactive 
treatment, which was shown to be capable of keeping the average CFR of cases seen at facilities 
at reasonable levels. However, responses to outbreaks always represent a stress on the local 
health care system in Zanzibar, which is already constrained by shortage of qualified personnel 
and resources; this may affect general primary health care services negatively. The priority for 
cholera vaccination, especially among rural residents who feared that health care would be 
negatively affected by cholera outbreaks (Chapter 5), is an indication that community concerns 
about the health care system need also be taken into consideration when revising the current 
cholera control strategy in Zanzibar from an economic perspective. 
8.2 Methodological issues 
8.2.1 Bridging epidemiology and anthropology for the benefit of 
diarrheal disease control 
Despite numerous attempts to bring the disciplines of epidemiology and anthropology together 
for the benefit of public health [22-25], James Trostle stated in his book Epidemiology and 
Culture [26] that “culture is less widely appreciated in the epidemiological worldview, but it has 
explanatory power and effectiveness comparable to the concept of society.” (p. 5) He thus 
argued “for a complementary alternative to social epidemiology, one that focuses attention on 
disease classification, meaning, risk, and behavior in addition to social variables such as income, 
marital status, and occupation.” (ibid.)  
 
Cultural epidemiology was developed in an effort to enhance the interface of anthropology and 
epidemiology. It was first implemented over 20 years ago in studies of diarrheal illnesses and 
oral rehydration solution (ORS) promotion [27]. An early validation of this approach was later 
done in Thailand when EMIC interviews were used to describe local diarrheal illnesses for 
public health policy recommendations [28]. Since then, however, few studies that systematically 
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integrated quantitative and qualitative methods have been published on the topic of diarrhea 
control. 
 
Findings presented in this thesis provided evidence for the hypothesis that cultural concepts of 
illness have equal or even more explanatory power than if only results from social epidemiology 
were used. Statistical methods enabled formal testing of this hypothesis by using the Akaike 
Information Criterion. Comparing focal models of illness experience, meaning and behavior 
with models containing only sociodemographic variables clearly demonstrated that categories of 
patterns of distress and perceived causes for cholera explained anticipated and actual OCV 
acceptance better than social epidemiology alone. Preliminary results from the OCV acceptance 
study from Kenya [29] and DRC [6] confirmed this finding, suggesting also considerable 
influence of cultural concepts of cholera on vaccination behavior in endemic sites. Findings 
reported in this thesis provide strong validation for Trostle’s call to integrate cultural concepts of 
illness into research for the benefit of public health planning. 
Limitations that need to be addressed in future studies 
Limitations in the presented studies (Chapter 3 to 6) require more attention for improving 
future studies of cultural epidemiology and vaccine acceptance.  
 
First, assessment of whether intention to take the vaccine is a (strong) predictor of uptake could 
not be firmly established. Because of this and because the literature, which is mostly reporting 
on social cognition models to examine the relation between attitudes and behavior [30], is 
mixed regarding whether intention to take a vaccine predicts uptake [31-34], further research is 
needed. Prevaccination assessments would benefit cholera control greatly if future studies 
conducted along with OCV mass vaccination campaigns would support the hypothesis that 
intention predicts acceptance. 
 
Second, based on research experience and observations in Zanzibar, complementing EMIC 
surveys with in-depth interviews would be an asset. Doing such interviews with the study 
population, and also other stakeholders in the community, would help contextualize the results 
better. Stakeholders, namely policy makers, allopathic and traditional health care professionals 
and formal and informal community leaders, were also studied within the framework of the 
OCV project in Zanzibar, but analysis is still ongoing. Once available, narrative data obtained 
from these interviews may be imported into the qualitative data analysis software MAXQDA; 
this would allow additional and potentially instructive comparisons between stakeholders’ views 
on cholera and vaccination and the community views presented in this thesis.  
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Third, on a more technical note, EMIC interviews require rigorous training of research 
assistants [35]. Despite regular supervision and technical input, working with EMIC interviews 
has been quite challenging to field workers in Zanzibar who had been more used to 
administering a questionnaire than to interview members of the general community. Data 
quality, especially narrative content, could be improved by the use of digital voice recorders. 
Provided respondents give consent, interviews should be recorded and at least verbatim 
transcription of key questions done.5 Even though this procedure requires more time for data 
entry, it would improve the explanatory power of cultural epidemiology, which is to a large 
extent based on the integrated analysis of quantitative and qualitative data.  
 
Finally, due to the increasing number of cholera outbreaks worldwide, development of tools for 
rapid prevaccination assessment of community willingness to vaccinate and of social and 
cultural determinants of OCV acceptance may become useful. Surveys using several hundred 
semi-structured interviews where each interview takes one hour or more to complete require a 
lot of time, financial resources and skilled manpower that are hardly available in most 
circumstances. Thus, future research for cultural epidemiological study of OCV acceptance 
should therefore focus on developing a scaled-down version of the EMIC interview that was 
used here. 
8.2.2 Estimating the CE of OCVs for endemic cholera control 
The current CE model has several limitations that need to be addressed in the next steps.6  
 
First, CE outcomes were reported as point estimates. To avoid making suggestions solely based 
on point estimates, the revised model should employ probabilistic sensitivity analysis, which 
takes into account the uncertainty around parameter estimates and enables computation of CE 
acceptability curves for easier interpretation of findings [36,37]. 
 
Second, indirect effects of OCVs on the public health impact need to be considered. Besides 
direct protection of vaccinees, vaccination may also induce protection in unvaccinated 
populations through indirect effects known as herd immunity or herd protection [38,39]. Herd 
immunity occurs only when live vaccines are administered to people; shedding of these 
organisms by vaccinees may then induce a protective immune response in unvaccinated people. 
Herd protection relates to the reduction of disease transmission by the fact that the probability 
of susceptible people to infection is reduced when they are surrounded by or live with 
                                                        
5Full transcripts are of course better, but require much more time (1 hour of interview typically requires about 5-6 
hours of transcription, and more if translation is required) and are too costly for many research projects. 
6It should be noted that making modifications to the cost-effectiveness model has to improve it considerably; else the 
time and financial resources invested are forgone to help other more important research needs. 
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immunized people. Herd protection is a feature of both live and inactivated vaccines, but only 
works if the pathogen is transmitted through person-to-person contacts. Herd protection was 
shown to play a role in a reanalysis of data from a trial using OCVs in Bangladesh [40]. After 
development of a mathematical model with these data, Longini et al. concluded that OCV mass 
campaigns may be useful to reduce endemic cholera even with moderate coverage levels [41]. 
This evidence has led to the consideration of herd protection effects in economic evaluation 
studies using OCVs [17,42-44]. In an economic evaluation of community-based vaccination 
programs in four countries (Bangladesh, India, Indonesia, Mozambique), Jeuland et al. showed 
that the use of OCVs was only cost-effective if herd protection was taken into consideration [17]. 
Although herd protection was not included in the present cost-effectiveness analysis (CEA) due 
to unavailability of relevant epidemiological data, it can be assumed that indirect effects would 
also decrease the ICER in Zanzibar.  
 
Third, economic indicators suggested that vaccination with Dukoral® was not cost-effective in 
Zanzibar when compared to the current practice of erecting CTCs in public health care facilities. 
This treatment approach may also cause additional costs that have not yet been included in the 
CEA. Such costs would mainly be related to non-diarrhea patients who are not treated or 
admitted by their local public health care facility during the time it caters exclusively for cholera 
patients (Chapter 7). For example, patients who need treatment for malaria will have to bear 
extra direct and indirect costs, e.g., related to additional travel or to the higher probability of 
serious complications due to delayed treatment, which may contribute to public costs and also 
increase inequity.  
 
Finally, provided that relevant data are obtainable, a generalized CEA that examines costs and 
effects of all possible cholera-related interventions to select the mix that ensures maximum 
population health within the context of constrained resources may be warranted [45]. 
Generalized CEA examines the CE of vaccination, other prevention activities like provision of 
safe water, sanitation and hygiene education etc., and treatment with regard to doing nothing. 
This would allow researchers to clearly determine the CE of different mutually exclusive cholera 
prevention and treatment packages and give health policy makers more comprehensive 
information to help them decide how to allocate resources most effectively. 
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8.3 Conclusions 
Research presented in this thesis assessed the use of OCV mass campaigns for endemic cholera 
control in Zanzibar.  
 
From the perspective of the affected population, this thesis suggests good prospects to use 
an OCV offered at no cost in mass vaccination campaigns for endemic cholera 
control in Zanzibar for the following reasons: 
 
• People’s perceptions showed that cholera was distinct from shigellosis and represented a 
serious and potentially fatal illness that requires professional help; 
 
• Community willingness to receive an OCV at no cost was almost universal; 
 
• Even though uptake of an OCV offered at no cost was lower than anticipated acceptance, 
analysis of sociocultural features of illness identified relevant determinants of acceptance 
that may be addressed in future campaigns; 
 
• Community behavior regarding OCVs was characterized by passive acceptance rather than 
active resistance or refusal; 
 
• Sociocultural features of illness associated with OCV uptake indicated a positive impact of 
the mass vaccination campaign and of sensitization activities on vaccine acceptance 
behavior; 
 
• Study of barriers to OCV uptake indicated a good campaign implementation and trust in 
the health system, but also highlighted the importance of logistical factors for future 
campaign planning. 
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From an economic perspective, this thesis suggests limited prospects to use OCV mass 
campaigns under current conditions for endemic cholera control in Zanzibar for 
the following reason: 
 
• Mass vaccination with OCVs at a purchase price of ~USD 10 and with annual incidence of 
0.65 per 1,000 was cost-ineffective compared to the current practice of responding to 
cholera outbreaks with decentralized treatment centers; 
 
However, OCV mass campaigns may become an alternative, and potentially also a financially 
affordable, option to treatment in Zanzibar if price negotiations would reduce OCV costs and/or 
if external financial support would be available. At a subsidized purchase price of ~USD 1 and 
subsidized delivery costs of ~USD 1 per immunized individual, OCV mass campaigns may 
become feasible for cholera control in high-incidence areas of Zanzibar. 
8.4 Implications for endemic cholera control with OCVs 
In general, future mass vaccination campaigns in endemic areas may be planned according to 
recently published practical guidelines compiled by the WHO.7 Findings reported here are 
directly applicable to periurban and rural cholera-endemic areas of Zanzibar; but they may in 
principle also be helpful to public health professionals and decision makers in mainland 
Tanzania and other African countries.  
8.4.1 Local level 
To maintain or improve campaign effectiveness in Zanzibar, planning for future OCV mass 
campaigns in cholera-endemic areas should consider the following points: 
 
• Campaigns should 
 
- offer OCVs at no cost to the target population; 
 
- be announced at least a few months before vaccination posts open, with repeated 
reminders in the target communities; 
 
- extend daily open hours or numbers of days for the vaccination, especially in rural 
areas; 
 
                                                        
7Oral cholera vaccines in mass immunization campaigns: guidance for planning and use [46] 
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- concentrate efforts among young adults, periurban areas, and men.  
 
• Information material for community sensitization and mobilization should 
 
- emphasize cholera as a cause of severe dehydration; 
 
- particularly point out the value of vaccination versus treatment of cholera with 
antibiotics; 
 
- better explain (the usually mild) side effects of OCVs versus the benefit of vaccination. 
 
 
CEA suggested the OCV mass campaign was not cost-effective in the base-case scenario with an 
OCV priced at ~USD 10; but this may change with the availability of cheaper OCVs.  
 
Thus, if cholera control through countrywide preemptive vaccination is envisaged in Zanzibar, 
such programs should focus on communities (Shehias) where incidence rates are highest, i.e., in 
settings characterized by a high population density and where inhabitants are less likely to 
benefit from an upgrade in their sanitation system in the near future. Such a revised cholera 
control strategy might also be more equitable because vaccination programs that tackle cholera 
in defined hotspots areas are more affordable to governments or donors and thus more likely to 
be implemented in the mid-term than water supply and sanitation interventions [19].  
8.4.2 Global level 
High community appreciation for OCVs in Zanzibar matches the recently reinforced global 
strategy to promote OCVs for endemic and also epidemic cholera prevention and control. 
Fuelled by large cholera outbreaks in Zimbabwe, Pakistan and Haiti [47-49], and by recent 
progress made in the field of OCV development, governments from low- and middle-income 
countries have become more and more interested in using OCVs for an integrated cholera 
control strategy. Efforts by the WHO and academic institutions, with strong financial, practical 
and scientific support by international and non-governmental organizations, recently led to a 
series of innovative clinical, public health and economic evaluation studies to reassess the use of 
OCVs as a supplement to classical prevention activities [44,50-53]. Trials with ShancholTM are 
ongoing [54] and further mass vaccination campaigns are planned for preemptive or reactive 
vaccination in endemic or epidemic situations in Haiti, the Solomon Islands and Thailand. 
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It is likely that global use of OCVs will rise notably in the near future because of three reasons: 
first, a growing number of cases worldwide coupled with increasing urbanization urging more 
and more people to reside in crowded and unsanitary informal housing conducive to cholera 
[55]; second, the availability of now two prequalified OCVs, which means more competition and 
thus probably lower prices and bigger flexibility for international agencies and donors. Finally, a 
proposal dating back to 1999 to create a global stockpile to better respond to cholera outbreaks 
[56] has now been declared a priority in a recent international meeting convened by the WHO.8 
It was in principle agreed to take action and develop a plan to finance and implement such a 
mechanism. 
 
Findings presented in this thesis may be particularly useful for future projects that intend to 
employ OCVs for endemic cholera control. Based on the premise that a strong government 
commitment is required and that willingness to receive OCVs in communities targeted for mass 
vaccination campaigns is pivotal to ensure maximum coverage, the following points merit 
attention: 
 
• Prevaccination assessments of community willingness should not only consider 
sociodemographic characteristics but also examine sociocultural features of cholera as 
potential determinants of OCV acceptance; 
 
• In communities that welcome OCVs in principle, campaign planners also need to carefully 
consider logistical arrangements and start community mobilization activities with repeated 
reminders well in advance of campaigns; 
 
• Alternative solutions to mass campaigns may be needed for population groups that value 
vaccines in principle but are more difficult to reach due to their specific daily or 
professional activities. 
8.5 Directions for future research 
The cultural epidemiological framework for study of vaccine acceptance in endemic 
communities may benefit from the following considerations: 
 
• Further research is needed to assess whether intention to take vaccines might be a 
predictor of uptake; 
                                                        
8Consultation on Oral Cholera Vaccine Stockpile Strategic Framework: Potential Objectives and Possible Policy 
Options, September 6-7, 2011, World Health Organization, Geneva. 
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• In-depth interviews with community residents and other stakeholders should be 
considered to complement findings from EMIC surveys; 
 
• Voice recording with verbatim transcription of key questions may improve narrative data 
quality; 
 
• A shorter version of the EMIC interview used in Zanzibar may be developed as tool for 
rapid assessment of social and cultural determinants of OCV acceptance. 
 
 
Further studies are required to gain more evidence on the economic viability of using OCVs for 
endemic cholera control through mass vaccination campaigns.  
 
• The current CE model developed for Zanzibar should be revised and extended according to 
the following points: 
 
- In addition to one-way sensitivity analyses, probabilistic sensitivity analyses should be 
employed to generate an empirical distribution of the ICER based on multiple input 
parameters and to compute CE acceptability curves; 
 
- Herd protection effects should be included to examine the extent to which base-case 
results presented here would change. Assessing herd protection effects would 
essentially require more data on local cholera incidence and vaccine protective efficacy 
and a more sophisticated approach to modeling [57]; 
 
- Direct and indirect costs incurred by the limited availability of services to non-
diarrhea patients during outbreaks should be included among public COI; 
 
- The revised model should be calculated for two scenarios, one with use of Dukoral® 
and one with use of ShancholTM; 
 
• Results from the revised model should be examined with regard to generalizability towards 
other cholera-endemic settings in Africa; 
 
• A sectoral priority setting exercise might be conducted to determine the CE of different 
mutually exclusive cholera prevention and treatment packages under varying assumptions 
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by using the generalized CEA approach. 
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AP P E N D I X 
9.1 Supporting information for Chapter 7 
 
Figure 9-1: One-way sensitivity analysis of the influence of key parameters on ICER in 2009 USD per 
DALY averted from model of mass oral cholera vaccination (health care provider perspective) in 
Zanzibar, 2009 
Tornado diagram presents parameters that were varied over their plausible ranges, as shown in brackets. Vertical line 
indicates base-case ICER of USD 119,339 per DALY averted. ICER: Incremental cost-effectiveness ratio, DALY: 
Disability-adjusted life-year 
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Cholera incidence (cases/1,000) [4; 0.1]
Discount rate (%) [0; 5]
Vaccine purchase price (2 doses)
(USD) [2.06; 12.34]
Duration of protection (years) [4; 2]
Campaign coverage (%) [66.8; 53.5]
Life expectancy at average age of
onset (years) [55.5; 36.4]
Vaccine delivery (USD) [1.06; 3.19]
ICER in 2009 USD/DALY averted
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Figure 9-2: One-way sensitivity analysis of the influence of key parameters on ICER in 2009 USD per 
death averted from model of mass oral cholera vaccination (health care provider perspective) in 
Zanzibar, 2009 
Tornado diagram presents parameters that were varied over their plausible ranges, as shown in brackets. Vertical line 
indicates base-case ICER of USD 1,878,142 per death averted. ICER: Incremental cost-effectiveness ratio 
 
 
Figure 9-3: One-way sensitivity analysis of the influence of key parameters on ICER in 2009 USD per 
case averted from model of mass oral cholera vaccination (health care provider perspective) in 
Zanzibar, 2009 
Tornado diagram presents parameters that were varied over their plausible ranges, as shown in brackets. Vertical line 
indicates base-case ICER of USD 16,171 per case averted. ICER: Incremental cost-effectiveness ratio 
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Table 9-1: Public variable costs of illness for cholera, Zanzibar, 2009 
 2009 USDa % 
Drugsb 8.03 (7.92) 87.8 
Antibiotic: Ciproxine 0.01 (0.08) 0.1 
Antibiotic: Doxycycline 0.01 (0.13) 0.1 
Antibiotic: Erythromycine 0.52 (0.41) 5.6 
Antibiotic: Erythromycine syrup 0.10 (0.48) 1.1 
Antibiotic: Metronidazole 0.01 (0.04) 0.2 
Antibiotic: Septrine 0.01 (0.04) 0.1 
IV fluid 7.08 (7.74) 77.3 
Oral rehydration solution 0.25 (0.14) 2.8 
Other drugs: Mebendazole (antihelminthic) 0.01 (0.01) 0.1 
Other drugs: Zinc sulphate 0.03 (0.07) 0.3 
Materialc 1.12 (0) 12.2 
Cannula (adults) 0.34 (0) 3.8 
Examination gloves 0.52 (0) 5.7 
IV giving set 0.20 (0) 2.1 
Zinc oxide plaster 0.05 (0) 0.6 
Total 9.15 (7.92) 100.0 
aMean costs and standard deviation in brackets; bDrug resource use based on patient interviews (n=95), drug unit 
costs include 6% for storage at medical store department and distribution; cStandard resource use per patient based 
on expert interview: cannula (1-2 pieces), examination gloves (8 pairs), IV giving sets (1 piece) and Zinc oxide plaster 
(30 cm); IV: Intravenous 
 
166 
Table 9-2: Delivery costs for a mass oral cholera vaccination campaign, Zanzibar, 2009 
  Totala Meanb % 
Vaccine transport, storage, water and cups 45,128 1.56 18.7 
International transport of vaccinec 19,803 0.68 8.2 
Purchase of cups and international transportd 9,326 0.32 3.9 
Purchase of bottled watere 4,628 0.16 1.9 
Storage and local transport of vaccines, cups and waterf 11,370 0.39 4.7 
International consultantsg 108,432 3.74 44.9 
Compensation, travel 108,432 3.74 44.9 
Training 9,461 0.33 3.9 
Training vaccinators 5,803 0.20 2.4 
Training social mobilizers 3,658 0.13 1.5 
Staff allowances 2,090 0.07 0.9 
Staff transport 290 0.01 0.1 
Material 642 0.02 0.3 
Refreshment 527 0.02 0.2 
Venue 108 0.00 0.0 
Implementation 78,270 2.70 32.4 
Vaccination 66,054 2.28 27.4 
Staff allowances 33,047 1.14 13.7 
Staff transport 7,104 0.25 2.9 
Material 25,552 0.88 10.6 
Communication 351 0.01 0.1 
Social mobilizationh 12,217 0.42 5.1 
Total 241,291 8.32 100.0 
aTotal delivery costs (2009 USD) to vaccinate a target population of 49,980 people; bMean delivery costs (2009 USD) 
per fully immunized individual based on actual coverage (58.0%); cVaccine transported from Stockholm, Sweden; 
dDisposable paper cups purchased at a price of 8 US cents and transported from Shanghai, China; e15,000 liters of 
drinking water procured from a local agent in 1.5 liter plastic bottles at TZS 600 (USD 0.5) per bottle; fCosts for 
storage of vaccines, cups and water at the medical store department including cold room facilities and generator 
maintenance and transport to vaccination posts; gInvolvement of two international consultants; hIncludes material 
(T-shirts, posters, leaflets, banners, radio/TV programs) and staff costs 
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Table 9-3: Key outcomes from model of mass oral cholera vaccination (societal perspective) in 
Zanzibar, 2009a 
  No vaccination Vaccination Difference 
Cholera burden  
Annual number of cases  30 7 23 
Annual number of deaths 0.26 0.06 0.20 
Annual number of YLD averted   0.02 
Annual number of YLL averted   3.08 
Annual number of DALY averted   3.10 
Total number of DALY averted over duration of protection     8.78 
Costs of outcome indicators, 2009 USD 
Annual costs of vaccination programb 0 371,850 -371,850 
Annual public costs of illness 1,968 453 1,515 
Private costs of illness (direct) 370 85 285 
Annual costs of treatment and vaccination program 2,338 372,388 -370,049 
Costs per death averted with vaccine  1,888,555  
Costs per case averted with vaccine  16,260  
Costs per DALY averted with vaccine  119,828  
Incremental costs and cost-effectiveness ratios (ICER), 2009 USD 
Incremental costsc   370,049 
ICER (death): Incremental costs/death averted   1,876,696 
ICER (case): Incremental costs/case averted   16,158 
ICER (DALY): Incremental costs/DALY averted     119,247 
aBase-case results from population of 50,000, with 3% annual discounting of effects; bExcluding costs for 
international consultants; cCosts of vaccination program minus public and private COI averted by vaccination (cost 
savings); YLD: Years of life lived with disability, YLL: Years of life lost, DALY: Disability-adjusted life-year, ICER: 
Incremental cost-effectiveness ratio 
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9.2 EMIC interview for cultural epidemiological study of 
cholera 
 
 
OCV SEB Study: Explanatory Model Interview Catalogue (EMIC) 
 
Survey Phase: 1, Study Level: IV 
Ministry of Health and Social Welfare of Zanzibar,  
in collaboration with  
World Health Organization, Geneva, and Swiss Tropical Institute, Basel 
 
English Version of 27/06/2008 (Final) 
 
 
Date interview (dd-mm-yyyy)  
 
 
EMIC ID (1-X-yyy) 
X: 1=Unguja, 2=Pemba 1-___-___ ___ __ 
 
General information 
Tick appropriate:  Tick one only: 
Site 1 Unguja 2 Pemba 
Sex 1 F 2 M  Approximate age (years)   Pregnant 1 Yes 2 No 
 
Introduction 
Thank you for letting me speak with you today. I will be asking you questions about health 
problems that could affect people in your community. You may recognize these conditions, or 
they may be unfamiliar. In either case I would like to understand your ideas about it. Your 
answers and thoughts will help us to assist people who have these problems. But first, a few 
questions about your background. 
Socioeconomic and demographic information 
1. Marital status 
Tick one only: 
1 Sijawahi kuoa 
au kuolewa 
Never 
married  
2 Nimeoa au 
nimeolewa 
Married  
3 Nimetengana 
Separated  
4 Nimeachik
a Divorced  
5 Tunaishi 
pamoja 
Living 
together  
6 Nimefiliwa na 
mume au mke 
Widowed  
7 Siwezi kusema 
Cannot say  
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2. Household size  
Idadi ya watu unaishi nao Number of people living in the household   
3. Children living in the household  
Enter 0 when answer is none for a given category: 
Idadia ya watoto  
Number of children  
Chini ya miaka 5  
< 5 yrs  
Miaka 5 mpaka 10  
5-10 yrs  
Miaka 10 mpaka 17  
10-17 yrs  
Wavulana Boys     
Wasichana Girls     
4. Relationship with household head  
Tick one only:  Tick sex of household head: 
1 Mwenyewe 
Self  
2 Mke/mume 
Spouse  
3 Wazazi 
Parent  
4 Ndugu 
Sibling  
5 Mtoto 
Offspring  
6 Uhusiano mwingine 
Other specify: 
  
 Sex  1 F  2 M  
5. Main occupational status  
Tick one only: 
1 Kilimo  
Agriculture  
2 Uvuvi  
Fishing  
3 Nimejiajiri  
Self-employment (not 1&2)  
4 Kuajiriwa rasmi  
Formally employed  
5 Mama wa nyumbani 
Housewife  
6 Mfanyakazi wa 
nyumbani 
Housemaid  
7 Kibarua  
Casual labourer  
8 Mwanafunzi  
Student  
9 Sifanji kazi/nimestaafu  
Not active/retired  
10 Mengine, eleza Other specify: 
6. Education  
Tick highest achieved level only: 
1 Sijasoma No 
education  
2 Madrassa ya 
Koran Koranic 
school  
3 Elimu ya 
msingi 
Primary school  
4 Elimu ya 
sekondari 
Secondary school  
5 Elimu amali 
Vocational 
school  
6 Elimu juu 
Higher 
education  
7. Years of education  
  Siwezi kusema Cannot say   
8. Religion  
Tick one only: 
1 Mwislamu Muslim  2 Mkristo Christian  3 Mengine, eleza Other specify:   4 Sielezi Undisclosed  
9. Nationality  
Tick one only: 
1 Mtanzania Tanzanian  2 Raia wa nchi nyingine, eleza Other specify:     
10. Is your household income usually reliable (and dependable)? 
Tick one only, not disclosed means uncertain: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to Q 12: 
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11. What main sources of income are there in your household? 
Narrative: _____________________________________________________________  
Tick all that apply: 
Sources of income Own  Others 
1 Kuajiriwa kwa mshahara Employment for cash    
2 Kuajiriwa kwa namna nyingine Employment in kind    
3 Kujiajiri mwenyewe katika sekta yoyote isiyo ya kilimo Non-farm self-
employment  
  
4 Kuuza mayao ya kilimo Selling agricultural produce    
5 Kuuza samaki na mazao ya baharini Selling fish and seafood    
6 Kukodisha (nyumba, shamba, duka) Rent    
7 Msaada kututoka nje Remittances (money sent from outside)    
8 Pensheni Pension    
98 Nyinginezo, eleza Other specify:  /     
99 Siwezi kusema Cannot say   
12. How much money did you make during the last month on your own? And what about your 
spouse and other household members? 
Narrative: _____________________________________________________________  
Query for items not mentioned, clarify if needed. If there is no income, enter 0 in TSh column. If respondent is widowed, then tick 
“cannot say” for category 2: 
Monthly income TSh    
1 Chake mwenyewe  
Own  
  Siwezi kusema 
Cannot say  
 
2 Cha mume/mke wake  
Spouse  
  Siwezi kusema 
Cannot say  
 
3 Cha watu wengine wanaoishi katika nyumba hii hii  
Additional household income  
  Siwezi kusema 
Cannot say 
 
 
Introduction to vignettes 
I appreciate your willingness to talk to me about a few health problems that affect people in 
your community. I want to understand how you think about it. It is your ideas that I am 
interested in so please don’t feel shy to tell me your personal opinion. I will tell you two 
different stories about persons who are having a particular problem. 
Vignette A 
Let me tell you the story about this [person]… 
13. What is the name of this disease? 
Specify name, summary term or short description in his/her own words. If ‘other’, specify term and explain here:  
 
Narrative: _____________________________________________________________  
Types of diarrhoea 
1 Kuharisha kawaida Normal diarrhoea  5 Kipindupindu Cholera  
2 Kuharisha maji Watery diarrhoea  6 Mchanganyiko Multiple  
3 Kuharisha marenda Mucous diarrhoea  98 Mengineyo, eleza Other, specify:     
4 Kuharisha damu Bloody diarrhoea  99 Siwezi kusema Cannot say  
Chapter 9 | Appendix  171 
 
Code the name from the above numbered list:  
 
Use the name as identified for this disease instead of referring to disease/problem and use the name of the person mentioned in the 
vignette in the following questions.  
14. Can you think of any other symptoms that this [person] is likely to experience besides the 
ones we already mentioned? 
Summarize the respondent’s account of problem in his/her own words:  
 
Spontaneous narrative: _______________________________________________________  
Based on the respondent’s account tick problems which are mentioned under the Spon column indicating a spontaneous response 
to the open-ended question above. Continue by probing for any categories not yet mentioned and tick them in the Prob column, 
indicating a probed response to screening. Make a cross when “no” or “cannot say” was the reply to probed categories. Shaded 
cells must not be probed.  
Physical symptoms Spon Prob  Spon Prob 
1 Kusokotwa na tumbo  
Abdominal cramps  
  13 Kunyauka, kukauka ngozi  
Skin (loose, dry, shrivelled)  
  
2 Kuumwa na tumbo  
Abdominal pain/discomfort  
  14 Kutokuwa na hamu ya kula  
Loss of appetite  
  
3 Kuumwa na misuli Muscle cramps    15 Maumiva ya kitchwa Headache    
4 Kutapika Vomiting    16 Kichefuchefu Nausea    
5 Choo kingi kupita kiasi Large amounts of stool    17 Homa Fever    
6 Kuharisha mara kwa mara  
Frequent passing of stool  
  18 Udhaifu  
Weakness  
  
7 Choo kama maji ya mchele Rice water-like stool    19 Kupaparikwa na moyo Palpitations    
8 Choo chenye usaha Pus in stool    20 Fadhaisha Confusion    
9 Choo chenye damu Bloody stool    21 Kupoteza fahamu Unconsciousness    
10 Maumivu sehemu ya kunyea  
Rectal pain  
  98 Dalili nyingine mwilini  
Other physical symptoms  
  
11 Kiu kali Very thirsty    99 Siwezi kusema Cannot say    
12 Macho kuingia ndani Sunken eyes       
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q 16: 
15. Among all these symptoms which one do you consider the single most troubling? 
Narrative: _____________________________________________________________  
Code the most troubling category from the above numbered list of patterns of distress:  
16. How do you think that this [disease] will affect [this person] emotionally, socially and 
financially in his/her daily life? 
Summarize the respondent’s account of problem in his/her own words:  
 
Spontaneous narrative: _______________________________________________________  
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Based on the respondent’s account tick problems which are mentioned under the Spon column indicating a spontaneous response 
to the open-ended questions above. Continue by probing for any categories not yet mentioned and tick them in the Prob column, 
indicating a probed response to screening. Make a cross when “no” or “cannot say” was the reply to probed categories. 
Impact  Spon Prob  Spon Prob 
Social impact Emotional impact 
1 Kutengwa na watu wengine  
Isolation from others  
  6 Huzuni, kukosa raha, wasiwasi  
Sadness, anxiety, worry  
  
2 Woga wa kuambukiza wengine  
Fear of infecting others  
  Financial impact 
3 Kusitisha huduma za afya  
Disruption of health services  
  7 Kuongezeka kwa gharama za maisha 
Costs (transportation, foods, drugs)  
  
4 Kuathiri shudhuli za kila siku  
Interference with work/daily activities  
  8 Kupoteza kipato cha familia  
Loss of family income 
  
5 Kuathiri uhusiano na watu wengine katika jamii 
Interference with social relationships  
  Miscellaneous 
   98 Mengine, eleza Other, specify:   
   99 Siwezi kusema Cannot say    
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q 18:  
17. Which of these problems that you have mentioned do you consider the single most 
troubling? 
Narrative: _____________________________________________________________  
Code the most troubling category from the above numbered list of impacts:  
18. How serious is this [disease] for [this person]? 
Tick one only: 
Mbaya sana Very serious 3 Mbaya kiasi Moderately serious 2  Haitabiriki Uncertain 1  Si mbaya Not serious 0  
 
Narrative: _____________________________________________________________  
19. What is the most likely health outcome of this [disease] for [this person] without 
appropriate treatment from outside? 
Tick one only: 
Kifo  
Usually fatal 
4  
Wakati mwingine inaweza 
kusababisha kifo  
Sometimes fatal 3 
Hali mbaya sana, lakini haisababishi 
kifo  
Serious but not fatal 2  
Haitabiriki 
Uncertain 1  
Kupona vizuri na 
haraka Full/quick 
recovery 0  
 
Narrative: _____________________________________________________________  
20. Have you or somebody else in your household ever had this [disease]? 
Tick one only:  
Ndio Yes 3  Inawezekana Possibly 2  Hakuna hakika Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If yes or possibly, enquire further otherwise go to Q 22: 
21. Who was that? 
Tick all that apply:  
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1 Mimi 
mwenyew
e Self  
2 Mke/Mume 
Spouse  
3 Wazazi 
Parent  
4 Watoto 
Children  
5 Dada/kaka/mdogo 
wangu  
Sibling  
6 Watu wengine 
wanaoishi ndani ya 
nyumba hii Other 
household member  
99 Siwezi 
kusema 
Cannot 
say  
 
Narrative: _____________________________________________________________  
22. In general, who is most likely to get this [disease]? Is it men or women? Adults or 
children? Rich or poor people? 
Enquire about the following categories if not clear from response and tick all that apply: 
Jinsia Sex  1 Wanaume Men  2 Wanawake Women  3 Si yeyote Neither  
Umri Age  1 Watu wazima Adults  2 Watoto Children  3 Si wowote Neither  
Hali ya maisha Social class  1 Matajiri Rich  2 Watu masikini Poor  3 Si yoyote Neither  
 
Narrative: _____________________________________________________________  
23. Each of us may explain something that happens in various ways. What do you think has 
caused this [person]’s problem? 
Summarize the respondent’s ideas about causes in his/her own words:  
 
Narrative: _____________________________________________________________  
Based on the respondent’s account tick perceived causes in the Spon column indicating a spontaneous response to the open-ended 
question above. Continue by probing for any category not yet mentioned and tick them in the Prob column, indicating a probed 
response to screening. Make a cross when “no” or “cannot say” was the reply to probed categories. 
Perceived causes  Spon Prob  Spon Prob 
Ingestion 8 Nzi Flies    
1 Kunywa maji machafu Drinking contaminated water    9 Malaria   
2 Chakula ambacho hakijahifadhiwa/kimeoza 
Unprotected/spoiled food (biological)  
  10 Minyoo  
Worms  
  
3 Chakula kilichokatazwa Forbidden food (taboo)    Magico-religious causes 
4 Kula udongo Eating Soil    11 Uchawi Witchcraft    
Behaviour 12 Rehema ya Mungu God’s will    
5 Kugusa maji machafu  
Contact with contaminated water  
  Miscellaneous 
6 Kutoosha mikono Not washing hands    98 Mengine, eleza Other, specify:   
Environment 99 Siwezi kusema Cannot say    
7 Mazingira machafu Dirty environment       
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q 25: 
24. Which one of these causes that you have mentioned do you consider the main cause? 
Narrative: _____________________________________________________________  
Code the most important category from the above numbered list of perceived 
causes: 
 
25. What do people do at home for a [person] with this [disease] before looking for treatment 
or help outside their homes? 
Summarize the respondent’s account of home-based treatment in his/her own words:  
 
Spontaneous narrative: _______________________________________________________  
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Based on the respondent’s account tick home-based treatment categories in the Spon column indicating a spontaneous response to 
the open-ended question above. Continue by probing for any home-based treatment categories not yet mentioned and tick them in 
the Prob column, indicating a probed response to screening. Make a cross when “no” or “cannot say” was the reply to probed 
categories. 
Home-based treatment  Spon Prob 
1 Kunywa maji mengi au vinywaji vingine Drinking more water or liquids    
2 Dawa za mitishamba (mizizi, magamba, majani) Herbal treatment (roots, bark, leaves)    
3 Kunywa dawa za vipaketi (ORS) zinazouzwa madukani Oral rehydration therapy    
4 Kuomba dua Prayers    
5 Kutumia dawa za antibiotics za kujinunulia mwenyewe Self-administered antibiotics/drugs    
6 Hapana Nothing    
98 Mengine, eleza Other, specify:         
99 Siwezi kusema Cannot say    
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q 27: 
26. Which one of all these things people do at home do you think is likely to be most helpful? 
Narrative: _____________________________________________________________  
Code the most helpful category from the above numbered list of home-based 
treatments: 
 
27. Where will this person usually go for treatment outside his/her home? 
Summarize the respondent’s account of outside treatment in his/her own words: 
 
Spontaneous narrative: _______________________________________________________  
Based on the respondent’s account tick outside treatment categories in the Spon column indicating a spontaneous response to the 
open-ended question above. Continue by probing for any outside treatment categories not yet mentioned and tick them in the Prob 
column, indicating a probed response to screening. Make a cross when “no” or “cannot say” was the reply to probed categories. 
Outside treatment Spon Prob 
1 Hospitali Health facilities    
2 Waganga wa kienyeji Traditional healers    
3 Maduka ya madawa Pharmacy or over-the-counter drugs    
4 Viongozi vya dini Faith healers (Imams, Sheikh)    
5 Ushauri kutoka kwa ndugu/jamaa na marafiki wanaofanya kazi vituo vya afya  
Informal help from health-worker, friend/relative  
  
98 Sehemu nyinginezo, eleza Other, specify:   
99 Siwezi kueleza Cannot say    
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q 29: 
28. Which one of these people they might consult do you think is most helpful? 
Narrative: _____________________________________________________________  
Code the most helpful category from the above numbered list of outside 
treatments: 
 
29. Do you think [this person] should not disclose [this disease] beyond his/her closest 
family? 
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Tick one only: 
Ndio Yes 3  Labda/mchanganyiko Possible/mixed 2 Haijulikani Uncertain 1 Hapana No 0 
 
Narrative: _____________________________________________________________  
30. If they knew, do you think some people might make [this person] feel ashamed or 
embarrassed because of [this disease]? 
Tick one only: 
Ndio Yes 3  Labda/mchanganyiko Possible/mixed 2 Haijulikani Uncertain 1 Hapana No 0 
 
Narrative: _____________________________________________________________  
31. Would others finding out about [this disease] cause problems for [this person]? 
Tick one only: 
Ndio Yes 3  Labda/mchanganyiko Possible/mixed 2 Haijulikani Uncertain 1 Hapana No 0 
 
Narrative: _____________________________________________________________  
32. Would others finding out about [this disease] cause problems for the family of [this 
person]? 
Tick one only: 
Ndio Yes 3  Labda/mchanganyiko Possible/mixed 2 Haijulikani Uncertain 1 Hapana No 0 
 
Narrative: _____________________________________________________________  
33. Might there be someone in the household who would hesitate to bring [this person] to 
treatment because they did not want the [disease] to be known? 
Tick one only: 
Ndio Yes 3  Labda/mchanganyiko Possible/mixed 2 Haijulikani Uncertain 1 Hapana No 0 
 
Narrative: _____________________________________________________________  
34. Is it likely that others outside the family finding out about [this disease] would be helpful 
to [this person]?” 
Tick one only: 
Ndio Yes 0  Labda/mchanganyiko Possible/mixed 1 Haijulikani Uncertain 2 Hapana No 3 
 
Narrative: _____________________________________________________________  
35. What can be done to prevent this [disease]? 
Summarize the respondent’s account of prevention options in his/her own words: 
 
Spontaneous narrative: _______________________________________________________  
Based on the respondent’s account tick prevention categories in the Spon column indicating a spontaneous response to the open-
ended question above. Continue by probing for any prevention categories not yet mentioned and tick them in the Prob column, 
indicating a probed response to screening. Make a cross when “no” or “cannot say” was the reply to probed categories. 
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Prevention Spon Prob 
1 Kuosha mikono Wash hands    
2 Maji yaliyochemshwa au yenye dawa Safe water    
3 Chakula safi na salama Clean/safe food    
4 Utupaji na uwekaji wa takataka vizuri Safe disposal of garbage    
5 Uhifadhi wa kinyesi vizuri Safe disposal of stool    
6 Dawa za kinga Preventive drugs    
7 Chanjo Vaccines    
8 Elimu ya afya Health education    
98 Mengine, eleza Other, specify:       
99 Siwezi kusema/hapana Cannot say/Nothing    
 
Probed narrative: __________________________________________________________  
If respondent has mentioned more than one category, enquire further, otherwise go to Q37: 
36. Which one of these ways of prevention do you think is most useful? 
Narrative: _____________________________________________________________  
Code the most useful way from the above numbered list of preventive measures:  
Vaccines 
37. Have you or anyone in your household received any type of vaccine? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to Q 39: 
38. Who got it? 
Tick all that apply: 
1 Mimi mwenyewe Self  2 Watoto Children  3 Watu wazima wanaokaa nyumba hii Adults in household  
 
Narrative: _____________________________________________________________  
39. Based on your experience, do you think vaccines are generally helpful? 
Tick one only: 
Ndio Yes 3  Wakati mwingine Sometimes 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
40. Do you think some vaccines are also likely to cause problems? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to Q 42: 
41. Please tell me about that. 
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Tick all that apply: 
Problems caused by vaccines  Tick 
1 Kuvimba/maumivu sehemu iliyochomwa sindano Pain/swelling at injection site   
2 Homa Fever  
3 Majipu/kidonda Infection/abscess  
4 Kovu Scar   
5 Mtoto kulia sana Crying baby  
98 Mengine, eleza Other, specify:    
 
Narrative: _____________________________________________________________  
42. If a vaccine that you swallow becomes available to prevent cholera, would you take it if it 
was made available without charge? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to next vignette. 
43. If the vaccine were to cost 1,000 TSh would you still take it? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to next vignette. 
44. If the vaccine were to cost 5,000 TSh would you still take it? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
If “yes” or “possibly”, enquire further, otherwise go to next vignette. 
45. If the vaccine were to cost 10,000 TSh would you still take it? 
Tick one only: 
Ndio Yes 3  Labda Possibly 2  Hakijulikani Uncertain 1  Hapana No 0  
 
Narrative: _____________________________________________________________  
Vignette B 
Let me tell you the story about this [person]… 
46. What is the name of this disease? 
Specify name, summary term or short description in the respondent’s own words. If ‘other’, specify term and explain here:  
 
Narrative: _____________________________________________________________  
Types of diarrhoea 
1 Kuharisha kawaida Normal diarrhoea  5 Kipindupindu Cholera  
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Types of diarrhoea 
2 Kuharisha maji Watery diarrhoea  6 Mchanganyiko Multiple  
3 Kuharisha marenda Mucous diarrhoea  98 Mengineyo, eleza Other, specify:     
4 Kuharisha damu Bloody diarrhoea  99 Siwezi kusema Cannot say  
 
Code the name from the above numbered list:  
 
Use the name as identified for this disease instead of referring to disease/problem and use the name of the person mentioned in the 
vignette in the following questions.  
47. Can you think of any other symptoms that this [person] is likely to experience besides the 
ones we already mentioned? 
Narrative: _____________________________________________________________  
Tick all that apply: 
Physical symptoms Tick  Tick 
1 Kusokotwa na tumbo  
Abdominal cramps  
 13 Kunyauka, kukauka ngozi  
Skin (loose, dry, shrivelled) 
 
2 Kuumwa na tumbo Abdominal pain/discomfort   14 Kutokuwa na hamu ya kula Loss of appetite   
3 Kuumwa na misuli Muscle cramps   15 Maumiva ya kitchwa Headache   
4 Kutapika Vomiting   16 Kichefuchefu Nausea   
5 Choo kingi kupita kiasi Large amounts of stool   17 Homa Fever   
6 Kuharisha mara kwa mara  
Frequent passing of stool 
 18 Udhaifu  
Weakness  
 
7 Choo kama maji ya mchele Rice water-like stool   19 Kupaparikwa na moyo Palpitations   
8 Choo chenye usaha Pus in stool   20 Fadhaisha Confusion   
9 Choo chenye damu Bloody stool   21 Kupoteza fahamu Unconsciousness   
10 Maumivu sehemu ya kunyea  
Rectal pain  
 98 Dalili nyingine mwilini  
Other physical symptoms  
 
11 Kiu kali Very thirsty   99 Siwezi kusema Cannot say   
12 Macho kuingia ndani Sunken eyes     
48. How do you think that this [disease] will affect [this person] emotionally, socially and 
financially in his/her daily life?  
Narrative: _____________________________________________________________  
Tick all that apply: 
Impact  Tick  Tick 
Social impact Emotional impact 
1 Kutengwa na watu wengine  
Isolation from others  
 6 Huzuni, kukosa raha, wasiwasi  
Sadness, anxiety, worry  
 
2 Woga wa kuambukiza wengine  
Fear of infecting others  
 Financial impact 
3 Kusitisha huduma za afya  
Disruption of health services  
 7 Kuongezeka kwa gharama za maisha 
Costs (transportation, foods, drugs) 
 
4 Kuathiri shudhuli za kila siku  
Interference with work/daily activities  
 8 Kupoteza kipato cha familia  
Loss of family income  
 
5 Kuathiri uhusiano na watu wengine katika jamii 
Interference with social relationships 
 Miscellaneous 
  98 Mengine, eleza Other, specify:  
  99 Siwezi kusema Cannot say   
49. How serious is this [disease] for [this person]? 
Tick one only: 
Mbaya sana Very serious 3 Mbaya kiasi Moderately serious 2  Haitabiriki Uncertain 1  Si mbaya Not serious 0  
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Narrative: _____________________________________________________________  
50. What is the most likely health outcome of this [disease] for [this person] without 
appropriate treatment from outside? 
Tick one only: 
Kifo  
Usually fatal 
4  
Wakati mwingine inaweza 
kusababisha kifo  
Sometimes fatal 3 
Hali mbaya sana, lakini haisababishi kifo  
Serious but not fatal 2  
Haitabiriki 
Uncertain 1  
Kupona vizuri na 
haraka Full/quick 
recovery 0  
 
Narrative: _____________________________________________________________  
51. Each of us may explain something that happens in various ways. What do you think has 
caused this [person]’s problem? 
Narrative: _____________________________________________________________  
Tick all that apply: 
Perceived causes  Tick  Tick 
Ingestion 8 Nzi Flies   
1 Kunywa maji machafu Drinking contaminated water   9 Malaria  
2 Chakula ambacho hakijahifadhiwa/kimeoza 
Unprotected/spoiled food (biological)  
 10 Minyoo  
Worms  
 
3 Chakula kilichokatazwa Forbidden food (taboo)   Magico-religious causes 
4 Kula udongo Eating Soil   11 Uchawi Witchcraft   
Behaviour 12 Rehema ya Mungu God’s will   
5 Kugusa maji machafu Contact with contaminated water   Miscellaneous 
6 Kutoosha mikono Not washing hands   98 Mengine, eleza Other, specify:  
Environment 99 Siwezi kusema Cannot say   
7 Mazingira machafu Dirty environment     
52. What do people do at home for a [person] with this [disease] before looking for treatment 
or help outside their homes? 
Narrative: _____________________________________________________________  
Tick all that apply: 
Home-based treatment  Tick 
1 Kunywa maji mengi au vinywaji vingine Drinking more water or liquids   
2 Dawa za mitishamba (mizizi, magamba, majani) Herbal treatment (roots, bark, leaves)   
3 Kunywa dawa za vipaketi (ORS) zinazouzwa madukani Oral rehydration therapy   
4 Kuomba dua Prayers   
5 Kutumia dawa za antibiotics za kujinunulia mwenyewe Self-administered antibiotics/drugs   
6 Hapana Nothing   
98 Mengine, eleza Other, specify:        
99 Siwezi kusema Cannot say   
53. Where will [this person] usually go for treatment outside his/her home? 
Narrative: _____________________________________________________________  
Tick all that apply: 
Outside treatment Tick 
1 Hospitali Health facilities   
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2 Waganga wa kienyeji Traditional healers   
3 Maduka ya madawa Pharmacy or over-the-counter drugs   
4 Viongozi vya dini Faith healers (Imams, Sheikh)   
5 Ushauri kutoka kwa ndugu/jamaa na marafiki wanaofanya kazi vituo vya afya  
Informal help from health-worker, friend/relative  
 
98 Sehemu nyinginezo, eleza Other, specify:  
99 Siwezi kueleza Cannot say   
Concluding advice from respondent 
Is there anything else you can tell me about the health problems we have discussed or about 
vaccinations from your experience? Any further comments, advice or suggestions will be 
appreciated. 
 
Narrative: __________________________________________________________ 
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9.3 Clinical vignettes for community study of cholera and 
shigellosis  
9.3.1 Vignette A—Cholera 
Jecha1 from Chumbuni2 who is 40 years old did not feel like going to visit his friends one 
morning last week. All of a sudden he had to run to the latrine. He became more and more 
concerned after the second and third time of running to the latrine that morning because he was 
passing lots of stool which looked like rice water. It was as if he were urinating instead of 
defecating. He also felt very miserable because he was vomiting terribly and the muscles in his 
arms and legs were very painful. 
9.3.2 Vignette B—Shigellosis 
When 25-year-old Makame1 woke up on Monday last week in his house in Chumbuni2 he was 
feeling feverish and also had pangs of pain in his belly. He was having a loose stool and when he 
looked at it he noticed red drops, probably blood, and a whitish substance like pus. He went to 
the toilet another 3 times that day but he did not feel better afterwards. The day after, he still felt 
the same urge to go to the toilet many times. But with each time he produced less and less stool 
although he strained a lot and his anus was painful. 
                                                        
1Local people’s names were used to make the story sound more familiar to the respondents. The names were always 
adapted to match the respondent’s sex. Jecha was the male and Sharifa the female name used in the cholera vignette 
while Makame (male) and Fatma (female) were featuring in the shigellosis vignette. 
2Chumbuni was used as the community name for Unguja and Mwambe for Pemba reflecting the respondents’ 
addresses.  
